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1 Zusammenfasssung 
Aktuelle klinische und tierexperimentelle Studien zeigen, dass das saure Sphingomyelinase 
(ASM)/Ceramid-System eine bedeutende Rolle in der Pathogenese der Majoren Depression (MD) 
spielt (Kornhuber et al. 2005; Gulbins et al. 2013; Rhein et al. 2017) und der antidepressive 
Effekt verschiedener allgemein gebräuchlicher Antidepressiva von der Inhibierung der ASM 
abhängt (Kornhuber et al. 2011; Gulbins et al. 2013). Das Ceramid-System hat zudem eine 
wichtige Bedeutung für die Zusammensetzung der Plasmamembran. Ein erhöhtes Vorkommen 
von Ceramid-Molekülen führt zur Bildung von „Lipid Rafts“ und geht mit einer Veränderung der 
Membranstruktur und der Signaltransduktion einher (Zhang et al. 2009; Grassmè, Riethmüller, 
and Gulbins 2007; Stancevic and Kolesnick 2010). Die Signaltransduktion der in der 
Plasmamembran lokalisierten TRPC6 Ionen Kanälen ist u.a. für synaptische Plastizität von 
Bedeutung (Li et al. 2005; Tai et al. 2008; Leuner et al. 2013), welche bei MD verändert ist 
(Duman et al. 2016). Daher stellte sich die Frage, ob eine bei MD vorliegende Dysregulation des 
ASM/Ceramid-Systems die TRPC6 Funktion beeinflusst. Da Antidepressiva die ASM-Aktivität 
inhibieren, wurden die Auswirkungen der ASM-Hemmung auf die TRPC6 Funktion untersucht.  
Es konnte sowohl in einer neuronalen Zelllinie als auch in primären Neuronen gezeigt werden, 
dass einige Antidepressiva und der direkte ASM-Hemmer ARC39 die ASM-Aktivität inhibieren, 
wobei eine Zell-spezifische Signatur vorlag. Die Reduktion der ASM-Aktivität wirkte sich zudem 
auf die Expression von TRPC6 aus: Antidepressive Behandlung oder genetische ASM-Defizienz 
veränderte die Expression von TRPC6 auf RNA oder Protein-Ebene. Durch die Hemmung der 
ASM-Aktivität wurde der durch TRPC6 vermittelte Calciumeinstrom in PC12-Zellen und in ASM 
defizienten kortikalen Mausneuronen inhibiert. Außerdem wurde durch die ASM-Inhibierung die 
Phosphorylierung des Transkriptionsfaktors CREB, der durch TRPC6 aktiviert wird, in Neuronen 
reduziert. Eine Analyse des Lipidoms von mit Antidepressiva behandelten Zellen, ließ die 
Abnahme des Ceramid/Sphingomyelin-Verhältnisses für „very-long chain“ Sphingolipidspezies 
erkennen, welches die Lokalisation von TRPC6 in „Lipid Raft“- und „Nicht-Raft“-Regionen in der 
Plasmamembran beeinflusste. Schlussfolgernd kann die ASM Hemmung, und die damit 
einhergehende verringerte Ceramid-Konzentration, die Lokalisation von TRPC6 in der 
Plasmamembran stören, was als mechanistische Erklärung für die Veränderungen im TRPC6-
vermittelten Calciumeinstrom und der Signaltransduktion dienen kann.  
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Zusammenfassend kann das bessere Verständnis der Interaktion zwischen dem ASM/Ceramid-
System und TRPC6 Ableitungen für die Pathogenese der MD zulassen. Meine in primären 
Neuronen gewonnenen Daten, in Kombination mit anderen vorrausgegangenen Daten in PC12-
Zellen (Ye 2015), lassen die Hypothese zu, dass ein ausbalanciertes Gleichgewicht von Ceramid 
nötig ist, um die physiologische TRPC6 Funktion in primären Zellen zu bewahren. Ein Anstieg der 
ASM Aktivität, wie er bei einer MD vorliegt, könnte somit ebenfalls in einer Dysfunktion von 
TRPC6 resultieren. Diese könnte jedoch durch eine Antidepressiva-vermittelte ASM Hemmung 
ausgeglichen werden, indem die physiologische Sphingolipid-Balance wiederhergestellt wird. 
Weitere Experimente mit ASM-transgenen Tieren werden helfen, diese Fragen zu beantworten. 
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Summary 
Recent clinical and murine studies indicated a critical role of the acid sphingomyelinase 
(ASM)/ceramide system in the pathogenesis of major depression (MD) (Kornhuber et al. 2005; 
Gulbins et al. 2013; Rhein et al. 2017). It was shown that the pharmacological antidepressive 
effects of several commonly used antidepressants, as fluoxetine, depend on the functional 
inhibition of ASM (Kornhuber et al. 2011; Gulbins et al. 2013). Further, the amount of ceramide 
molecules in the plasma membrane regulates the clustering of membrane proteins that 
influences signalling via microdomain and lipid raft organization (Zhang et al. 2009; Grassmè, 
Riethmüller, and Gulbins 2007; Stancevic and Kolesnick 2010). TRPC6 ion channels are located in 
the plasma membrane and are crucially involved in synaptic plasticity (Li et al. 2005; Tai et al. 
2008; Leuner et al. 2013). Synaptic plasticity has been shown to be compromised in MD (Duman 
et al. 2016). Therefore the question was, if a dysregulation of the ASM/ceramide system might 
impact the TRPC6 functioning. Since antidepressants induce an inhibition of ASM activity, I 
aimed at investigating their consequences for TRPC6 function. 
I could show that some antidepressants and the direct ASM inhibitor ARC39 inhibited ASM 
activity, but the experimental parameters differed regarding to cell types. The reduction in ASM 
activity also affected TRPC6 biology: antidepressant treatment induced TRPC6 protein 
expression in PC12 cells and rat cortical neurons, and the genetic ablation of ASM in a mouse 
model affected TRPC6 RNA levels in a sex-specific pattern. Inhibition of ASM activity was found 
to impair the TRPC6-mediated Ca2+ influx in PC12 cells and in ASM-deficient cortical mouse 
neurons. Moreover, the TRPC6 downstream effector - activated transcriptional factor phospho-
CREB - was reduced in ASM-deficient and ASM-inhibited neurons. A lipidomic analysis of PC12 
cells, which were inhibited in ASM activity, revealed a decrease in ceramide/sphingomyelin ratio 
in particular for very-long chain sphingolipid species. This affected TRPC6 localisation to lipid 
rafts and non-raft regions at the plasma membrane. Deductively, disturbed localisation of TRPC6 
at the plasma membrane, due to ASM inhibition and subsequent decrease of ceramide levels, 
could serve as a mechanistical explanation for observed impaired TRPC6-mediated Ca2+ influx 
and downstream signalling. 
In summary, the better understanding of the interaction of the ASM/ceramide system and 
TRPC6 will help to draw conclusions for the pathogenesis of this disease. My primary cell data 
together with other previous findings in PC12 (Ye 2015) lead to the hypothesis that a sensitive 
ceramide balance is necessary for proper functioning of TRPC6 in primary cells. It can be 
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speculated that an increase in ASM activity, that was correlated with MD, also results in the 
dysfunction of TRPC6 and could be rescued by antidepressant mediated ASM inhibition via 
restoration of physiological sphingolipid balance. Further experiments with ASM-transgenic 
animals will help to elucidate these questions in the future. 
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2 Introduction 
2.1 Major depression 
There are different types of affective disorders. They can be classified in episodic or recurring 
major depression (= unipolar), mania, bipolar disorder, persistent disorders as dysthymia and 
cyclothymia, and others (World Health Organization 2004). 
Major depression (MD) is a devastating affective disease listed as 11th frequent cause of death 
worldwide for women and 23rd for men (American Psychiatric Association 2013; GBD 2017 DALYs 
and HALE Collaborators 2018). MD is defined as a depressive episode and can be described 
according to the International Statistical Classification of Diseases and Related Health Problems 
(ICD-10, chapter V) (World Health Organization 2004) and/or the Diagnostic and Statistical 
Manual of Mental Disorders (DMS-5) (American Psychiatric Association 2013). Classification into 
specific subgroups can be made according to severity (e.g. mild or severe), duration and course 
(e.g. recurrent), symptom profile (e.g. melancholic or atypical), response to treatment (e.g. 
resistant) and etiology (e.g. endogenous or reactive) (National Collaborating Centre for Mental 
Health (UK) 2010). In general, symptoms can be psychological, behavioural, and physical. A 
depressed episode is present when at least two key feature and two further symptoms occur for 
at least two weeks. Main symptoms include a depressed mood, loss of interest or pleasure in 
most activities which are normally pleasurable and decreased energy or increased fatigue. These 
main symptoms are accompanied by vegetative, cognitive and psychomotor symptoms as sleep 
disturbances, alterations in appetite or weight, attenuated ability to concentrate, psychomotor 
agitation or retardation, feelings of worthlessness or guilt and recurrent thoughts of suicide 
(reviewed in CASSANO AND FAVA 2002 (Cassano and Fava 2002; WHO 1993)). 
The median age of onset of MD is in the early to mid-twenties (Andrade et al. 2003). Accordingly 
to several researchers the 12 month prevalence of suffering from an unipolar depression is 8.1-
10.6 % in women and 3.8-4.8 % in men (Jacobi et al. 2014; Busch et al. 2013). Furthermore, a 
total lifetime prevalence of a diagnosed depression is defined as 11.6 %, while women (15.4 %) 
are again twice more affected than men (7.8 %). Interestingly, the age group with the highest 
12-month prevalence is 50 to 59 years, while the age group with the highest lifetime prevalence 
is 60 to 69 years. In correlation to an increase in socioeconomic status the prevalence of 
diagnosis in women decreases (Busch et al. 2013). 
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The GLOBAL BURDEN OF DISEASE STUDY 2017 shed a light of current research regarding disability-
adjusted life-years (DALY). This is a parameter which quantifies the burden due to specific 
diseases or injuries. For this end, the sums of years which are lost due to this condition are 
compared to an idealised health expectation. MD represented in total 32.800.000 DALYs, which 
means that world-wide women lost 20.100.000 years and men 12.700.000 years due to a poor 
health quality in MD (GBD 2017 DALYs and HALE Collaborators 2018). These findings emphasize 
the devastating character of this mental disease. 
 
 Risk factors for MD 
The development of MD is a multifactorial process connecting psychosocial emotional burden, 
genetic predispositions and biological risk factors. 
Psychosocial parameters contribute to MD. The main factors which show a strong correlation 
with MD are the loss of a beloved person, disability or medical illness, lack of social support, and 
childhood maltreatment. Other factors include refugee status, workplace stressors and obesity. 
Although the exact mechanisms which link psychosocial factors to biological processes in 
depression remain elusive, focus has been put on epigenetic changes, the increased activity in 
the hypothalamic-pituitary-adrenal (HPA) axis and inflammatory response (Coulter et al. 2017). 
The influence of genetic background has been studied in numerous family studies. Heritability of 
MD in general is between 31 % to 42 % (Sullivan 2000) (Sullivan, Neale, and Kendler 2000). 
Environmental factors are discussed to introduce mutations in genes which can be involved for 
instance in monoamine physiology and signalling as the monoamine oxidase A gene (Fan et al. 
2010) or in the system of cortisol response as the glucocorticoid receptor (van Rossum et al. 
2006). Furthermore, epigenetic changes as 5-methylcytosine DNA and histone acetylation are 
discussed to be of importance (Sun, Kennedy, and Nestler 2013; Fraga et al. 2005). Moreover, as 
described in section 2.1 female gender is a risk factor since women are twice more affected than 
men. 
Studies connected the onset of MD with disturbed stress response regulation which relates to 
the HPA system in the human body. Changes in cortisol secretion, regulation of 
adrenocorticotropic hormone and secretion of corticotropin-releasing hormone are present. 
One reason for these finding could be an impairment in corticosteroid receptor signalling 
(Holsboer 2000; Ising et al. 2019). Another protein which is involved in stress signalling is FK506-
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binding protein 51 (FKBP51), which is expressed by the gene FKBP5 that inhibits the 
glucocorticoid receptor. FKBP51 was found to be elevated in blood samples of depressed 
patients, and in turn decreased in patient who responded to antidepressant treatment (Ising et 
al. 2019). 
The secretion and production of proinflammatory cytokines as TNF-α, IL-1β and IL-6 (Yu et al. 
2019) have been shown to be increased under stressed or depressed conditions. Cytokines from 
the periphery could enter the brain via leaky regions in the blood-brain barrier, active transport 
molecules and afferent nerve fibres. Antidepressant drugs can attenuate concentrations of these 
cytokines or even stimulate anti-inflammatory cytokines as IL-10. Moreover, electro-convulsive 
shock therapy and psychotherapy also seems to impact on inflammatory activity (Raison, 
Capuron, and Miller 2006). Remarkably, treatment with anti-TNF-α antibody infliximab, which is 
induced in Crohn’s disease, reduces depression symptoms in these patients (Lichtenstein et al. 
2002). Furthermore, chemokines as CCL2 and CXCL12 seem to be activated in depressed patients 
which is postulated to go along with microglial activation in the brain (Milenkovic et al. 2019). 
Furthermore, dysregulations in levels of small peptides as the brain-derived neurotrophic factors 
(BDNF), vascular endothelial growth factor (VEGF), glial cell line-derived neurotrophic factor 
(GDNF) or the insulin-like growth factor-1 seem to connect to MD. BDNF is a neuropeptide of 
pivotal importance for neuroplasticity. In depressed patients low BDNF levels have been found, 
which in turn could be elevated after antidepressant treatment (Sen, Duman, and Sanacora 
2008). The improvement of patients symptoms, which is represented as changes in depression 
score, correlates with alterations in BDNF level (Brunoni, Lopes, and Fregni 2008). VEGF can 
impact on brain physiology via regulation of both, vascular and neuronal functions. In depression 
it has been postulated that decreased blood flow impacts on supply of hippocampus and 
prefrontal cortex (Newton, Fournier, and Duman 2013). Different studies showed diverging 
results related to VEGF expression under depressed conditions, however most studies 
postulated increased peripheral VEGF levels (Sharma et al. 2016). ELFVING ET AL. reasoned that 
serum levels of VEGF remained constant while VEGF levels in the hippocampus and frontal 
cortex were decreased (Elfving, Plougmann, and Wegener 2010). GDNF acts via activation of 
tyrosine kinase signalling, prevents oxidative and neuro-inflammatory damage and is therefore 
important for survival and maintenance of neurons (Sharma et al. 2016). GDNF blood levels 
seem to be decreased in depressed patients, nevertheless treatment with antidepressants does 
not clearly indicate GDNF increase due to diverging study designs and results (Lin and Tseng 
2015). Another growth factor acting via tyrosine kinase signalling is IGF-1. This peptide binds to 
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the IGF-1 receptor, which modulates neuronal signalling, adult neurogenesis and 
neuroprotection in pro-neuroinflammatory conditions (Sharma et al. 2016; Szczesny et al. 2013). 
Total IGF-1 levels relate to HPA system activity and are increased in serum of depressed patients 
(Weber-Hamann et al. 2009). 
Moreover, the comorbidity with other central and peripheral diseases is postulated to 
contribute to the risk profile. Contrarily to outdated assumptions, generalized and social anxiety 
disorders are not only a consequence of a depressed episode but frequently precede the 
development of a MD. The comorbidity of an anxiety disorder with depression dramatically 
increases the mental burden of the patients (Moffitt et al. 2007; Beesdo et al. 2007). Metabolic 
syndrome (e.g. arterial hypertension, obesity, adverse lipid profile, and glycaemic abnormalities) 
is recurrently associated with depression disorder (Gil et al. 2006; Virtanen et al. 2017; Pan et al. 
2012), in particular visceral obesity occurs in depressed men and an elevated glucose level is 
present in depressed women (Gil et al. 2006). Low HDL cholesterol and high triglyceride levels 
are connected to a delayed recovery of patients (Virtanen et al. 2017). There is a bidirectional 
correlation of MD and metabolic syndrome. As discussed above, a metabolic syndrome is 
postulated to increase the risk of depression. However, in turn, depression increases the risk for 
the development of obesity (Luppino et al. 2010). PAN ET AL. reviewed biological mechanism by 
which depression connects to metabolic syndrome. These authors declare that the underlying 
etiologies of both diseases are quite similar: chronic inflammation, obesity or insulin resistance. 
Furthermore, factors as involvement of the endocrine system connected to HPA axis activity or 
adverse lifestyle parameters (as low physical activity, sleep disturbances, unfavorable nutrition) 
could promote a metabolic syndrome. Moreover, symptoms of metabolic syndrome might favor 
the development of depression disorder as inflammation (TNF-α, CRP, and IL-6), adverse 
glucose-insulin homeostasis or vascular damage (Pan et al. 2012; Nousen, Franco, and Sullivan 
2013). Also, coronary artery disease (CAD) has been shown to correlate with MD. A study of 
KENDLER ET AL. presented the bidirectional relation of MD and CAD. In the same year after the 
onset of CAD, the risk for MD is 3-fold higher, and 2-fold higher in the subsequent year. Vice 
versa, the onset on MD correlates with a 2.5-fold risk for CAD in the same year, and a modest 
risk in the subsequent year (Kupfer, Frank, and Phillips 2012; Kendler et al. 2009). 
In summary, risk factors and etiology of MD are extremely diverse which emphasizes the 
heterogeneity of the patient’s population.  
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 Hypotheses of pathogenesis 
In accordance with the described risk factors scientist formulated hypotheses for the 
pathogenesis of MD. 
The first hypothesis which related to the pathogenesis of MD was the so-called monoamine 
hypothesis and formulated during the 1950s and 1960s. Researchers claimed that a decrease in 
monoamine concentration as serotonin, norepinephrine or dopamine in the synaptic cleft could 
weaken synaptic signalling (Schildkraut 1965). This hypothesis was built on fortuitous findings of 
pharmacological action of drugs which were commonly used during this time and impacted on 
the monoamine concentration in the brain in different ways. Iproniazid was used for the 
treatment of tuberculosis and showed to be an inhibitor for monoamine oxidase, an enzyme 
involved in monoamine metabolism. In a small cohort, this drug exhibited a beneficial effect on 
depressed, deteriorated and regressed patients (Loomer, Saunders, and Kline 1957). Imipramine 
was originally investigated due to its hypnotic-sedative action (Kuhn 1957), nevertheless 
imipramine exhibited antidepressive effects, which was confirmed by the studies of other 
researchers (Lehmann, Cahn, and De Verteuil 1958; Kuhn 1957). LEHMAN ET AL. claimed that both, 
iproniazid as well as imipramine influenced the serotonin system, which therefore must play a 
role for antidepressant effects (Lehmann, Cahn, and De Verteuil 1958). Another fact, also 
speaking for the involvement of the monoamine system in MD, was the finding that patients 
which were treated due to arterial hypertension with rauwolfia serpentina, a herb containing 
reserpine, or its alkaloid reserpine alone, developed depressive episodes during this treatment 
(Lemieux, Davignon, and Genest 1956; Freis 1954). This effect was explained by the action of 
reserpine to deplete monoamines as serotonin or norepinephrine in the brain (Brodie et al. 
1966). Following these findings, the research and development of antidepressant drugs focused 
on molecules which elevated monoamine concentrations at the synapse (see section 2.1.3.2). 
However, as research progressed limitations of the monoamine hypothesis became present. 
Tianeptine is an atypical antidepressant drug which has no monoamine reuptake inhibition 
properties, however in turn rather increases the serotonin reuptake (Mennini, Mocaer, and 
Garattini 1987). Moreover, tianeptine was postulated to be involved in glutamate signalling 
connected to AMPA receptor phosphorylation, which downstream regulates the MEK/MAPK 
pathway (Svenningsson et al. 2007; Qi et al. 2009). Other limitations to the monoamine 
hypothesis relate to the delayed onset of antidepressant action which usually takes two to four 
weeks. This is contrarily to the increase in monoamine concentration in the synaptic cleft which 
is a rapid effect of antidepressant drugs (Fuller 1994). Furthermore, the finding that anti-
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inflammatory treatment showed to be efficient in some cases of depression disorder gave a hint 
to a broader spectrum of depression pathophysiology than the monoamine hypothesis alone. 
As discussed in section 2.1.1. dysregulation of cortisol, the HPA axis and cytokines was found to 
be involved in depression disorder. Multiple different drugs with anti-inflammatory properties as 
nonsteroidal anti-inflammatory drugs, cytokine inhibitors, glucocorticoids, statins, minocycline 
or pioglitazone were in the focus of a meta-analyses of ANDRADE 2019 due to their potential 
antidepressive effects (Andrade 2019). All these drugs, except for pioglitazone, showed 
antidepressive actions. Nevertheless, the author portends that due to study design some studies 
showed limitations and that therefore anti-inflammatory properties alone could not be ascribed 
to antidepressive effects of these drugs (Andrade 2019). 
Especially the delayed onset of antidepressant action moved scientists to discuss impaired 
neurogenesis and insufficiency of neuronal networks and plasticity in the context of MD, since 
these processes demand timeframes of several weeks (Neto et al. 2011). Patients with unipolar 
depression show an atrophy of the hippocampal region (Videbech and Ravnkilde 2004). Other 
regions which appear to be impaired in volume are prefrontal and anterior cingulate cortices, 
and also caudate nucleus and putamen (Bora et al. 2012). In rats treated with cortisol as a model 
of chronic stress, endothelial cell proliferation as maker for angiogenesis was analyzed. 
Angiogenesis was decreased in hippocampus and prefrontal cortex. These effects were rescued 
by environmental enrichment (Ekstrand, Hellsten, and Tingström 2008). Neural stem 
cells/progenitor cells (NSPC) generate new neurons during adult neurogenesis thereby impacting 
on memory formation and learning (Braun and Jessberger 2014). Under psychiatric conditions, it 
has been shown that NSPC activity and survival is attenuated and the integration and maturation 
of newborn neurons in existing networks is impaired (Braun and Jessberger 2014). Several 
reviews evaluated the effect of antidepressants on neurogenesis and synaptic plasticity (D'Sa 
and Duman 2002; Duman et al. 2016). They found that chronic antidepressant treatment 
promotes neurogenesis in the adult hippocampus. The mechanism behind the beneficial 
plasticity and survival modulation most probably was connected to an up-regulation of the cyclic 
adenosine monophosphate (cAMP) and the neurotrophic signalling pathway. This effect involved 
the transcription factor cAMP response element-binding protein (CREB) and the neurotrophic 
growth factor, brain derived-neurotrophic factor (BDNF) (D'Sa and Duman 2002). Interestingly, 
BDNF also strongly connects to synaptic plasticity, here it is required for activity-dependent 
formation and maintenance of synaptic connections. A further key player in synaptic plasticity is 
mTORC1, which also senses regulations in synaptic activity (neurotrophic factor signalling, 
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hormones, metabolism, nutrition and energy) and consequently impacts synaptic protein 
synthesis. Signalling proteins of mTORC1 were found to be reduced after chronic stress in 
rodents and the mTORC1 expression was decreased in prefrontal cortices of MD patients. In 
summary, antidepressant treatment has shown to beneficially modulate synaptic plasticity and 
neurogenesis (Duman et al. 2016). 
However, the lack in neurogenesis cannot fully explain the pathological picture of MD, since 
treatments as sleep deprivation, electroconvulsive therapy or ketamine show beneficial effects 
which are too fast to be explained by neurogenesis, maturation and neuronal network 
integration alone. Therefore, the research in depression pathology is still ongoing. More recent 
hypotheses concerning the development of MD include autophagy or dysregulations in the lipid 
system. 
The role of autophagy in depression and antidepressive action was reviewed by several authors 
(Gassen and Rein 2019; Jia and Le 2015). Autophagy is a process crucial for homeostasis of cells 
(Rubinsztein, Shpilka, and Elazar 2012; Noda and Inagaki 2015). Autophagy can be modulated by 
stress which can be represented as dietary deprivation, hypoxia, reactive oxygen species (ROS), 
DNA damage, protein aggregates, damaged organelles, or intracellular pathogens (Kroemer, 
Mariño, and Levine 2010). In general, the balance in autophagic activity is crucial since an over 
activity is harmful to the cells and shares common pathways with apoptosis (Maiuri et al. 2007). 
Scientists found that nicotine, which induces autophagic response, ameliorated effects which 
can be evident in mice exposed to unpredictable chronic stress or in PC12 cells treated with 
corticosterone. Activation of PI3K/Akt/mTOR signaling is important in this setting (Xiao et al. 
2018). Recently the group of GULBINS ET AL. found that some antidepressant drugs, called 
functional inhibitors of acid sphingomyelinase (FIASMAs), induce autophagy by mediating the 
activity of acid sphingomyelinase (ASM). For this effect the accumulation of sphingomyelin in the 
endoplasmic reticulum is needed. Concomitantly with the blockade of autophagy, the 
antidepressant action is impeded. These findings direct to a new approach on the development 
of antidepressant drugs (Gulbins et al. 2018). 
 
 Pharmacological treatment 
The origin of antidepressant treatment leads back many centuries and is clearly connected to 
phytopharmaceutical applications in early centuries. One of the most well-known herbal 
antidepressants is St. John’s wort. It has been used since medieval times as fuga deamonum for 
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exorcism and for expulsion of ghosts. Later it was described to be used against melancholic 
symptoms (Czygan 2003). Nowadays, the NATIONAL S3-GUIDLINE FOR THE TREATMENT OF UNIPOLAR 
DEPRESSION (VERSION 5) provides recommendations for the pharmacological treatment of unipolar 
depressed patients (DGPPN et al. 2015 [cited: 2019-07-11]). 
 
 Phytopharmaceutical antidepressant hyperforin 
Phytopharmaceutical medication of depression is connected to self-treatment and to doctoral 
prescription (Linden et al. 2008). Nevertheless, the herbal remedy St. John’s wort has proven 
evident for its antidepressant action in multiple studies and meta-analyses for mild to modest 
forms of depression disorder (Linde, Berner, and Kriston 2008). The biological implications of its 
active ingredient hyperforin will be discussed in the following chapter. 
The herb hypericum perforatum L. (Hypericaceae) is commonly known as St. John's Wort and 
the aerial part of this plant has been used for centuries as a medicinal remedy (Czygan 2003). St 
John's wort contains a wide range of biologically active constituents, including flavonoids (e.g. 
rutin, quercetin, and quercitrin), naphthodianthrones (e.g. hypericin) and phloroglucinols (e.g. 
hyperforin (fig. 1)) (reviewed in NAHRSTEDT AND BUTTERWECK (Nahrstedt and Butterweck 1997)). In 
1975 the chemical structure of hyperforin was revealed by Russian scientists (Bystrov et al. 
1975): 
 
Figure 1: Hyperforin 
Hyperforin is the most active ingredient of the herbal remedy St. John’s wort for the treamtent of mild to 
moderate MD. (Structure adapted from ERDELMEIER 1998 (Erdelmeier 1998).) 
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The pharmacological effects of extracts made from St. John’s wort or hyperforin itself have been 
studied intensively over the last decades (partly reviewed in ZANOLI ET AL. (Zanoli 2004)), 
implicating there is a wide range for applications as infection, inflammation, enzyme regulation, 
metabolism and brain disease treatment including depression. 
In the past, St. John’s wort was used for skin wounds or ulcers (Schempp et al. 2002). The 
antimicrobial activity of St. John’s wort has been known for a long time and has been 
investigated amongst others in a recent study by SADDIQE ET AL. against a broad spectrum of 
bacterial and fungal strains. Extracts exhibited potent effects against gram-positive bacteria, and 
hyperforin was the compound to be identified as the antibacterial agent (Saddiqe, Naeem, and 
Maimoona 2010). Further studies described effects of hyperforin on the growth of various 
bacteria including the methicillin-resistant staphylococcus aureus (MRSA) and of yeast candida 
albicans (Schempp et al. 1999).  
In several studies hyperforin exhibited diverse antitumoral and anti-inflammatory effects 
(Lorusso et al. 2009; Schempp et al. 2005; Chiang et al. 2017; Chen et al. 2018). Moreover, it has 
been shown to inhibit sirtuins 1 and 2, which are NAD+-dependent deacetylases involved in gene 
expression and mitosis, respectively (Gey et al. 2007). Besides that, hyperforin showed to be 
involved in apoptosis by triggering the activation of caspases in leukemia K562 and U937 cells 
(Hostanska et al. 2003). CABRELLE ET AL. 2008 found hyperforin to be a potent inhibitor in 
inflammatory response including the attenuation of symptoms in an experimental model for 
autoimmune encephalomyelitis (EAE), which is a Th1-mediated autoimmune disease of the CNS 
(Cabrelle et al. 2008). EAE has also been studied as model for multiple sclerosis, here St. John’s 
wort and hyperforin prevented immune cell infiltration and expansion of Treg cells (Nosratabadi 
et al. 2016). In the context of inflammatory lung fibrosis hyperforin showed beneficial properties 
(Dell'Aica et al. 2007). 
Some enzymes have been studied in particular. Hyperforin controls the activity of prostaglandin 
E2 synthase-1 leading to suppression of prostaglandin E2 synthesis (Koeberle et al. 2011). 
Moreover, this phloroglucinol derivate inhibits cyclooxygenase-1 and 5-lipoxygenase, which are 
important enzymes in production of arachidonic acid derived from eicosanoids (Albert et al. 
2002).  
Hyperforin is also suspected of interfering with co-administrated drugs, since it shows dose-
depending binding properties to pregnane X receptor, which is a nuclear receptor that regulates 
expression of the cytochrome P450 (CYP) 3A4 monooxygenase, and thereby inducing hepatic 
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drug metabolism (Moore et al. 2000; Mueller et al. 2009). Moreover, hyperforin induces the 
transcriptional expression of CYP 2C genes in primary human hepatocytes to increase the 
metabolism of CYP 2C family members, particularly CYP 2C9 (Chen and Goldstein 2009; 
Komoroski et al. 2004). Hyperforin shows no effects on CYP 1A2 or CYP 2D6, which also belong 
to the group of prominent drug-metabolizing enzymes (Komoroski et al. 2004). 
 
St. John’s wort and hyperforin also exhibit effects on cells and processes involved in brain 
function.  
In a study of WANG ET AL. (Wang et al. 2011) hyperforin stimulated the development and function 
of oligodendrocytes and increased mitochondrial function. In reference to microglia, hyperforin 
attenuated activation preventing microglial-mediated neuroinflammation (Lee et al. 2014). In a 
neuronal PC12 cell model hyperforin treatment enhanced the release of secretory fragments of 
amyloid precursor protein (Froestl, Steiner, and Müller 2003). While in a rat model of 
amyloidosis, hyperforin was found to decrease amyloid deposit formation, prevent Aβ-induced 
neurotoxicity and neuropathological changes as well as behavioral impairments. These effects 
were ascribed to a disaggregation property of hyperforin towards amyloid deposits in a dose and 
time-dependent manner and to a decreased Aβ aggregation and amyloid formation (Dinamarca 
et al. 2006). In line with this study BRENN ET AL. showed that St. John’s wort extract (5 % 
hyperforin) promoted P-glycoprotein production which reduced β-amyloid accumulation in male 
APP/PS1(+/-) mice (Brenn et al. 2014). Moreover, in a rat model of stroke hyperforin prevented 
brain damage by inhibition of NMDA-activated calpain-mediated TRPC6 degradation and by 
CREB phosphorylation activation (Lin et al. 2013). 
Intriguingly, various studies have shown that St. John’s wort extracts and hyperforin also relate 
to antidepressive effects and alcohol drinking (Gambarana et al. 1999; De Vry et al. 1999; 
Butterweck et al. 1997; Perfumi et al. 2005). These effects strongly correlated with hyperforin 
content of extracts implicating hyperforin as the effective principle (Wright et al. 2003; 
Chatterjee et al. 1998). PANOCKA ET AL. suggested that the antidepressant-like effect of herbal 
extract (0.3% hypericin, 3.8% hyperforin) found in forced swim test (FST) was connected to an 
interaction with sigma receptors and also to some extent by increased serotonergic 
neurotransmission (Panocka et al. 2000). The increase in the number of both 5-HT1A and 5-HT2A 
receptors by 50 % was another molecular finding connected to long term application of St. 
John’s extracts. This phenomenon was consistent with effects of synthetic antidepressants, 
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leading to modifications of the expression levels of serotonergic receptors (Teufel-Mayer and 
Gleitz 1997). In another study, the subchronic treatment of rats with herbal extracts induced on 
the one hand a down-regulation of β-receptors and on the other hand an up-regulation of 5-HT2-
receptors in the frontal cortex (Müller et al. 1997). A hyperforin-enriched (38 %) CO2 extract also 
lead to a significant β-receptor down-regulation after subchronic treatment (Müller et al. 1998). 
Researchers discussed that regulation of receptors like 5-HT1A and 5-HT2A, α-adrenergic and D1 
by constituents of St. John’s wort could account for prepulse inhibition disruption (Tadros et al. 
2009). The study of MÜLLER ET AL. (Müller et al. 1997) also revealed St. John’s wort extracts to 
inhibit MAO-A and MAO-B activity only in a weak manner, but to prevent the synaptosomal 
uptake of neurotransmitters like serotonin (5-HT), dopamine and norepinephrine with about 
equal affinity (2 µg/ml) (Müller et al. 1997). In synaptosomal preparations hyperforin showed to 
be a potent monoamine uptake inhibitor with IC50 values of about 0.05 - 0.10 µg/ml for 
serotonin (5-HT), dopamine, noradrenaline, GABA and IC50 0.5 µg/ml for L-glutamate (Chatterjee 
et al. 1998). In line with described biochemical findings and animal studies, meta-analyses of 
clinical trials including MD patients described St. John’s wort to be effective for mild-to 
moderate depressive conditions. It exerted comparable antidepressive effects with commonly 
used antidepressants as selective serotonin reuptake inhibitors (SSRIs) and further it displayed a 
similar therapeutic safety. In some cases, the rate of side effects under St. John’s wort treatment 
was even reduced compared with classical antidepressants. Interestingly the dropout rate from 
studies of patients treated with St. John’s wort was also significant lower compared with SSRIs 
(Ng, Venkatanarayanan, and Ho 2017; Linde, Berner, and Kriston 2008; Apaydin et al. 2016). 
This nonselective profile of hyperforin with regard to neurotransmitters indicated that 
hyperforin binds not directly to transporters like other antidepressants. However, authors 
suggested it might rather mediate its antidepressant effect in a non-specific manner as inhibition 
of Na+ gradient which is needed for monoamine reuptake of monoamine-transporters 
(Malandro and Kilberg 1996). Moreover, hyperforin showed to impact on ionic conductance 
since it blocked partially voltage gated and ligand gated ionic molecules like AMPA or NMDA 
receptor in purkinje, cortical and hippocampal neurons (Chatterjee et al. 1999; Fisunov et al. 
2000; Kumar et al. 2006). Finally, findings of TREIBER ET AL. 2005 suggested hyperforin to activate 
non selective cation channels, increasing both Na+ and free intracellular Ca2+ concentrations 
(Treiber et al. 2005). 
Most importantly and in line with TREIBER ET AL. 2005, LEUNER ET AL. revealed hyperforin to be a 
TRPC6 channel activator in 2007, which is nowadays known as the antidepressive principle of 
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hyperforin (Leuner et al. 2007). Hyperforin exhibited modulating effects in ion channel 
recordings, induced internal Ca2+ concentrations and neurite outgrowth, modulated spine 
morphology in a beneficious manner, contributed to neuroprotection and inhibited uptake of 
monoamines (Lin et al. 2013; Leuner et al. 2010; Leuner et al. 2013). Downstream to TRPC6 
activation by hyperforin, Ca2+ influx induced calmodulin conformational changes (Klee et al. 
1986; Farnsworth et al. 1995), leading to the activation of Ras/MEK/ERK, Ras/PI3K/Akt and 
Ca2+/calmodulin-dependent kinase IV (CaMK IV), and subsequently to the phosphorylation and 
activation of cAMP response-element binding protein (CREB). This transcriptional factor induced 
the expression of the brain-derived neurotrophic factor (BDNF)-receptor tropomyosin receptor 
kinase B (Trk B) and TRPC6 (Gibon et al. 2013; Heiser et al. 2013). Furthermore, in CA1 and CA3 
pyramidal neurons of rats, hyperforin simulated effects of BDNF (Leuner et al. 2013). 
 
 Common synthetical antidepressant drugs 
According to their pharmacological action profile, common synthetical antidepressant drugs can 
be divided into subgroups as non-selective monoamine reuptake inhibitors, selective serotonin 
reuptake inhibitors (SSRI), dual serotonin and noradrenalin reuptake inhibitors (SNRI), 
monoamine oxidase inhibitors (MAO) and other substances. Furthermore, specific drugs can be 
used for an augmentation of the antidepressant treatment. These drugs will not be further 
discussed in this underlying thesis (DGPPN et al. 2015 [cited: 2019-07-11]).  
Non-selective monoamine reuptake inhibitors are also called “TCA” in respect to their chemical 
structure (tri- or some tetracyclic antidepressants). Members of this group are represented for 
instance by amitriptyline, doxepin, imipramine or nortriptyline. TCA antidepressants are further 
suggested as “dirty drugs” due to their unspecific binding properties (Wong, Nikam, and Shahid 
2008). They prevent the reuptake of neurotransmitters out of the synaptic cleft by inhibition of 
serotonin- and noradrenalin-reuptake transporters. Moreover, these drugs show antagonistic 
effects on histamine 1 receptors (H1), α1 adrenergic receptors or cholinergic receptors. This 
unspecific profile serves as an explanation for multiple side effects (Müller and Eckert 2016; 
DGPPN et al. 2015 [cited: 2019-07-11]; Arroll et al. 2005). 
Selective serotonin reuptake inhibitors are for example sertraline, fluoxetine, citalopram or 
escitalopram. This class is the first choice for the pharmacological treatment of a depression 
episode. Like tricyclic antidepressants, SSRIs also inhibit serotonin reuptake transporters which 
results in an increase in serotonin in the synaptic cleft. Therefore, side effects related to SSRIs 
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mainly connect to an increase of serotonin and serotonin transporter inhibition also in other 
body compartments (DGPPN et al. 2015 [cited: 2019-07-11]; Arroll et al. 2005). 
The small group of dual serotonin and noradrenalin reuptake inhibitors is made up of 
venlafaxine and duloxetine. These drugs inhibit serotonin and noradrenalin reuptake 
transporters and in accordance with this, they show serotonin and noradrenalin related side 
effects (DGPPN et al. 2015 [cited: 2019-07-11]). Studies showed that venlafaxine might be more 
effective than SSRIs (Anderson 2001). 
The class of monoamine oxidase inhibitors includes tranylcypromine and moclobemide and 
interferes with the metabolism of neurotransmitters. They show similar antidepressant effects 
compared to TCA (Anderson 2001). Tranylcypromine inhibits both, the MAO-A and MAO-B. That 
is why, patient who are taking this drug have a strict diet towards tyramine, since otherwise a 
hypertensive crisis might occur. Moclobemide is a selective MAO-A inhibitor and has therefore a 
lower potential for side effects (DGPPN et al. 2015 [cited: 2019-07-11]; Anderson 2001). 
Further substances are used for the treatment of unipolar depression which cannot be classified 
accordingly to established groups of antidepressants. Bupropion is a dual noradrenalin and 
dopamine reuptake inhibitor. It has been shown to exert high tolerability with fewer side effects 
compared to other drugs and might be especially suited for patients with problems in weight 
gain or sexual function (DGPPN et al. 2015 [cited: 2019-07-11]; Patel et al. 2016). Mirtazapine 
blocks postsynaptically 5-HT receptors and presynaptic adrenergic autoreceptor α2R, and has 
been widely used due to its sedative effects or less potential for sexual dysfunctions (Dolder, 
Nelson, and Iler 2012). Similar to Mirtazapine, Minanserin blocks presynaptic autoreceptor α2R, 
but additionally α1R (DGPPN et al. 2015 [cited: 2019-07-11]). Agomelatine is a melatonin agonist 
(MT1/MT2) and has therefore, additionally to its antidepressive effects, a positive modulatory 
action towards re-establishment of a healthy sleep rhythm. Furthermore, it blocks 5-HT2c 
receptors (Fuchs, Simon, and Schmelting 2006; DGPPN et al. 2015 [cited: 2019-07-11]). 
Tianeptine is an atypical drug within the group of antidepressants. It induces serotonin reuptake 
and regulates glutamate signalling (Mennini, Mocaer, and Garattini 1987; Svenningsson et al. 
2007). A drug which is recently in the focus of investigation is ketamine. Ketamine exerts rapid 
depression symptom elevation, which might be regulated by growth factor release mediated by 
remodeling of the glutamatergic system (Duman 2014). 
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 Several antidepressants inhibit acid 
sphingomyelinase activity 
Acid Sphingomyelinase (ASM) is a sphingomyelin phosphodiesterase involved in the sphingolipid 
metabolism, which degradates sphingomyelin into phosphorylcholine and ceramide (Schneider 
and Kennedy 1967). 
ASM was first related to tricyclic antidepressants by ALBOUZ ET AL. in 1981 (Albouz et al. 1981). 
They found that incubation of murine neuroblastoma and fibroblast cell cultures with 
imipramine or desipramine for 1 h to 2 h inhibited ASM activity (Albouz et al. 1981). During the 
last decades further drugs were found to inhibit the ASM functionally, these drugs were 
therefore called functional inhibitors of the ASM (FIASMA) (Kornhuber et al. 2008; Kornhuber et 
al. 2011). The action of FIASMAs is described as “indirect”, since they do not inhibit the enzyme 
directly at the catalytic center but rather promote the enzyme’s degradation. FIASMAs are weak 
bases which can diffuse the plasma membrane and the lysosomal membrane. As soon as they 
are exposed to the low pH in the lysosomes, these molecules become protonated and are 
subsequently trapped in this compartment. Due to their positive charge, which is a hindrance for 
further diffusion, they cannot leave the lysosome anymore. In the lysosome FIASMAs interact 
with L-ASM which catalyzes under normal conditions the degradation of sphingomyelin to 
ceramide, while it is electrostatically attached to the inner membrane of the lysosome. An 
electrostatically interaction of FIASMA and ASM leads to the detachment of ASM from the 
membrane and promotes degradation of the enzyme. Therefore the enzyme is inhibited 
functionally (mechanism described in detail by KORNHUBER ET AL 2008 (Kornhuber et al. 2008).  
In 2005 KORNHUBER ET AL. found that ASM activity of blood mononuclear cells were elevated in 
depressed patients compared with healthy controls and the enzyme activity correlated with the 
severity of symptoms. The treatment with FIASMAs reduced ASM activity in a cell culture model. 
(Kornhuber et al. 2005). In a next step, the increase in ASM activity in depressed behaviour was 
investigated in an animal model. Here the findings of KORNHUBER ET AL. 2005 were confirmed. A 
study of GULBINS ET AL. displayed that the antidepressive action of commonly used drugs for the 
treatment of MD (as amitriptyline or fluoxetine) depended on ASM inhibition (Gulbins et al. 
2013). In summary, these drugs decreased the levels of ceramide in the hippocampus, which 
turned out to be the biological mechanism for antidepressive effects. The subsequent treatment 
with FIASMAs increased neuronal proliferation, maturation, survival and improved behaviour. 
Another approach led to an artificial abundance of ceramide in hippocampus due to genetic 
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modifications of animals or direct injection of ceramide 16 into the hippocampus. Neuronal 
proliferation, maturation, survival was impaired (Gulbins et al. 2013). Furthermore, these 
animals which overexpressed ASM activity showed depression-like behaviour, which was 
rescued by the application of FIASMAs. Animals lacking ASM in turn showed exaggerated 
induced behaviour, illustrating that an ASM balance could be crucial for brain physiology 
especially in the context of MD (Gulbins et al. 2013). The ASM/ceramide system related 
hypothesis of the pathogenesis of MD derived from these observations. According to KORNHUBER 
ET AL. MD can be described as “ceramidose” which links central and peripheral symptoms in MD 
(Kornhuber et al. 2014). Pro-inflammatory cytokines as TNF-α and ROS stimulate ASM activity, 
while ROS are induced by ceramide itself. The dysregulation of the HPA axis could be correlated 
to ceramide-promoted hippocampal atrophy. Hippocampal atrophy could disturb the control on 
the HPA. This might lead to the elevation of serum cortisol levels and to the decrease of 
serotonin levels in the CNS. Furthermore, ceramide-induced pro-inflammatory cytokines of the 
periphery impact on CNS monoamine levels in the brain. As described in section 2.1.1, metabolic 
syndrome is linked to MD, this status could also relate to an abundance of ceramide (reviewed 
by KORNHUBER ET AL. 2014 (Kornhuber et al. 2014). This suggests ceramide as a key player in the 
pathogenesis of MD. 
In summary, the remarkable investigation that some of the commonly used antidepressants 
inhibit ASM activity, together with the new finding that ASM was increased in depressed patient 
highlighted a new approach for depression pathogenesis. The assumption could be made that a 
dysregulated ASM activity might be rebalance by the administration of antidepressants 
(Kornhuber et al. 2008; Kornhuber et al. 2005). Intriguingly, the sphingolipid system, including 
sphingomyelin and ceramide, could provide a model which is able of connecting the observed 
central and peripheral symptoms of this disease (Kornhuber et al. 2014).  
 
2.2 Sphingolipids in health and disease 
In 2005 the International Lipid Classification and Nomenclature Committee (ILCNC) developed a 
“Comprehensive Classification System for Lipids”. According to hydrophilic and hydrophobic 
elements of each lipid, eight lipid classes were established: fatty acyls, glycerolipids, 
glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids, and polyketides 
(Fahy et al. 2009; Fahy et al. 2005). The lipid classes which are mostly present at eukoryontic cell 
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membranes are glycerolipids, sterols and sphingolipids (reviewed in LAHIRI AND FUTERMAN (Lahiri 
and Futerman 2007)). 
 
 The sphingolipid system 
Lipids as sphingolipids have first been described as membrane components (Singer and Nicolson 
1972). Intriguingly, later scientists have found some sphingolipids beeing bioactive as signalling 
molecules involved in the formation of rafts, caveolae, cytosolic or extracellular vesicles 
(Stuermer 2011; Goñi and Alonso 2002; Verderio, Gabrielli, and Giussani 2018) and the 
interaction with extracellular matrix and neighbouring cells (Baron et al. 2014; Shigetomi et al. 
2018; Guillaume et al. 2013). The sphingolipidome homeostasis includes the balancing of 
biosynthesis, degradation, recycling, and processes that introduce exogenous sphingolipids to 
cells or remove them (Merrill 2011). 
 
 Sphingolipid physiology and the sphingolipid rheostat 
Ceramide, ceramide-1-phosphate (C1P), sphingosine and sphingosine-1-phosphate (S1P) are 
important representatives of sphingolipids according to their high impact on cell function 
(Hannun and Obeid 2008). 
Sphingolipids can be linked to different classes according to their physicochemical properties. 
Charged sphingolipids with two hydrophobic moieties (as C1P) mostly reside in their 
compartment of generation in membranes. Sphingolipids with two hydrophobic moieties and 
without charge (as ceramide) are also localised to their site of generation, but are able to flip-
flop across membranes (López-Montero et al. 2005). Sphingolipids as sphingosine, carry only one 
hydrophobic moiety and are therefore partly soluble to the cytoplasm. The overall divergent 
sphingolipid localisation within the cell already emphasises the understanding that sphingosine, 
ceramide, S1P and C1P exert highly diverse characteristics according to their cellular functions 
(reviewed in Hannun and Obeid 2008 (Hannun and Obeid 2008)). 
 
Ceramide has a role in apoptosis (Obeid et al. 1993) and senescence (Venable et al. 1995). 
Further, it is involved in stress and apoptotic stimuli singnaling including CD95, CD40, DR5/TRAIL, 
FcγRII, CD5, LFA-1, CD28, TNFα, interleukin-1 receptor, pAF-receptor, infections with different 
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strains auf bacteria and virus, irradiation, UV-light, Cu2+ and some cytostatic drugs (reviewed in 
JERNIGAN ET AL. 2015 (Jernigan et al. 2015)). Ceramide conducts its regulatory effects via lipid raft 
modulation (see section 2.2.3) or direct protein interaction. For the latter, ceramide is involved 
in apoptotic processes and early inflammatory cytokine action as caspase-9 and -3 activiation via 
Bid and cathepsin D (Heinrich et al. 2004), Bad activation via the kinase supressor of Ras (KSR) 
and the Ras/Raf pathway (Basu et al. 1998), phosphorylation of n-type potassium channel Kv1.3 
during FAS induced cell death (Gulbins et al. 1997), mitophagy via LC3B (Sentelle et al. 2012), 
arachidonic acid release via PLA2 (Huwiler et al. 2001), and phosphorylation by protein kinase C 
zeta (PKCζ) (Müller et al. 1995).  
Intriguingly, not every single species of the group of ceramides exerts the same biological effect. 
Researches claimed that long chain ceramide species rather show pro-inflammatory and pro-
apoptotic effects compared to very-long chain ceramides which mostly relate to anti-
inflammatory and pro-survival processes. Multiple studies revealed long chain ceramides as 
Cer16, Cer18, Cer20 to inhibt tumor growth and cell proliferation and induce inflammation, 
mitochondrial damage and apoptosis (Koybasi et al. 2004; Mercker, Hartmann, and Marciniak-
Czochra 2013; Stiban and Perera 2015; Siskind et al. 2010; Garić et al. 2017), whereby very-long 
chain ceramides as Cer24, Cer24:1 promote cell survival and anti-inflammatory effects (Mercker, 
Hartmann, and Marciniak-Czochra 2013; Garić et al. 2017). Moreover, Cer24 is postulated to 
partially inhibit Cer16 promoted mitochondria-mediated apoptosis by stabilising the 
mitochondrial permebilization effect of Cer16, which revealed an inter-ceramide regulation 
pattern (Stiban and Perera 2015). In an inflammatory setting, as cystic fibrosis, long chain 
cermides are elevated, while very-long chain species are decreased. Treatment with fenretinide, 
an antineoplastic and chemopreventive agent, inverted the relation of long to very-long chain 
ceramides (Garić et al. 2017). However, the sterotypes of long chain ceramides as pro-apoptotic 
and very-long chain as pro-survival do not persist throughout all studies. Unexpectatly, Cer16 
was found to rescue carcinoma cells from ER stress and apoptosis, while “the longer-chain” 
Cer18 inhibited tumor growth (Senkal et al. 2010). Furthermore, elevated levels of Cer24:1 in 
extracellular vesicles were connected to aging and senecense (Khayrullin et al. 2019).  
S1P bioactive properties completely differ from ceramide action. S1P exert a role in enhanced 
cell survival, angiogenesis, cell migration (as metastasis) and immune response (Hla 2004; 
Beesdo et al. 2007; Spiegel and Milstien 2003; Newton et al. 2015). S1P seems to impact the 
immune cell migration closely related to its enrichment in the blood and lymph circulation, and 
gradient towards the tissue (Yanagida and Hla 2017). S1P also has been shown to play a major 
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role in sepsis and in breakdown of blood brain barrier function (Vutukuri et al. 2018). S1P binds 
to G-protein coupled receptors (S1PR1-5) at the plasma membrane where several S1PRs activate 
then the pro-survival signalling pathway connected to ERK and Akt. Furthermore, S1P is also an 
intracellular second messenger (Spiegel and Milstien 2003; Rosen et al. 2013). According to their 
opposed characters, ceramide and S1P can be described as “opponents”. This description 
becomes clearer, when considering for instance autophagy and autophagic death. Lipidomic 
analyses revealed that for complex processes as autophagy not one lipid species contributes to 
essential processes but rather an ensemble of sphingolipids, since they have temporal and 
spatial synergistic effects. (Zheng et al. 2006). Elevated ceramide and dihydroceramide levels 
have been connected to autophagosome formation with later cathepsin release, caspase 
activation and subsequent cell death. However and remarkably, the concomitant generation of 
S1P facilitates cell survival and inhibits autophagic death (Zheng et al. 2006). In the context of 
cell growth these opposing effects of ceramide and S1P can be further described. Ceramide 
induces cell cycle arrest and cell death, while S1P promotes cell proliferation and survival. This 
concept has been widely investigated in terms of cancer and cancer therapy (Newton et al. 
2015). The balance between ceramide and S1P levels in the cell and their regulatory effects 
seems to determine the cell’s fate (Cuvillier et al. 1996). By sphingolipid scientist this 
phenomenon is called “the sphingolipid rheostat” (Newton et al. 2015). 
Further important representatives of sphingolipids are sphingosine and C1P. Sphingosine 
induces cell cycle arrest and apoptosis via PKC inhibition (Smith et al. 2000). C1P is another 
phosphorylated sphingolipid and is found to be involved in inflammation (Chalfant and Spiegel 
2005; Mitsutake et al. 2004) and more precisely in phagocytosis, inflammasome activation as 
well as pro-inflammatory eicosanoid production (Mishra et al. 2018; Hinkovska-Galcheva et al. 
2005). Moreover, C1P regulates autophagy (Mishra et al. 2018). 
 
Taken together, sphingolipids and their enzymes are highly inter-connected via their 
metabolism, meaning that dysreagulation of one sphingolipid or enzyme could also affect 
others. This is especially pronounced by the fact that sphinomyelin is way more enriched in cells 
compared to ceramide, which means that already a minor increase in sphingomyelin 
degradation to ceramide could induce high abundance of ceramide. Equally to this, sphingosine 
and S1P show lower levels as ceramide, and therefore an induced ceramide degradation could 
introduce major alterations of sphingosine and S1P levels (Hannun and Obeid 2008). In summary 
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it can be postulated that cell fate is highly dependend on metabolic sphingolipidome regulation 
and further on the specified action of specific sphingolipid species. 
 
 The sphingolipid metabolism 
Sphingosine (C18H37O2N, 2-Amino-1,3-dihydroxy-4-trans-octadecen) represents the backbone of 
all sphingolipids. Ceramide is generated via N-acetylation of sphingosine. Fatty acids for N-
acetylation are usually unsaturated, nevertheless very-long fatty acids partially contain double 
bonds (as Cer24:1). The hydroxyl function at the C-1 position of ceramide can interact with 
phosphorylcholine to produce sphingomyelin, or interact with specific sugars (as glucose or 
galactose) to form gluco- and galactosphingolipids (reviewed in LAHIRI AND FUTERMAN (Lahiri and 
Futerman 2007)).  
 
Figure 2: C16-sphingomyelin (C16-SM) 
Sphingosine-, ceramide- and phosphorylcholine-moieties are marked in frames: dotted line (big dots) = 
sphingomyelin, continious line = ceramide, dotted line (small dots) = sphingosine, dots and lines = 
phosphorylcholine. 
 
The different pathways in the sphingolipid system which converge into the production of 
ceramide have been widely reviewed (Lahiri and Futerman 2007; Li et al. 2014). The single 
activity of one of these pathways underlies strict specific regulation patterns (Becker et al. 2005). 
In general, non-sphingolipid molecules can entrance the sphingolipid pathway via the de novo 
synthesis and exit via the degradation of S1P into its non-sphingolipid breakdown products. 
Sphingolipids can be converted into other sphingolipid species by a complex set of enzymes. 
 Introduction 
48 
Nevertheless, the central molecule in the whole pathways is represented by ceramide (Hannun 
and Obeid 2008). 
First, ceramide can be formed by de novo synthesis at the cytosolic leaflet of the endoplasmatic 
reticulum (ER) (fig. 4 I) (Michel and van Echten-Deckert 1997). Serine palmeotyltransferase 
catalyses the condensation of L-Serine and palmitoyl-CoA to form 3-keto-sphinganine. The keto 
function of 3-ketosphinganine is reduced by 3-ketosphinganine reductase to sphinganine (= 
dihydrosphingosine). Under the action of ceramide synthase and acyl-CoA, dihydroceramide is 
formed. Finally, dihydroceramide destaurase oxidizes C4 - C5 to form a double bond and 
generate ceramide (Hanada 2003; Pewzner-Jung, Ben-Dor, and Futerman 2006). Second, 
ceramide can be gererated during the salvage pathway of sphingosine via ceramide synthase 
and acyl-CoA or via reverse activity of ceramidase (fig. 4 II) (Okino et al. 2003; Becker et al. 
2005). Third, ceramide can be generated by the degradation of sphingomyelin via 
sphingomelinases (fig. 4 IIIa) (see section 2.2.2). Ceramide can be further formed by the 
degradation of complex glucosphingolipids of the plasma membrane as galactosylceramide by β-
galactosidase, or as glucosylceramide by β-glucosylceramidase (GBA) at the plasma membrane 
(GBA2) or lysosome (GBA1) or in the cytosol (fig. 4 IIIb) (Ishibashi et al. 2007; Massimo et al. 
2016; Aureli et al. 2011). 
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Figure 3: Pathways of ceramide (Cer16) formation 
There are three different main pathways in the sphingolipid system which converge into the production of 
ceramide: the de novo synthesis (I), the salvage pathway (II) and the degradation pathway of 
sphingomyelin and complex sphingolipids (IIIa and IIIb) (Lahiri and Futerman 2007, Li, Li et al. 2014). 
 
Ceramide can be further processed to numerous products. There are four main pathways.  
Ceramide kinase induces a phosphorylation at the C-1 position of ceramide to form ceramide-1-
phosphate (C1P) (fig. 5 I). The localisation of the enzyme is not fully clear and could be the 
plasma membrane (PM), Golgi apparatus and cytoplasm (Van Overloop, Gijsbers, and Van 
Veldhoven 2006; Mitsutake et al. 2004; Carrè et al. 2004). Ceramidase deacetylates ceramide to 
form sphingosine (fig. 5 II). Different ceramidase species reside at subcellular localisations of the 
cell depending on their pH optima for catalytic activity. Acid ceramidase can be found at the 
endosome and/or lysosome (Bernardo et al. 1995). Neutral ceramidase resides at the PM. It has 
also been reported to localise to the mitochondria, however this seems to be different across 
species and cell lines (Hwang et al. 2005). Alkaline ceramidase localises to the ER and Golgi 
apparatus and primarilly degradates very-long chain ceramides as Cer24:1. It also shows major 
impact on sphingosine and S1P regulation (Mao et al. 2003; Xu et al. 2006). Sphingosine can be 
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further processed by sphingosine kinase-1 to form SP1 at the PM, ER and at high kinase levels in 
the cytosol. These enzymes are rapidly shuttled between compartments (Siow et al. 2011). 
Sphingosine kinase-2 generates S1P in the nucleus, impacting for instance on histone acetylation 
(Song, Zhou, and Sheng 2018). For the SM synsthesis out of ceramide, ceramide transport 
protein (CERT) transfers ceramide (Cer16 - Cer20) which is generated at the ER to the Golgi 
apparatus (fig. 5 III) (Hanada 2006). Sphingomyelin synthase-1 or -2 (SMS1, or SMS2) catalyzes 
the condensation of phosphatidylcholine and ceramide at the Golgi apperatus (SMS1) or plasma 
membrane (SMS2) thereby producing SM and diacylglycerol (DAG) (Futerman et al. 1990; 
Pagano 1988; Tafesse, Ternes, and Holthuis 2006; Huitema et al. 2004). A fourth pathway 
describes the production of high complex sphingolipids. Ceramide can be glycosylated with 
galactose at the ER to form galactosylceramide (GalCer) by ceramide galactosyltransferase (fig. 5 
IVa) (Sprong et al. 1998; Sprong et al. 2003). Moreover, ceramide can by glycosylated with 
glucose by glucosylceramide synthase at the Golgi apparatus to form glucosylceramide (GlcCer) 
(fig. 5 IVb) (Jeckel et al. 1992; Marks et al. 1999). GlcCer can be further galactosylated to form 
lactosylceramide (LacCer), while complex gangliosides are further processed from LacCer by a 
series of glycosyl- and sialyl -transfers. The nomenclature of gangliosides is as follows: G (= 
ganglioside), M/D/T/Q (= mono-/di-/tri-/tetra; number of sialic acid residues), “number” (= 
3>2>1, migration order of the gangliosides on thin layer chromatography). According to further 
sialic acid residues at the inner residue of additional galactose, letters are introduced “asialo, a, 
b and c” (Palmano et al. 2015). 
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Figure 4: Pathway for ceramide (C16) derived sphingolipids 
Ceramide can be further processed via four pathways: formation of phosphorylated derivatives as C1P (I) 
or via sphingosine to S1P (II), the gerneration of sphingomyelin (III) and the production of sugar-bound 
and highly complex sphinglipids (IVa and IVb). 
 
Ceramide, which is needed for the generation of glucosylceramide (as represented in fig. 5 IVb), 
is transfered to the Golgi apparatus via a CERT independent machanism (Hanada et al. 2003). 
Human 4-phosphate adaptor protein 2 (FAPP2) is another transporter, which is essential for the 
trafficking of sphingolipids to the trans-Golgi compartment for complex carbohydrate residue 
formation (Ochoa-Lizarralde et al. 2018). Furthermore, FAPP2 regulated also the sphingolipid 
vesicular transfer from Golgi apparatus to the plasma membrane (D'Angelo, Rega, and De 
Matteis 2012). While vesicular transport facilitates the usual sphingolipid supply at the cell 
surface, C1P-specific transfer protein (CPTP) is responsible for the trafficking of C1P (Maceyka 
and Spiegel 2014; Mishra et al. 2018). 
The balance of metabolic fate of ceramide can be further controlled by heteromeric 
complexation of enzymes which are involved in sphingolipid metabolism, therefore promoting 
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the catalytic activity of mainly one of the interaction partners while suppressing the others 
(Hayashi et al. 2018). 
 
 The role of sphingolipids in the central nervous system 
Sphingolipids are highly regulated during the life span of a human beeing, from the embryonic 
stage until adulthood and aging (for a review see OLSEN AND FÆRGEMAN 2017 (Olsen and 
Færgeman 2017)). On the one hand, gangliosides are pivotal factors in brain development, in 
particular for neurons. Different sphingolipid species show specific expression patterns, 
according to individual developmental stage and importantly play a role during dendrite 
arborization, outgrowth of axons and synaptogenesis (Svennerholm et al. 1989). On the other 
hand, galactosylceramides and sphingomyelin are precisely elevated during the oligodendrocyte-
mediated formation of myelin sheads (Pfeiffer, Warrington, and Bansal 1993). Very-long chain 
ceramides Cer22 and Cer24, together with their metabolic GalCer products, also contribute to 
myelin stability in the brain (Ben-David et al. 2011). Moreover, OLSEN AND FÆRGEMAN 2017 
summarized multiple studies, which revealed Cer18 to be the dominating ceramide species 
found in the grey matter (neuronal bodies) of the brain, while Cer24 appeared prominent in the 
white matter (axons and glial cells) (Olsen and Færgeman 2017). In summary and as already 
described in the preceding and successive chapters, sphingolipids highly impact on neuronal and 
glial cell function in a direct way or via die formation of microdomains or rafts, and are therefore 
crucial regulators in brain physiology and disease. 
 
 Sphingolipid-related genetic diseases 
There are several pathological conditions associated with defects in the sphingolipid metabolism 
(Moskot et al. 2018). Diseases connected to gangliosides represent gangliosidosis 1, Tay-Sachs 
disease, Sandhoff disease, gangliosidosis 2 AB-variant or ganglioside GM3 synthase deficiency. 
These ganglioside-related diseases correlate with a devastating progressing phenotype in infants 
and mostly affecting the central nervous system. Other sphingolipid diseases linked with defects 
and mutations in the metabolism of high complex carbohydrate-ceramides are sialidosis, Fabry 
disease, Gaucher disease and Krabbe disease. An affected ceramide metabolism can associate 
with Farber disease, which relates to the deficiency of acid ceramidase resulting in ceramide 
accumulation in the lysosome. However, most interestingly due to its broad implications to 
other conditions, is Niemann-Pick disease (NPD). NPD causes dysfunction of lysosomal storage 
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due to modulation in cholesterol or sphingomyelin levels. While NPD type C correlates with 
defects in cholesterol trafficking (Vanier 2010), NPD type A and B result from sphingomyelin 
accumulation due to deficient or impaired function of the enzyme ASM which usually catalyzes 
sphingomyeline degradation in the lysosome (Brady et al. 1966; Schuchman and Wasserstein 
2015). Features of NPD type A and B will be discussed in section 2.2.2.2. 
 
 ASM 
In general, there are three different types of sphingomyelinases in the mammalian cell 
depending on their catalytical activity at a specific pH: ASM, neutral sphingomyelinase and 
alkaline sphingomyelinase (Goñi and Alonso 2002). This study will predominantly focus on ASM. 
Four genes coding for sphingomyelin phosphodiesterase have been identified (SMPD 1–4). 
SMPD1, which codes for ASM, and SMPD3, which codes for neutral sphingomelinase (nSMase2). 
SMPD2 codes for nSMase and SMPD4 codes for nSMase3. ASM degradates sphingomyelin to 
ceramide mostly at the inner leafelet of the lysosome, while neutral sphingomyelinases reside at 
the outer cytosolic site of intracellular vesicles. nSMase is expressed ubiquitously, while 
nSMase2 can be found predominantly in neurons (Stoffel et al. 2005) and nSMase3 majorily in 
muscel cells (Moylan et al. 2014). Alkaline sphingomyelianse (NPP7) is encoded by ENPP7 and 
does not share structuar similiarities with other sphingomyelinases, it rather belongs to the 
nucleotide pyrophosphatase/phosphodiesterase family (Gorelik et al. 2017). It resides at the 
intestine intestinal lumen and the mucosal membrane where it digests sphingomyelin (Duan 
2006). 
 
 ASM physiology and regulation of ASM 
ASM (EC 3.1.4.12, Smpd1, optimum pH 5.0) is a sphingomyelin phosphodiesterase, which 
catalyzes the cleavage of sphingomyelin into phosphorylcholine and ceramide (Schneider and 
Kennedy 1967). At present, three different forms of ASM are known. First, lysosomal ASM (L-
ASM) usually localises to lysosomes and can be translocated to microdomains at the 
extracellular side of plasma membranes due to specific stimuli as CD95 or TNF-α (Grassmè et al. 
2001). Here it has great impact on the signalling of plasma membrane located molecules 
(Grassmè et al. 2001). Furthermore, this species has been found residing on extracellular 
particels impacting on multiple functions of distant cells (Verderio, Gabrielli, and Giussani 2018). 
Second, due to its glycosylation pattern, Zn2+-activated secretory ASM (S-ASM) can be secreted 
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into the extracellular space and be catalytically active at neutral pH, therefore also impacting on 
distant cells (Schissel et al. 1996; Schissel et al. 1998). L-ASM is also Zn2+-dependent, but due to 
the Zn2+ abundance it the lysosome it does not need further Zn2+ stimulation (Arenz 2010). The 
third form has not been in the focus of research so much and is expressed in or at the 
mitochondria. Here it binds to procaspase-3 upon presence of nitric oxide (NO) (Matsumoto et 
al. 2003). 
The processing of the ASM protein starts with a 75 kDa prepro-form (with a protein core of 65 
kDa). This propro-form is proteolytically cleaved to a 72 kDa ASM pre-cursor protein (protein 
core of 61 kDa). This pre-cursor protein is further processed to the mature ASM (70 kDa, protein 
core 61 kDa). Since the weight of the pre-cursor protein and the mature form do not differ in 
protein core, it is claimed that introduced modification are due rather to posttranslational 
changes than proteolysis. The translocation of the mature form to lysosomes most probably 
depends on the phosphomannosyl specific receptor (Man-6-mediated) pathway (Hurwitz et al. 
1994). SCHISSEL ET AL. demonstrated that both, L-ASM and S-ASM derive from the same gene, and 
conclude that S-ASM differs from L-ASM due to posttranslational changes which enable S-ASM 
to be secreted extracellularilly (Schissel et al. 1996). 
In this underlying thesis the naming of “ASM” will always refere to “L-ASM”, as long as not 
declared otherwise. 
Furthermore, oxidants have been postulated to activate ASM. Tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) and CD95 acitvate ASM via a redox mechanism, which can be 
blocked with antioxidants (Dumitru and Gulbins 2006). ASM is involved in a positive feedback 
loop of ROS activation during bacterial infection in macrophages (Zhang et al. 2008) and ASM at 
extracellular microdomains can be activated after peptide hormone vasoactive intestinal peptide 
(VIP) induced stimulation of G-protein coupled receptors and consequent H2O2 release (Abu-
Arish et al. 2019). In some cases, this oxidant-mediated activation includes the intracellular 
activation and translocation of ASM from lysosomes to the plasma membrane (Li, Gulbins, and 
Zhang 2012) or the direct activation of ASM at the extracellular space (Abu-Arish et al. 2019). 
However, these authors admit that the direct activation of ASM at the plasma membrane might 
also relate to S-ASM and not L-ASM (Abu-Arish et al. 2019). 
Cysteine at position 629 (Cys629) has been claimed to have a regulatory function for enzyme 
activity, since ASM activity was dramatically increased after chemical modification or deletion of 
this amino acid residue or dimerization of the enzyme via Cys629 (Qiu et al. 2003). The 
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phosphorylation at Serine 508 (Ser508) relates to PKC-delta (PKCδ) induction and leads to ASM 
activation and translocation to the plasma membrane (Zeidan and Hannun 2007). 
Some small endogenous ASM inhibitors have been found. Cytosolic L-carnitine moderatly 
inhibits ASM probably via transformation to the more active L-acylcarnitine (Di Marzio et al. 
1997). Furthermore, L-alpha-phosphatidyl-D-myo-inositol-3,5-bisphosphate (PtdIns3,5P2 or 
PIP2) has been demonstrated to strongly and selectively inhibit ASM (Kölzer et al. 2003). The 
applicational aspects of described inhibitors are an interesenting target for further studies. 
Respiratory topical administration of PIP2 already proved beneficial effects on lung injury and 
could be used in the future for neonates with hypoxemic respiratory failure (Preuss et al. 2012). 
Moreover, growth factors as VEGF showed to inhibit ASM (Jacobi et al. 2017).  
 
 ASM dysregulation in diseases 
Mutations in the SMPD1 gene coding for the enzyme ASM cause Niemann Pick diseases (Brady 
et al. 1966). According to a resulting full or partial ASM deficiency this disorder is called NPD 
type A or B, respectively. Both types of this pathology are characterized by progressive visceral 
organ abnormalities, including hepatosplenomegaly, pulmonary insufficiency and cardiovascular 
disease (Schuchman and Desnick 2017). Cells, derived from NPD patients, are characterized by 
SM accumulation in lysosomes, therefore both type A and B are described as lysosomal storage 
disorders (Conzelmann and Sandhoff 1983). NPD type A displays a rapidly progressive 
neurodegenerative pathology concomitant with mental retardation and finally leads to death in 
early childhood. However, NPD type B is a later-onset form and exhibits little or no neurological 
involvement. The diverging course of onset and severity relate to the remaining ASM activity in 
the patients. While NPD A patients only show residual ASM activity lower than 1 %, NPD B 
patients have a remaining ASM activity from at least 4-8 %, which seems to protect these people 
from the devastating neurological phenotype (Graber, Salvayre, and Levade 1994; Jones et al. 
2008). It has been claimed that residual ASM activity must fall below a critical threshold and the 
degradation rate of SM should be lower than the rate of influx to generate a dysregulation in 
lysosomal storage (Conzelmann and Sandhoff 1983). The preclusion of a neurological 
involvement in NPD B patients could therefore account to the lower SM influx in neural cells 
compared to liver, spleen or lymph nodes. Conclusively, low remaining ASM activity seems to be 
sufficient to prevent lysosomal accumulation in neurons (Graber, Salvayre, and Levade 1994). 
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To study the molecular implications in a fully ASM-deficient context, an ASM KO mouse was 
created in 1995 (Horinouchi et al. 1995; Otterbach and Stoffel 1995). Particularly striking was the 
accumulation of distended lysosomes within the cytoplasm of neurons representing a “foamy” 
appearance. Furthermore, fibres and synaptic terminals were majorly affected and showed signs 
of damage (Horinouchi et al. 1995; Otterbach and Stoffel 1995; Macauley et al. 2008). An 
atrophy of the cerebellum and the complete loss of the ganglionic cell layer of Purkinje cells 
became evident from the age of 7 weeks on and peaked after 20 weeks. This led to severe 
impairment of neuromotor coordination (Horinouchi et al. 1995; Otterbach and Stoffel 1995; 
Macauley et al. 2008).  
Neurological findings related to the AMS KO mouse were partially reviewed by LEDESMA ET AL. in 
2011 (Ledesma et al. 2011). ASM KO neurons exhibited elevated SM levels in detergent-resistant 
domains at the plasma membrane, which could contribute to changes in cell signalling (Galvan et 
al. 2008). Furthermore, cerebellar neurons in ASM KO mice were characterized by dysregulated 
Ca2+ homeostasis. This was accompanied by a progressive time-dependent loss of inositol 1,4,5-
triphosphate receptor (IP3R) and sarco/endoplasmic reticulum Ca2+-ATPase (SERCA). These 
proteins are involved in the release of Ca2+ from the ER to the cytosol and the transfer from Ca2+ 
into the ER, respectively (Ginzburg and Futerman 2005). The activity of plasma membrane 
calcium ATPase was also shown to be inhibited by high levels of SM in ASM KO neurons. This 
further induced imbalances in Ca2+ homeostasis and oxidative stress (Pérez-Cañamás et al. 
2017). GALVAN ET AL. found an aberrant protein distribution between axons and dendrites, which 
was most likely related to defects in internalization caused by disturbed RhoA activation (Galvan 
et al. 2008). A further study by ARROYO ET AL. demonstrated that inhibited RhoA activation in ASM 
KO mice was linked to reduced expression of metabotropic glutamate receptors type I 
(mGluR1/5). This caused low levels of filamentous actin which resulted in a reduced spine 
number and size (Arroyo et al. 2014). Interestingly, ASM deficiency caused a synaptic phenotype 
as well. Due to a mis-regulated Munc18-syntaxin1 complex formation the number of docking 
vesicles at the active zone was impaired, which was further represented in electrophysiological 
recordings with increased paired-pulse facilitation. Moreover, they found a decrease in synapse 
size, while the levels of neurotransmitter receptors remained similar as in ASM WT mice, which 
could indicate problems in learning and memory (Camoletto et al. 2009; Ledesma et al. 2011). 
Sphingomyelinase activity, mediated by sphingomyelinase on synaptic vesicles themselves, 
regulated Ca2+ sensitivity and accordingly Ca2+-mediated vesicle fusion, due to lipid raft 
localisation of fusion-involved proteins. However, too high enzyme activity might therefore 
disturb microdomain organisation and consequently fusion events (Rogasevskaia and Coorssen 
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2006). Furthermore, it was demonstrated that sphingomyelinase activity was needed for SNARE 
complex formation, which could (at least in chromaffin cells) enhance kinetics and extent of the 
exocytotic fusion pore formation, catecholamine release and probability for fusion events 
(García-Martínez et al. 2015; García-Martínez et al. 2013). Taken together, again, these findings 
demonstrate the necessity of balanced enzyme activity for a physiological synaptic function in 
this context. 
ASM KO glial cells were also affected by ASM deficiency. The metabolism in oligodendrocytes 
seemed to be affected which resulted in a hypomyelination. Taken together with the neuronal 
findings, this could further explain mental deficits (Buccinna et al. 2009). The release of IL1β-
carrying microparticles from astrocytes was also affected and might associate to an increase in 
susceptibility to infection according to impaired immune response (Bianco et al. 2009; Ledesma 
et al. 2011). However, on the other hand, ASM deficiency protected from lipopolysaccharid (LPS) 
induced endothelial apoptosis or focal brain ischemia, both by interfering the TNFα signalling 
(Haimovitz-Friedman et al. 1997; Yu et al. 2002). 
FIASMA antidepressants have shown to inhibit ASM activity. This principle was found to be 
crucial for the antidepressive effect of these drugs (Gulbins et al. 2013). As described above, 
long-term exposure to ASM deficiency develops a devastating phenotype. However, since this is 
a progressive process, in young ASM KO animals these findings are not fully present yet. 
Therefore, they will be used as a suitable model for the analysis of biological implications after 
ASM inhibition in this study. 
 
Moreover, there is a wide range of diseases which, instead of referring to a decrease in ASM 
activity as NPD, they relate to an increase in ASM activity. The implications of elevated ASM 
activity in MD have been already intensively discussed in section 2.1.4 (Gulbins et al. 2013; 
Kornhuber et al. 2005). However, other conditions show an abundant ASM activity. Interestingly, 
high ASM activity has shown to play a role in inflammatory states as peripheral inflammation, 
like cystic fibrosis, (Samapati et al. 2012) and also central inflammation diseases, like multiple 
sclerosis (Becker et al. 2017). Furthermore, chronic stress (Reichel et al. 2018) was connected to 
elevated ASM activity, which in turn could also link again to MD, since as described in section 
2.1.1, chronic stress clearly correlated in some MD pathologies. And further, bacterial infection 
in cystic fibrosis also went along with elevated ASM activity (Becker et al. 2010).  
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 Proposed model of lipid raft microdomains 
In 1972 SINGER AND NICOLSON presented the fluid mosaic model of the cell plasma membrane, 
describing lipids as components to solve proteins in the membrane (Singer and Nicolson 1972). 
However, some years later it became more pronounced that lipids are not only equaly 
distributed within the cell membranes and lipids can be actively trafficked (van Meer 1989). 
Membrane lipids were found to confluence and to confine or bind membrane molecules, 
therefore impacting on membrane organization inclusively special membrane domains (Kusumi 
and Sako 1996). Those membrane domains were enriched in cholesterol and sphingolipids to 
form microdomains. Rafts or caveolin-associated hairpin-looped caveolae represent 
microdomains which were further stabilized by flotillins or caveolin respectively, and cluster 
proteins for trafficking or internal signalling (for convenience the following text will referre to 
rafts or microdomains as superordinate concept and not distinguish between these terms). The 
inclusion or exclusion of membrane molecules in these domains was not a random but rather a 
selective process (Simons and Ikonen 1997; Stuermer 2011). In the following decades more 
evident was revealed for the existence of lipid rafts. More researchers described that 
sphingolipid composition could regulate receptor clustering and signalling across the plasma 
membrane. Thereby not only initiating or inhibiting the signalling but also regulating the 
amplitude or fate (Zhang et al. 2009; Grassmè, Riethmüller, and Gulbins 2007; Stancevic and 
Kolesnick 2010). Remarkably in 2009, EGGELING ET AL. managed to observe the nanoscale 
dynamics of lipid rafts in living cells (Eggeling et al. 2009). How exactly sphingolipids and rafts 
modulate signalling is not fully understood and might diverge between proteins and cell types. 
However, some principles as changes in channel localisation, loss of lipid raft-mediated protein - 
protein or protein - lipid interactions have been discussed to interfere and even to result in 
changes of receptor conformation (Allen, Halverson-Tamboli, and Rasenick 2007). 
 
In neuronal cells, a broad spectrum of G-protein coupled receptors (GPCRs), growth hormone 
receptors and ion channels have been associated with membrane microdomains and/or seemed 
to be regulated by sphingolipids (for instance see review OLSEN AND FÆRGEMAN 2017 (Olsen and 
Færgeman 2017)).  
GPCRs involved in glutamate signalling as AMPA and NMDA have been shown to be associated 
with sphingolipid microdomains. Ceramide abundance or destabilization of lipids rafts by 
cholesterol depletion with methyl-β-cyclodextrin (MβCD) were associated with changes in 
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synaptic plasticity, as depression or enhancement in post-synaptic currents (Yang 2000), 
decrease in receptor clustering concomitantly with loos of synapses and spines (Hering, Lin, and 
Sheng 2003), and increase in NMDA subunit localisation to lipids rafts (as NR1 or GluN2B) 
(Wheeler et al. 2009), which was most probably mediated by specific changes in 
phosphorylation pattern of this molecule by external stimuli (like TNFα) or S1PR activation 
(Besshoh et al. 2005; Attiori Essis et al. 2015).  
Moreover, some growth hormone receptors showed to be regulated by sphingolipid 
microdomains. Nerve-growth factor (NGF) induced neurite outgrowth via tropomyosin receptor 
kinase A (Trk A) activation, which was depended on GM1, a sphingolipid found at lipid rafts 
(Mutoh et al. 1998). The BDNF-induced Trk B signalling was disturbed by cholesterol oxidation. 
The oxidation product changed membrane fluidity which reduced the translocation of Trk B from 
non-raft to raft regions (Sharma et al. 2019). And the epidermal growth factor receptor (EGFR) 
localisation in lipid rafts and maintenance was GD3 dependent. Consequently, GD3 deficiency 
negative regulated neuronal stem cell self-renewal capability (Wang and Yu 2013).  
Furthermore, some ion channels localise to microdomains. α7 nicotinic acetylcholine receptors 
(α7nAchR) are involved in neurotransmitter release, signalling cascades and are interesting 
targets for neurodegenerative disease as Alzheimer’s. Cotreatment with MβCD and SMase (to 
degrade sphingomyelin) decreased kinetics α7nAchR desensitization and increased agonist 
affinity as well as single-channel conductance (Colón-Sáez and Yakel 2011). In cerebellar granule 
neurons the activity of PKA and CaMKII was modified by MβCD-induced lipid raft disruption. This 
influenced the phosphorylation pattern of the β2 subunit of L-type calcium channels (LTCCs) 
which resulted in decreased Ca2+ influx and led to an pro-apoptotic stage (Fortalezas, Marques-
da-Silva, and Gutierrez-Merino 2018). The function of some members of the TRP ion channel 
family was affected, as well by sphingomyelin hydrolysis, MβCD or ganglioside breakdown with 
myriocin in rat trigeminal neurons or rat peripheral sensory nerve endings. Ion channels as 
TRPV1, TRPA1, TRPM8 and TRPM3 play a role in noci- and thermosensation. At the cell bodies, 
ligand activated Ca2+ flux through TRPV1, TRPA1 and TRPM8 were prevented, but not through 
TRPM3. At nerve terminals, calcitonin gene related peptide (CGRP) release via TRPV1 and TRPA1 
was also inhibited. These authors speculated this effect might be linked to changes in opening 
properties of the channels (Sághy et al. 2015). For interaction of TRPC6 channels and 
sphingolipids see section 2.4. 
Moreover, in non-neuronal cells, channels and receptors were also found to be regulated by 
sphingolipids, which might also be important in a neuronal context. The positively charged 
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voltage-sensing domains of some voltage-activated K+ channels (Kv) showed to be dependent on 
the negatively charged phospho-headgroup of sphingomyelin in oocytes membranes. 
Enzymatical removal of this head group created an almost unbreachable hindrance in channel 
activation (Xu, Ramu, and Lu 2008). The serotonin1A receptor (5-HT1A) is normally an important 
receptor in the synaptic cleft and was analysed by PAILA ET AL. 2010 in CHO cells in respect to its 
sphingolipid interaction potential. They revealed a necessity of sphingolipids for ligand binding 
and downstream signalling (Paila, Ganguly, and Chattopadhyay 2010). If these observed 
interactions in non-neuronal systems could persist also for primary neuronal cells, remains to be 
elucidated in the future.  
 
In the context of the ASM/ceramide system, which is in focus of this thesis, it is thought that 
ceramide is produced by ASM that resides in lysosomes and at the outer leaflet of the plasma 
membranes and there might be catalytically active in acidified lipid rafts microdomains (Grassmè 
et al. 2001; Bourguignon et al. 2004). Produced ceramide confluences to ceramide-enriched 
membranes and bigger platforms which impact membrane microdomain function, membrane 
blebbing and vesiculation, fusion/fission and vesicular trafficking (van Blitterswijk et al. 2003). 
Transient ceramide formation could enhance receptor clustering in lipid rafts and the formation 
of endosomes. Therefore, specific plasma molecules can be preferentially in- or ex-cluded for 
instance to initiate stress signals and immune response (Jernigan et al. 2015; van Blitterswijk et 
al. 2003; Cuschieri et al. 2007). Clustering of receptor complexes, such as the CD95L/Fas-
receptor has been described upon stimulation of ASM activity and formation of ceramide 
enriched plasma membrane domains (Chung et al. 2016). Also the assembly of the toll-like 
receptor 4 (TLR4) within lipid rafts depends on the activation of acid sphingomyelinase, to lead 
downstream to TNFα activation under lipopolysaccharide application (Cuschieri et al. 2007). 
Inhibition of ASM by FIASMAs as imipramine or escitalopram, has also shown to impact on lipid 
raft organization (Cuschieri et al. 2007; Singh et al. 2018). FIASMA antidepressant imipramine 
promotes Gαs translocation from lipid rafts toward increased association with adenylyl cyclase 
(AC), which in turn promotes cAMP production and pCREB formation (Singh et al. 2018). The 
total deficiency of ASM, represented by the ASM KO mouse, also induces changes to lipid raft 
localisation of plasma membrane molecules. The plasma membrane calcium ATPase (PMCA) 
balances the intracellular calcium concentration. Abundant sphingomyelin levels in ASM KO 
neurons decrease PMCA activity via reduction of lipid raft localisation, which causes increased 
Ca2+ levels and oxidative stress to the cells (Pérez-Cañamás et al. 2017). 
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2.3 TRPC6 ion channels 
Transient receptor potential (TRP) proteins cluster to hetero- or homo-tetramers to form 
functioning channels. Each protomer consists of six-transmembrane domains. Although these 
domains show homologies in-between TRP proteins, the members of the TRP superfamily exert 
diverse gating properties and selectivity towards various stimuli. While some channels become 
activated by temperature or chemical agents, others are regulated by mechanical forces. The 28 
TRP channel proteins of mammals can be further divided into seven subgroups: TRPC (= 
canonical, 7 members), TRPV (= vanilloid, 6 members), TRPM (= melastatin; 8 members), TRPP (= 
polycystin, 3 members), TRPA (= ankyrin, 1 member), TRPML (= mucolipin, 3 members) 
(reviewed by VENKATACHALAM AND MONTELL 2007 (Venkatachalam and Montell 2007)). 
Canonical transient receptor potential channel 6 (TRPC6) are ubiquitously expressed plasma 
membrane non-selective cation channels, conductive for Ca2+ and Na+ (Hofmann et al. 1999). 
This protein is distributed all over the body and can be found in many tissues as smooth muscle 
cells, immune cells, kidney, lung and most importantly the CNS, where it contributes to diverse 
physiological functions (Ramirez et al. 2018; Malczyk et al. 2017; Ma, Chaudhari, and Li 2016; 
Dietrich and Gudermann 2014). More details towards pharmacological importance of TRPC6 in 
the CNS can be found in section 2.1.3.1. 
The most prominent disease in the context of TRPC6 pathologies is presumably focal and 
segmental glomerulosclerosis (FSGS), which is caused by a TRPC6 gain of function mutation and 
results in end-stage renal disease (Winn et al. 2005). Besides involvement in renal disorders as 
FSGS and unbeneficial diabetic renal progression (Staruschenko, Spires, and Palygin 2019), 
TRPC6 was related to migration and invasion of human hepatocellular carcinoma cells and to 
gastric cancer (Tian and Zhu 2018; Ding et al. 2018), cystic fibrosis (Grebert, Becq, and 
Vandebrouck 2019), inflammatory processes involved in fibroproliferative disorders (Inoue, 
Kurahara, and Hiraishi 2018), and central disorders as Alzheimer's disease and mild cognitive 
impairment (Lu et al. 2018) or autism spectrum disorders (Griesi-Oliveira et al. 2015). 
 
 TRPC6 regulation and signalling 
Under physiological conditions TRPC6 and TRPC3 activation is regulated by endogenous 
diacylglycerol (DAG) which is formed in the CNS after BDNF-mediated Trk B activation. 
Subsequently activated phospholipase C induces phosphatidylinositol 4,5 bisphosphonate (PIP2) 
 Introduction 
62 
degradation to generate phosphatidylinositol 3,4,5 triphosphate (IP3) and DAG (Hofmann et al. 
1999). PLC can also be induced by Gq coupled GPCRs (Itsuki et al. 2014). The inward migrating 
Ca2+ represents a highly important intracellular messenger and, in general, plays diverse roles in 
cellular functions since cytosolic enzymes and signalling molecules respond to the rise and fall of 
intracellular Ca2+ concentrations ([Ca2+]i) (Zhu, Tuo, and Yang 2016). In the case of TRPC6-
mediated Ca2+ influx, the RAS/MEK/ERK pathway, Ras/PI3K/Akt pathway as well as CaMK IV 
become activated which converges downstream to the phosphorylation of the transcriptional 
factor cAMP response element binding protein (CREB) (Heiser et al. 2013). The phosphorylation 
of CREB induces a dimerization, which enhances the binding properties to promotor regions and 
consequently the transcription of genes (Heiser et al. 2013). Genes which are encoded by CREB 
regulated proteins are connected to neuronal growth and survival, neuroprotection and synaptic 
plasticity (Lin et al. 2013; Lonze and Ginty 2002). More precisely, target genes of CREB relate to 
neurotransmission control, cell structure, growth hormones as BDNF, signalling as ion channels, 
transcription, and metabolism (Lonze and Ginty 2002). In accordance with CREB regulated 
proteins, BDNF shows a high importance in depression, stress disorders and neurogenesis (Smith 
et al. 1995; Siuciak et al. 1997; Numakawa, Odaka, and Adachi 2017). Moreover CREB 
overexpression in the hippocampus has been connected to an elevation of depression symptoms 
in behavioral studies (Chen et al. 2001). 
To further broaden the insight into regulation patterns for TRPC6 activity it is worth to take a 
closer look into regulatory phosphorylation sites. Phosphorylation of serine 14 induces TRPC6 
membrane expression. Kinases involved are most likely MAPKs and proline-directed kinases as 
cyclin-dependent kinase 5 (Cdk5) (Hagmann et al. 2018). Phosphorylation at tyrosine 284 by Src 
family kinase also induced enhanced TRPC6 trafficking to the plasma membrane (Kanda et al. 
2011). Whereby, phosphorylation of serine 448 by PKCδ showed to inhibit TRPC6-mediated Ca2+ 
entry (Bousquet, Monet, and Boulay 2010), as well as phosphorylation at threonine 69 by 
protein kinase G (Nishida et al. 2010). 
Interestingly, TRPC6 can be directly activated by exogenous hyperforin, which is a phloroglucinol 
derivate and the active ingredient of the antidepressant herbal remedy St. John’s wort 
(Chatterjee et al. 1998; Müller 2003; Leuner et al. 2007). Hyperforin was used in multiple studies 
to investigate TRPC6 activity-dependent functions. 
The lipid-mediated changes in TRPC6 signalling have just been started to be focused on in 
research (see review Beech 2012 (Beech 2012)). Several lipids have been found to interfere with 
TRPC6 activity as phosphatidylinositol 4,5 bisphosphonate, phosphatidylinositol 3,4,5 
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triphosphate, diacylglycerol, arachidonic acid including its metabolite 20-
hydroxyeicosatetraenoic acid (Beech 2012). Therefore, the lipid composition in membranes for 
TRPC6 activity gains more and more importance. In a few studies this concept has already 
proven evident concerning TRPC6 function regulated by lipid raft microdomains (see section 
2.4). 
 
 The role of TRPC6 in the central nervous system 
TRPC6 is predominantly expressed in the adult’s brain cortex. In the hippocampus, the 
expression is developmentally regulated and peaks between P0 and P14 in young mice (Li et al. 
2005). The inhibition of TRPC6 channel degradation after cerebral ischemia (Du et al. 2010) or 
after cerebral artery occlusion (Lin et al. 2013) promotes neuronal survival. Furthermore, 
cerebellar granule neurons are protected against serum deprivation-induced cell death in 
cultures via BDNF-mediated TRPC6 activity (Jia et al. 2007). BDNF-mediated growth cone 
guidance is fully blocked under TRPC3- or TRPC6-deficient conditions (Li et al. 2005), as well as 
the neuritic outgrowth which depends on TRPC6 activity and can be induced by TRPC6 
overexpression that in turn increases also CREB phosphorylation (Tai et al. 2008). Interestingly, 
TRPC6 is involved in the formation of excitatory synapses and resides within the presynaptic 
compartment of the synapse (Zhou et al. 2008). However, the knockout of TRPC6 leads to severe 
changes in spine morphology (Leuner et al. 2013), which further proves the importance of TRPC6 
for synaptic plasticity. Moreover, TRPC6 contributes to healthy brain physiology. For instance, it 
has been found that TRPC6 specifically interacts with APP which leads to an inhibition of its 
cleavage by γ-secretase and reduction in Aβ production (Wang et al. 2015). 
TRPC6 expression in the brain can be mediated by specific NMDA subunits in a different manner. 
While glutamate signalling mediated by NR2A subunits leads to calcineurin activation and TRPC6 
expression, the NR2B subunit-mediated glutamate signalling results in calpain activation. (Qu et 
al. 2017). Calpain induces proteolysis of the N-terminal domain of TRPC6 at lysine 16 and 
therefore decreases TRPC6 expression (Du et al. 2010). 
In a behavioral context, it was found that rats exposed to chronic unpredictable stress combined 
with isolation rearing (as a depression model) exhibited an impaired spatial cognition and 
attenuation in long-term potentiation recordings which went along with a decrease in TRPC6 
expression. This resulted further in a reduction in dendritic length, dendritic spine density and 
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number of excitatory synapses. Remarkably these phenotypes could be rescued by TRPC6 
activation with hyperforin (Liu et al. 2015). 
 
Figure 5: The downstream signalling pathway of TRPC6 
TRPC6 can be activated by endogenous DAG or exogenous hyperforin to induce Na+ and Ca2+ influx. 
Increased Na+ levels inhibit monoamine reupatke from the synaptic cleft. While, elevated Ca2+ 
concentrations induce calmodulin, which in turn stimulate different kinases as CaMK IV, via RAS the 
PI3K/Akt and the MEK/ERK pathway. All pathways converge in the phosphorylation of CREB. pCREB 
dimerizes, binds to cAMP response element (CRE) and coactivator CBP (CREB-binding protein) (Montminy 
and Bilezikjian 1987; Yamamoto et al. 1988; Kwok et al. 1994), and promotes transcription of neurotrophic 
genes to express Trk B and TRPC6 itself. 
 
2.4 Interaction of ASM/ceramide system and TRPC6 ion 
channels 
Only few studies can be found concerning the interaction of TRPC6 ion channels with the 
AMS/ceramide system or other sphingolipids and enzymes involved in sphingolipid metabolism. 
SAMAPATI ET AL. aimed to investigate a signalling cascade connected to platelet-activating factor 
(PAF) which induced vascular permeability of lung endothelial cells (Samapati et al. 2012). They 
found that PAF activated TRPC6 ionic flux by recruiting these channels in caveolae in an ASM-
activity dependent manner, while intracellular Ca2+ concentration correlated with loss of barrier 
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function and oedema formation. Both, ASM or TRPC6 deficiency blocked this process (Samapati 
et al. 2012). Already a study by LANG ET AL. in 2010 has considered PAF to activate ASM. Produced 
ceramide impacted on the activity of a non-selective cation channel, most likely TRPC6, in 
erythrocytes to induce eryptosis (Lang et al. 2010). TABELING ET AL. investigated human artery 
smooth muscle cells in the context of cystic fibrosis (Tabeling et al. 2015). Under hypoxic 
conditions cystic fibrosis transmembrane conductance regulator (CFTR) interacted with TRPC6 
promoting TRPC6 translocation into caveolae where Ca2+ flux was induced. This translocation 
was dependant on nSM. Hypoxia also enhanced S1P production and subsequent activation of 
S1P2/4 which resulted in phospholipase C (PLC) formation. PLC activated TRPC6 and rho kinase 
which triggered vasoconstriction (Tabeling et al. 2015).  
The activity of TRPC6 seems to be strongly regulated by its localisation within lipid rafts, since 
disruption of lipid rafts or caveolae by methyl-β-cyclodextrin (MβCD) or by the expression of 
dominant-negative caveolin-1 in mouse embryonic fibroblasts inhibited the PLC-activated 
TRPC6-mediated Ca2+ flux (Lei et al. 2014). The inhibition of TRPC6 activity or TRPC6 expression 
by MβCD-mediated cholesterol depletion was also observed in T-cells, podocytes and glomerular 
mesangial cells (Carrillo et al. 2012; Zhang and Ji 2013; Kim et al. 2013).  
Dalton et al. (Dalton et al. 2017) presented a regulatory pathway of soluble Klotho (sKlotho), 
which impacted on TRPC6 activity in an indirect manner via lipid rafts. sKlotho has diverse 
effects as extension of lifespan, cardioprotection, and tumour inhibition via down-regulation of 
growth factor-driven PI3K/Akt signalling. This effect is exerted by sKlotho binding to 
monosialogangliosides of rafts, thereby disturbing microdomains properties and consequent 
disturbance of PI3K signalling which usually locates to these lipid rafts. This results in inhibition 
of PI3K-dependent exocytosis of TRPC6 and TRPC6 Ca2+ signalling in cardiomyocytes and 
glomerular podocytes (Wright et al. 2017; Dalton et al. 2017) 
In summary, in mentioned studies TRPC6 activity or TRPC6 expression was dependent on 
sphingolipid levels and TRPC6 translocation to ceramide enriched plasma membrane 
microdomains. 
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2.5 Aim of the study: elucidation of potential interaction 
of ASM/TRPC6 systems in central nervous system 
Diverging hypotheses of MD pathology still leave open questions about disease development 
(see section 2.1.2). Varying and sometimes contradictory antidepressant action profiles only 
partly fit the proposed hypotheses of pathology. Recently, a specified group of antidepressants 
called FIASMA was described as involving the ASM/ceramide in their antidepressant action 
(Kornhuber et al. 2008). However, the underlying mechanism and the manner in which enzyme 
activity can affect cell physiology and pathophysiology remain unclear. 
TRPC6 is a plasma membrane-bound ion channel for cations with many roles. In the context of 
healthy CNS physiology and has been recognized for instance as a key player in growth factor 
signalling (see section 2.1.3.1 and 2.3). The ASM/ceramide system is claimed to affect signalling 
of plasma membrane located molecules by impacting local lipid compositions and microdomain 
formation (see section 2.2.3). This underlines the necessity of investigating ASM interaction with 
TRPC6 and its contribution to CNS pathology and antidepressant action. 
Consequently, the aim of this study was to elucidate the potential interaction of ASM/ceramide 
system with TRPC6 ion channels in the central nervous system in the context of MD. To this end, 
specific aims were defined: 
1. To examine the consequences of antidepressant treatment on ASM activity, PC12 and 
primary cells were studied. 
2. To determine the extent of ASM’s interaction with TRPC6, RNA and protein expression 
as well all Ca2+ influx and downstream signalling were analyzed. 
3. To approach a mechanistic explanation of interaction, TRPC6 distribution within the 
plasma membrane and lipid composition were subjects of interest.  
4. To give first insights into impact of ASM and TRPC6 on synapse physiology, synapse 
density and synapse vesicle recycling were investigated, respectively. 
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3 Materials and methods 
3.1 Materials 
 Devices and software 
Table 1: Devices and software 
Name of device or software 
 
Company 
20x /0.75 ∞/0.17 WD 1.0 objective (Plan APO 
Nikon CFI) 
Nikon Corporation (Chiyoda, Tokio, Japan) 
40x /0.80 W ∞/0/FN26.5 objective (LUMPlan 
FL N) 
Olympus (Shinjuku, Tokio, Japan) 
60x /A/1.20 WI ∞/0.15-0.18 DIC N2 WD 1.0 
objective (Plan APO VC Nikon CFI) 
Nikon Corporation 
Abs Quant/2nd Derivative Max software Roche Diagnostics GmbH (Mannheim, Germany) 
Adobe Photoshop CS6 software Adobe Incorporated (San José, California, USA) 
Amersham Imager 600 Amersham Bioscience #29083461 (= GE 
Healthcare; Chicago, Illinois, USA) 
Andor camera (Model No: DU-885K-CSO-#VP) Andor Technology (Belfast, UK) 
Bio-Rad Trans-Blot Turbo Transfer-System Bio-Rad (Hercules, California, USA) 
Centrifuge 5415R Eppendorf AG (Hamburg, Germany) 
Centrifuge Heraeus Multifuge 3SR+ Thermo Fisher Scientific (Waltham, 
Massachusetts, USA) 
ClarioStar software BMG Labtech (Ortenberg, Germany) 
Electrophoresis Power Supply EPS 301 Amersham Bioscience 
EndNote software Clarivate Analytics (Philadelphia, Pennsylvania, 
USA) 
gel documentation device (GelDoc) Gel Stick Touch device (INTAS, Göttingen, 
Germany) 
GraphPad Prism 7 software Graphpad Software Incorporated (San Diego, 
California, USA) 
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Image Studio V5.2 software Li-Cor Bioscience (Bad Homburg vor der Höhe, 
Germany) 
ImageJ NIH (download: 
https://imagej.nih.gov/ij/download.html) 
Led-HUB (LED light engine, generates light of 
340 nm, 384 nm, 455 nm, 471 nm, 550 nm, 
625 nm) 
Omicron-laserage Laserprodukte GmbH 
(Rodgau, Germany) 
Li-COR Odyssey Infrared Imager Li-Cor Bioscience  
LightCycler SW 1.5 Roche Diagnostics GmbH (Mannheim, Germany) 
Mars software BMG Labtech (Ortenberg, Germany) 
Microsoft Office Excel software Microsoft Corporation (Redmond, Washington, 
USA) 
Microsoft Office Word software Microsoft Corporation 
Milli-Q Reference Merck Millipore (Burlington, Massachusetts, 
USA) 
Nano Drop Spectrophotometer (ND-1000) PeqLab Co. (Shanghai, China) 
Neubauer counting chamber (improved) Paul Marienfeld GmbH & Co.KG #T729.1 (via 
Carl Roth GmbH + Co. KG; Karlsruhe, Germany) 
Nikon Eclipse Ti microscope Nikon Corporation 
Nis Element software Nikon Corporation 
Olympus BX51W1 immersion microscope Olympus 
OpenView software from N. Ziv (Tsuriel et al. 2006) 
Optima LE-80K Ultracentrifuge Beckman Coulter Incorporated 
QuantityOne software (= Quantity One 1-D 
Analysis Software) 
Bio-Rad 
Sorvall RC5B Plus Marshall Scientific (Hampton, New Hampshire, 
USA) 
SS-34 Rotor Thermo Fisher Scientific 
SW 41 rotor Beckman Coulter Incorporated (Brea, California, 
USA) 
ThermoCycler (LabCycler) SensoQuest GmbH (Göttingen, Germany) 
Tilluxe PX45 Xenon-light source formerly FEI Munich GmbH (Till Photonics), now 
Thermo Fisher Scientific (Waltham, 
Massachusetts, USA) 
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TillVision Live Acquisition and Offline Analysis 
software 
formerly FEI Munich GmbH (Till Photonics), now 
Thermo Fisher Scientific 
Typhoon Trio scanner Cambridge Scientific #14509 (= GE Healthcare) 
VisiView software Visitron Systems GmbH (Puchheim, Germany) 
Zeiss Stemi DV4 (dissection microscope) Carl Zeiss (Oberkochen, Germany) 
 
Table 2: Fluorescence filters for Nikon microscope 
Detection of secondary 
antibody 
 
Excitation [nm] Dichroic mirror [nm] Emission [nm] 
DAPI 378/11 HCBS409 447/60 
488 472/30 HCBS495 520/35 
Cy3 543/22 HCBS562 593/40 
Cy5 628/40 BS660 692/40 
 
 Chemicals and proteins 
All chemicals for basic biochemical lab work were purchased from Carl Roth GmbH + Co. KG 
(Karlsruhe, Germany) or Sigma-Aldrich (= Sigma; St. Louis, Missouri, USA) if not been stated 
otherwise. 
Table 3: Chemicals and proteins 
Name of chemical or protein 
 
Company 
0.025 % ethidium bromide solution Carl Roth #HP47.1 
Agarose Universal PeqLab Co. #351.020 
Ara-C Sigma #C1768 
ARC39 (=C10 bisphosphonate 1-aminodecane-
1,1-bisphosphonic acid) 
Avanti Polar Lipids Incorporation #860480P 
(Alabaster, Alabama, USA) 
BSA (bovine serum albumin) Thermo Fisher Scientific #23209 
BSA standard ampules, 2 mg/ml Pierce #23209 (= Thermo Fisher Scientific; 
Waltham, Massachusetts, USA) 
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cOmplete Protease Inhibitor Cocktail Roche #04693116001 (1 tbl. in 50 ml) (= 
Hoffmann-La Roche AG; Basel, Switzerland) 
Dabco Carl Roth #0718.2 
Dispase II Roche #04942078001 
DMSO Carl Roth #4720.4 
DNase I (for murine Banker’s culture and rat 
neuronal culture) 
Roche #11284932001  
DNase I (for PPD) Worthington #LS0002139 (= Worthington 
Biochemical Corporation; Lakewood, New 
Jersey, USA) 
dNTP Set 5 x 4 x 0,25 ml, 100 mM solution Rovalab GmbH #R105 (Teltow, Berlin, 
Germany) 
Fluoxetine HCl Sigma #F132 
Fura-2 acetoxymethyl ester (AM) Invitrogen #1221 (= Thermo Fisher Scientific; 
Waltham, Massachusetts, USA) 
Isoflurane CP 1 ml/ml CP-Pharma #1214 (Burgdorf, Germany) 
Mowiol 4-88 Carl Roth #0713.2 
Na-hyperforin Dr. Willmar Schwabe GmbH (Karlsruhe, 
Germany) 
Nortriptyline HCl Sigma #N7261 
Papain Worthington #LK003176 
PFA (paraformaldehyde) Sigma #6148 
PhosSTOP (phosphatase inhibitor tablets) Roche #04906837001 (1 tbl. In 10 ml) 
PLL (poly-L-lysine) Sigma #P1524 
Sertraline HCl Sigma #S6319 
Trypan Blue solution Sigma #T8154 
Venlafaxine HCl Sigma #V7264 
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 Buffers, solutions and consumables of 
manufacturers 
Table 4: Buffers and solutions of manufacturers 
Name of buffer or solution 
 
Company 
0.5 % trypsin with EDTA 10 x GIBCO #15400-054 (= Thermo Fisher Scientific; 
Waltham, Massachusetts, USA) 
2.5 % trypsin 10 x GIBCO #15090-046 
anti/anti (100x) 
= 10,000 units/ml penicillin, 10,000 µg/ml 
streptomycin, 25 µg/ml amphotericin B 
GIBCO #15240-062 
B27 50x supplement GIBCO #17504-044 
CytoTox 96 Non-Radioactive Cytotoxicity Assay  
 
Promega Corporation #G1780 (Madison, 
Wisconsin, USA) 
Kit included: 
 CytoTox substrate mix 
 CytoTox assay buffer 
 CytoTox lysis solution (10x) 
 CytoTox stop solution 
DMEM GIBCO #41966029 
DMEM, high glucose (for PC12) GIBCO #41965039 
EBSS Worthington #LK003188 
ECL Select Western Blotting Detection Reagent GE Healthcare #GERPN2234 (Merck KGaA; 
Darmstadt, Germany) 
FCS (fetal calf serum) Biochrom GmbH #S00115 (Berlin, Germany) 
Fluoroshield mounting media with DAPI Sigma #F6057 
Genotyping of ASM ko mouse strain: KAPA 
HotStart Mouse Genotyping Kit 
Roche #KK7352 
Kit includes: 
 10x KAPA Express Extract Buffer 
 1 U/µl KAPA Express Extract Enzyme 
 2X KAPA2G Fast HotStart Genotyping 
Mix with dye 
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Genotyping of ASM tg mouse strain: Tfi DNA 
Polymerase 
Invitrogen #30342-024 (= Thermo Fisher 
Scientific) 
Kit includes: 
 Tfi DNA Polymerase 
 5X Tfi PCR Reaction Buffer  
 50 mM magnesium chloride 
GlutaMax (0.2 M) GIBCO #35050-038 
HBSS -/- GIBCO #14175-053 
HBSS +/+ GIBCO #14025-050 
Horse serum GIBCO #26050-088 
iTaq Universal Probes Supermix Bio-Rad #1725131 
L-Glutamine (0.2 M) GIBCO #25030-024 
Neurobasal GIBCO #12348-017 
Neurobasal A GIBCO #12349-015 
PBS 1x GIBCO #10010-015 
Pierce Cell Surface Protein Isolation Kit Thermo Fisher #89881  
Kit includes: 
Sulfo-NHS-SS-Biotin #1859385 
Quencing solution #1859386 
Pierce Lysis buffer 1.0 #1859387 
NeutrAvidin Agarose #165759 
Pierce Wash Buffer 1.0 #1859389 
qScript cDNA Synthesis Kit Quanta Bio #95047-100 (Beverly, 
Massachusetts, USA) 
Kit included: 
 qScript Reaction Mix (5X) 
 qScript Reverse Transcriptase (RT), 20X 
concentration 
 nuclease-free water 
RDD buffer Quiagen #1011132 (Hilden, Germany) 
Sodium pyruvate (0.1 M) GIBCO #11360-070 
TaqMan GAPDH-VIC Thermo Fisher #Mm99999915_g1 
TaqMan TRPC6-FAM Thermo Fisher #Mm01176083_m1 
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Table 5: Consumables of manufacturers 
Name of consumable 
 
Company 
1 ml-tips NerbePlus GmbH #07-379-2015 (Winsen 
(Luhe), Germany) 
10 % polyacrylamide TGX stain free gels  Bio-Rad #456-8033 
100 µm Cell Strainer Falcon #352360 (= neoLab Migge GmbH; 
Heidelberg, Germany) 
12-well plate TPP #92012 (= Techno Plastic Products AG; 
Trasadingen, Switzerland) 
18 mm menzel glass cover slips VWR International #631-1342 (Radnor, 
Pennsylvania, USA) 
20 mm x 0.17 mm glass cover slips LaCon #0730.015 (Erbach, Germany) 
6 cm culture petri dish (= 22.1 cm2) TPP #93060 
6-well plate TPP #92406 
70 µm Cell Strainer Falcon #352350 (= neoLab Migge GmbH) 
96-well plate flat bottom Greiner Bio-One #655101 (Kremsmünster, 
Austria) 
96-well plate round bottom Greiner Bio-One #650101 
BD Discardit II syringe BD #309110 10 ml, #309050 5 ml, #300928 2 
ml 
(=Becton Dickinson Corporation, Franklin 
Lakes, New Jersey, USA) 
black incubation boxes Biozym #541096BLACK (L-07040-003) (= 
Biozym Scientific GmbH; Hessisch Oldendorf, 
Germany) 
Brown Sterican cannula (Ø 0.45x25mm 26Gx1” 
Gr.18) 
Braun #C718.1 (via Carl Roth GmbH + Co. KG) 
Cell scraper Greiner Bio-One #CE60.1 (via Carl Roth GmbH 
+ Co. KG) 
CryoPure Tube 1.6ml Sarstedt AG and Co. KG #72.380 (Nümbrecht, 
Germany) 
Eppendorf tubes 1.5 ml (safe lock) Eppendorf AG #0030 120.086 
Eppendorf tubes 2 ml (safe lock) Eppendorf AG #0030 120.094 
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Falcon 100 µm nylon cell strainer Corning Incorporation #352360 (Corning, New 
York, USA) 
Falcon 70 µm nylon cell strainer Corning #352350 
Glass slides 76 x 26 x 1 mm neoLab Migge GmbH #1-6274 
Immobilon-FL PVDF, 0.45 µm Merck Millipore #IPFL00010 
Open-top Polyclear Tubes 11 x 6 cm Seton Scientific #7010 (Petaluma, California, 
USA) 
Parafilm foil 10 cm x 38 m via “Zentrallager” #200963 (Bemis Company 
Incorporated, Oshkosh, Wisconsin, USA) 
Silica gel 60 Å plates  Macherey-Nagel #REF 818232 (Düren, 
Germany) 
T 25 cell culture flask 25 cm2 TPP #90026 
T 75 cell culture flask 75 cm2 TPP #90076 
Trans-Blot Turbo RTA Midi PVDF Transfer Kit Bio-Rad #1704273 
Kit included:  
 Trans-Blot Turbo 5xoTransfer Buffer 
#10026938 
 Trans-Blot Turbo Transfer Stacks 
#10026930 
 Trans-Blot Turbo PVDF Membrane 
#10026933 
Yellow Sterican cannula (Ø 0.9x40mm 
20Gx1½” Gr.1) 
Braun #C721.1 (via Carl Roth GmbH + Co. KG) 
 
 Self-made solutions 
Table 6: Self-made solutions 
Name of solution 
 
Composition 
1.5 % agarose gel 2.25 g agarose 
+ 150 ml 1x TBE 
+ 5 drops of 0.025 % ethidium bromide 
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1.85x TNE (modified from PÉREZ-CAÑAMÁS ET AL. 
2017 (Pérez-Cañamás et al. 2017)) 
87.5 mM TRIS HCl 
275 mM NaCl 
7.33 mM EDTA 
1.85 % TritonX-100 
cOmplete Protease Inhibitor Cocktail 
PhosSTOP (phosphatase inhibitor tablets) 
in MQ 
10x Laemmli buffer 250 mM TRIS 
1.92 M Glycine 
1 % SDS 
Ad 1000 ml MQ 
10x TBS 200 mM TRIS 
1.5 M NaCl 
900 ml with MQ 
adjust pH to 7.6 with HCl 
Ad 1 L with MQ 
1x TBE 250 ml 20x TBE 
+ 4,750 ml MQ 
1x TBS 100 ml 10x TBS 
+ 900 ml MQ 
Adjust pH to 7.6 with HCl 
1x Transfer Buffer  200 ml Trans-Blot Turbo 5x Transfer Buffer 
+ 200 ml EtOH 
+ 600 ml MQ 
20x TBE 1.74 M TRIS 
1.77 M boric acid 
40 mM EDTA 
in MQ 
4x PAP 250 mM TRIS 
5.5 M Glycerol 
8 % SDS 
400 mM DTT 
0.01 % bromophenol blue 
Ad 10 ml MQ 
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Ara-C stock solution 150 mM 100 mg Ara-C 
+ 2.74 ml MQ 
Ara-C working solution 1.5 mM 0.1 ml Ara-C stock solution 
+ 9.9 ml MQ 
ARC39 1 mM in MQ 
stored in -20 °C 
ASM reaction buffer 
 
50 mM sodium acetate pH 5.0 
0.3 M NaCl 
0.2 % NP 40 
0.5 mM ZnCl2 
0.58 µM BODIPY FL C12 
Biotin solution 
 
1 vial Sulfo-NHS-SS-Biotin 
+ 48 ml 1x PBS 
Blocking solution 10 % FCS 
0.1 % glycine 
in 1x PBS 
DMEM-media DMEM 
10 % FCS 
1 % glutamine 
1 % anti/anti 
Sterile filtered after preparation 
DNase I solution (for murine Banker’s culture 
and rat neuronal culture) 
100 mg DNase I in 10 ml MQ = 10 mg/ml stock 
solution 
1 ml stock solution 
+ 9 ml HBSS -/- 
+ 120 µl 1 M MgCl2  
= 1 mg/ml working solution 
DNase I solution (for PPD) 100 mg DNase I in 10 ml MQ 
FCS/media mix NBA-media mix no. 2 or 3 
10 % FCS 
Prepared and sterile filtered just before use 
fluoxetine HCl 10 mM in MQ 
stored in -20 °C 
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Homogenisation Buffer (HB) 5 mM TRIS HCl 
320 mM sucrose 
cOmplete Protease Inhibitor Cocktail 
PhosSTOP (phosphatase inhibitor tablets) 
in MQ 
Lipid Raft Buffer (Lazarevic et al. 2011) 10 mM TRIS HCl 
150 mM NaCl 
2 % SDS 
1 % sodium deoxycholate 
1 % TritonX-100 
cOmplete Protease Inhibitor Cocktail 
PhosSTOP (phosphatase inhibitor tablets) 
in 50 ml MQ 
Mobile phase for chromatography 1 % acetic acid in ethylacetate (v/v) 
Mouse glial freezing media plating media 
+ 10 % DMSO 
Mowiol solution for ICC 9.6 g Mowiol 4-88 
24 ml MQ 
24 ml glycerol 
48 ml 0.2 M TRIS pH 8.5 
2.5 g Dabco 
stored in -20 °C 
Na-hyperforin 10 mM in DMSO 
stored in -20 °C 
NBA-Media Mix no. 1 Neurobasal A 
2 % GlutaMax 
2 % B27 50x 
1 % sodium pyruvate 
1 % anti/anti 
Prepared and sterile filtered just before use 
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NBA-Media Mix no. 2 Neurobasal A 
1 % GlutaMax 
2 % B27 50x 
1 % sodium pyruvate 
1 % anti/anti 
Prepared and sterile filtered just before use 
NBA-Media Mix no. 3 Neurobasal A 
1 % GlutaMax 
2 % B27 50x 
1 % sodium pyruvate 
1 % anti/anti 
KCl (final conc. 25 mM) 
MgCl (final conc. 5 mM) 
Prepared and sterile filtered just before use 
NB-media mix Neurobasal 
0.4 % glutamine 
2 % B27 50x 
1 % anti/anti 
Prepared and sterile filtered just before use 
nortriptyline HCl 10 mM in MQ 
stored in -20 °C 
Papain solution 100 mg in 5 ml EBSS 
PC12 freezing media PC12 media mix:FCS:DMSO = 5:4:1 
PC12 media mix DMEM, high glucose (for PC12) 
10 % FCS 
5 % horse serum 
1 % anti/anti 
permeabilization solution 10 % TritonX 100 
in 1xPBS 
PFA solution 4 % PFA 
4 % glucose 
in 1x PBS 
pH adjusted to 7.2 
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Pierce Lysis buffer 2.0 
 
Pierce Lysis Buffer 1.0 
cOmplete Protease Inhibitor Cocktail 
Pierce Sample Buffer Pierce SDS Page Sample Buffer 
+ DTT 50 mM 
Pierce Wash Buffer 2.0 
 
Pierce Wash Buffer 1.0 
cOmplete Protease Inhibitor Cocktail 
Plating-media DMEM 
10 % FCS 
0.5 % glutamine 
1 % anti/anti 
Prepared and sterile filtered just before use 
Poly-L-lysine solution (mouse) 2.5 mg/ml poly-L-lysine in 150 mM borate 
buffer pH 8.4 
Poly-L-lysine solution (rat) 0.5 mg/ml poly-L-lysine in 150 mM borate 
buffer pH 8.4 
PPD-mix (Deußer 2013) HBSS -/- 
0.01 % papain 
0.1 % dispase II 
0.01 % DNase I 
12.4 mM MgSO4  
rat glial freezing media DMEM media 
10 % DMSO 
RIPA buffer 50 mM TRIS HCl, pH 7.4 
150 mM NaCl 
1 % NP40 
0.5 % sodium deoxycholate 
0.1 % SDS 
cOmplete Protease Inhibitor Cocktail 
PhosSTOP (phosphatase inhibitor tablets) 
in MQ 
SDS Sample Buffer (for Pierce Cell Surface 
Protein Isolation Kit) 
62.5 mM TRIS HCl 
10 % glycerol 
1 % SDS 
in MQ 
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sertraline HCl 10 mM in MQ 
stored in -20 °C 
staining solution 3 % FCS 
in 1x PBS 
TBS/T 100 ml 10x TBS 
+ 900 ml MQ 
+ 1 ml Tween 20 
Adjust pH to 7.6 with HCl 
Tyrodes Buffer with high KCl conc. (pH 7.4) 25 mM HEPES 
30 mM glucose 
52.5 mM KCl 
2 mM MgCl2 
2 mM CaCl2 
69 mM NaCl 
in MQ 
Tyrodes Buffer with physiological KCl conc. (pH 
7.4) 
25 mM HEPES 
30 mM glucose 
2.5 mM KCl 
2 mM MgCl2 
2 mM CaCl2 
119 mM NaCl 
in MQ 
venlafaxine HCl 10 mM in MQ 
stored in -20 °C 
 
 Antibodies 
Western Blot antibodies were diluted in 5 % BSA/TBST. ICC staining antibodies were diluted in 
staining solution. 
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Table 7: Primary antibodies 
Primary 
antibody 
 
Sp. Dilution Company App. Experiment 
flotillin-1 rb 1:1.000 CST  
(#18634) 
WB PC12: lipid raft extraction 
GAD 65 gp 1:500 SySy 
(#198104) 
ICC mouse neurons: pCREB analyses 
rat neurons: pCREB analyses 
GAPDH ms 1:80.000 Millipore 
(#MAB374) 
WB rat neurons: TRPC6 expression 
PC12: lipid raft extraction 
MAP 2 ms 1:1.000 Sigma 
(#M4403) 
ICC mouse neurons: pCREB analyses 
rat neurons: pCREB analyses 
pCREB (Ser133) rb 1:1.000 CST 
(#9198) 
ICC mouse neurons: pCREB analyses 
rat neurons: pCREB analyses 
S100B gp 1:500 SySy 
(#287004) 
ICC mouse neurons: pCREB analyses 
SHANK 2 gp 1:500 SySy 
(#162204) 
ICC mouse neurons: density of 
synapses 
synapsin 1/2 rb 1:1.000 SySy 
(#106002) 
ICC mouse neurons: density of 
synapses 
synapsin 1/2 gp 1:1.000 SySy 
(#106004) 
ICC rat neurons: synaptotagmin AB 
uptake assay 
synaptotagmin-
1-oyster550  
ms 1:250 SySy 
(#105311C3) 
ICC rat neurons: synaptotagmin AB 
uptake assay 
TRPC6 rb 1:400 Alomone 
(#ACC170) 
WB PC12: biotinylation assay 
rat neurons: TRPC6 expression 
TRPC6 rb 1: 200 CST 
(#16716) 
WB PC12: lipid raft extraction 
vGlut 1 rb 1:1.000 SySy 
(#135303) 
ICC rat neurons: synaptotagmin AB 
uptake assay 
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Table 8: Secondary antibodies 
Secondary 
antibody 
 
Sp. Dilution Company App. Experiment 
Donkey alexa 488 gp 1:1.000 Jackson Im. R. 
(#706-545-148) 
 
 
ICC mouse neurons: density of 
synapses 
mouse neurons: pCREB analyses 
rat neurons: pCREB analyses 
Donkey alexa 488 rb 1:1.000 Jackson Im. R. 
(#711-545-152) 
ICC rat neurons: synaptotagmin AB 
uptake assay 
Donkey Cy3 rb 1:1.000 Jackson Im. R. 
 (#711-165-152) 
ICC mouse neurons: pCREB analyses 
rat neurons: pCREB analyses 
Donkey Cy5 ms 1:1.000 Jackson Im. R. 
 (#715-175-150) 
ICC mouse neurons: density of 
synapses 
mouse neurons: pCREB analyses 
rat neurons: pCREB analyses 
Donkey Cy5 gp 1:1.000 Jackson Im. R. 
 (#706-175-148) 
ICC rat neurons: synaptotagmin AB 
uptake assay 
Goat IgG, H & L 
Chain Specific 
Peroxidase 
Conjugate 
rb 1:20.000 Millipore 
(#401315) 
WB PC12: biotinylation assay 
rat neurons: TRPC6 expression 
Goat IgG, H & L 
Chain Specific 
Peroxidase 
Conjugate 
ms 1:20.000 Millipore 
(#401253) 
WB rat neurons: TRPC6 expression 
IRDye® 680RD 
Donkey IgG (H + L) 
ms 1:15.000 Li-Cor 
(#925-68072) 
WB PC12: lipid raft extraction 
IRDye® 800CW 
Donkey IgG (H + L) 
rb 1:15.000 Li-Cor 
(#925-32213) 
WB PC12: lipid raft extraction 
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3.2 Methods 
 PC12 cell culture 
PC12 is a cell line made from rat adrenal pheochromocytoma cells and was first described by 
GREENE AND TISCHLER in 1976 (Greene and Tischler 1976). These cells respond to nerve growth 
factor and provide useful properties for neurochemical and neurobiological analyses (Greene 
and Tischler 1976).  
PC12 cells were used for experiments between passages 4 – 8. They were cultured in T 75 flasks 
in PC12 media mix and split when 80 – 90 % confluent, approximately every 4 days. For PC12 
stock preparation, PC12 cells were harvested, centrifuged at 1,000 rpm for 5 min and 
supernatant was discarded. Cells were resuspended in PC12 freezing media and immediately 
filled in cryotubes precooled within a “Mr. Frosty” cryo box, stored over night at -80 °C and 
afterwards stored in a fluid nitrogen tank for the long term. 
 
 Rat cell culture (mixed culture of glial cells and 
neurons) 
Pregnant albino Sprague Dawley rats (RjHan:SD) carrying embryos E12 were ordered from 
Janvier Labs (Le Genest-Saint-Isle, France). They were housed for one week at FPZ and embryos 
were collected at E18. 
 
The method of isolation and cultivation of rat cells has already been established previously 
(Frischknecht et al. 2009). 
Cover slips were baked for 6 h at 200 °C and coated with poly-L-lysin solution for 3 days at 37 °C, 
5 % CO2, humidified atmosphere. 6-well plates were coated with poly-L-lysine solution and also 
incubated. Just before rat cell preparation, cover slips and 6-well plates were washed three 
times with sterile filtered Millipore water (MQ) and cover slips were placed into 12-well plates. 
A pregnant rat was anesthetized with isoflurane, decapitated and E18 embryos were removed 
and killed by cephalic segregation. Brains were collected and placed in cold HBSS -/- and 
meninges were removed. 
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For glia preparation whole forebrains were taken. For neuronal culture, cortices were separated 
from hippocampi. Forebrains and cortices were washed three times in HBSS -/- and trypsin 0.25 
% was applied. Tissue was incubated at 37 °C for 20 min and afterwards washed 5 times with 
HBSS -/-. DNase I (final conc. 0.01 mg/ml) was added and cells were triturated 3 times with a 
yellow cannula and 3 times with a brown cannula.  
For a glial cell preparation, 2 ml of cell suspension was mixed together with 8 ml of DMEM media 
and put into a T 75 flask. The next day, the media was changed to fresh DMEM, and this was 
repeated every 3 - 4 consecutive days. After 10 - 14 days, glial cells were confluent and split 1:2. 
After another 7 days, glial cells were harvested and frozen in rat glial freezing media for long 
term storage (according to protocol of murine glial cells, see section 3.2.3.2).  
For a neuronal cell preparation, the cell suspension was filtered through a 100 µm nylon cell 
strainer and healthy neurons were counted in a Neubauer counting chamber with trypan blue. 
Cells were mixed with DMEM media to yield the desired dilution and 1 ml of cell suspension was 
placed in every well of a 12-well plate (representing 100,000 cells). For 6-well plates 500,000 
cells/well were plated. 24 h later, DMEM media was removed and wells were filled carefully with 
1 ml (12-well plate) or 2 ml (6-well plate) of NB-media mix. Every 7 days cells were fed by 
application of 200 µl equilibrated NB-media mix/well for the 12-well plates and 300 µl NB-media 
mix/well for the 6-well plates. Neurons were used for experiments after 20 - 23 days of culture. 
 
 Mouse cell culture 
A C57BL/6J mouse served as a control “wildtype” species. This mouse is broadly known as “black 
six”. Originally, C57BL was generated by Jackson lab founder Dr. C.C. Little in 1921. From this 
strain, a sub-strain was later picked, known as C57BL/6J (The Jackson Laboratory n.a.). 
The ASM-deficient mouse was created in the lab of Prof. Schuchman, Department of Human 
Genetics, University of New York, USA, and was first described in (Horinouchi et al. 1995). To 
achieve full enzyme deficiency, Exon 2 of the SMPD1 gene, which codes for the ASM enzyme, 
was disrupted by the implementation of a PGKneo expression cassette inserted in the reverse 
orientation relative to the ASM coding sequence. To enable better comparisons between labs, 
both, our department and the members of Prof. Gulbins lab, Institute for Molecular Biology, 
University Essen, Germany, back crossed this mouse exclusively with C57BL/6J, to conserve 
equal research backgrounds. Within this study this mouse strain is also called “ASM KO”. 
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The ASM-transgenic mouse was generated in the lab of Prof. Gulbins and first described in 2013 
(Gulbins et al. 2013). A cDNA of murine SMPD1 was created and inserted into the deleted 
hypoxanthine phosphoribosyltransferase gene locus lying on the X-chromosome. The 
implemented SMPD1 gene was expressed under the control of the ubiquitous cytomegalovirus 
immediate early enhancer/chicken β-actin fusion promoter. For a conditional regulation by the 
action of a Cre-recombinase, a loxP-flanked STOP cassette was also included between the 
promoter and the transgene. Concomitant with the ASM-deficient mouse strain, the ASM-
transgenic mouse strain was back crossed only with C57BL/6J. Within this study this mouse 
strain is also called “ASM tg”. For experiments, ASM tg mice were bred together with an 
EMX1/Cre strain, resulting in selective overexpression of ASM in excitatory forebrain neurons 
and glial cells (Gorski et al. 2002). 
 
Mice were bred at the Franz-Penzoldt-Zentrum, a center for preclinical animal experiments in 
Erlangen. Wildtype mice were needed for glia preparation and bred in breeding cages consisting 
of two females and one male in an age range of 8 – 54 weeks. Mice heterozygous for ASM-
deficiency were needed for glia and neuron preparation and used between 8 – 54 weeks. 
According to Mendel’s law, ratio of offspring would be expected as follows: wildtype, 
heterozygous or deficient for ASM in a ratio of 1:2:1. Two ASM tg female mice were bred 
together with one EMX1/Cre male mouse. All offspring could be used for neuronal culture 
preparation and exhibited tg (females), WT (females and males) and heterozygous (= tg/wt or 
+/-) (males) genotypes. In general, for the breeding of the two different ASM mice strains, two 
females of one strain were placed into one breeding cage. The breeding regime was directed as 
the male was only put together with the two females for two days every week according to a 
strict time schedule. Since pregnancy of mice usually takes 21 days, it was therefore possible to 
calculate estimated delivery days, which was extremely useful since pups could only be used for 
neuronal cell culture at P 0 or P 1. 
 
 Optimization of the preparation procedure 
Before starting any experiment with respect to ASM deficiency or overexpression, the culture 
preparation and cultivation of primary mouse cells needed to be established. There was a wide 
variety of possible preparation procedures, ranging from compositions of digestion enzymes 
mixtures to differences in texture and quality of pipet tips, cover slips or coating solutions. The 
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mouse cells needed to be cultivated for ca. 14 days, depending on the specific parameter of 
investigation. A precise composition of media was required to ensure a consistent quality of 
cells. Depending on preparation methods, it was possible to plate higher or lower number of 
cells. Eventually, it was important to gain a cell culture with a density of 100,000 for Banker’s 
culture and 200,000 cells per coverslip for mixed culture, giving the individual dendrites enough 
space to be easily analysed while still enabling sufficient networking possibilities.  
For first experiments, Banker’s culture (Kaech and Banker 2006) was established using a 
modified protocol of AG Fejtová’s lab in Magdeburg (Davydova et al. 2014). With this culture it 
was possible to grow neurons with a density of 100,000 cells per coverslip just concomitantly in 
the same media with glial cells of the same or even different genetic background. Since the 
quality of Banker’s culture proved inconsistent, a new protocol was established based on FACCI 
AND SKAPER 2018 (Facci and Skaper 2018). To achieve a better outcome, modifications in 
digestion enzyme mixture (Deußer 2013) were introduced. This preparation procedure enabled 
us to grow cells with a density of 200,000 cells/cover slip (NBA-Media Mix no. 2, containing a 
physiological KCl concentration of 5 mM). However, for depolarising experiments another media 
with high KCl 25 mM and MgCl2 5 mM concentrations was used at a later time point (NBA-Media 
Mix no. 3). 
 
 Banker’s culture 
Glia cells general protocol and glial cells for Banker’s culture 
For glial cell preparation newborn pups were used between P 0 to P 3. Pups were killed by 
cephalic segregation, scull and meninges were removed and forebrains were taken immediately 
in cold HBSS -/-. Forebrains were washed once with cold HBSS -/-, trypsin was added to create a 
0.25 % trypsin solution and incubated for 15 min at 37 °C. Cells were washed three times with 
HBSS -/- to remove residual trypsin and filled up to 1 ml HBSS -/- plus DNase 0.1 mg/ml per 
single brain. Tissue was dissociated by trituration three times with a yellow cannula and three 
times with a brown cannula. 1 ml cell suspension was added together with 9 ml plating media 
and filled in a T 75 flask. Cells were incubated at 37 °C, 5 % CO2, in a humidified atmosphere. The 
media was changed 1 day and every 3 – 4 following days after plating. As soon as cells became 
confluent, usually after 10 - 14 days, they were trypsinated and split 1:2. After another 7 days of 
culturing, cells were washed with HBSS -/-, trypsinated, harvested, centrifuged for 5 min at 1,000 
g. Old media was discharged and the cell pellet was resuspended in 1 ml mouse glial freezing 
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media per initially T 75 flask and filled in cryotubes. Cryotubes were placed in a cold “Mr. Frosty” 
box and stored over night at -80 °C. For long term storage, cells were placed in a liquid nitrogen 
tank at -150 °C. 
For preparation of Banker’s culture, breeding mice were monitored for pregnancy. As soon as a 
pregnancy was discovered - usually one week before delivery - glia cells were thawed, 1 ml cell 
suspension was mixed with 4 ml plating media and filled in a 6 cm petri dish. Media was changed 
to a fresh plating media 24 h after plating. Cells were incubated at 37 °C, 5 % CO2, in a humidified 
atmosphere. 
 
Cortical neurons for Banker’s culture 
Coverslips were cleaned 24 h in conc. HNO3, subsequently washed and boiled in MQ to gain pH 7 
and dried on lint free paper tissue. They were baked for 6 h at 200 °C, equipped with three small 
paraffin dots at a 120 ° angle and coated with poly-L-lysine solution for 24 h. Cover slips were 
washed three times with sterile filtered MQ and placed in 12-well plates just before the start of 
cell preparation. 
For cortical cell preparation, newborn pups were used between P 0 to P 1. After killing the pups 
by cephalic-segregation, scull and meninges were removed and cortices were taken immediately 
in cold HBSS -/-. Tissue was washed once with cold HBSS -/- and trypsin was added to incubate 
15 min at 37 °C. The trypsin solution was removed, and cells were washed 3 times with HBSS -/-. 
For each brain, 1 ml of plating media was added together with DNase 0.1 mg/ml and tissue was 
dissociated by the use of a yellow cannula (3 times) and a brown cannula (3 times). Cells were 
rinsed through a 70 µm nylon filter and filters were washed with 500 µl media. Healthy neurons 
were counted using a Neubauer counting chamber and trypan blue, and subsequently diluted 
with plating media to a concentration of 100,000 cells/100 µl/cover slip. Cells were plated on 
prepared coverslips as a 100 µl drop in the middle of the glass and incubated at 37 °C, 5 % CO2, 
humidified atmosphere. In the meantime, media of glial cells in 6 cm petri dishes, which were 
usually plated one week before, was changed to 5 ml NBA-Media Mix no. 1. After 1 h incubation 
of cortical cells on cover slips, coverslips were transferred upside down to lie on the surface of 
glial cells in 6 cm petri dishes and finally incubated at 37 °C, 5 % CO2 in a humidified atmosphere. 
1 day and 3 days after plating 2 µl Ara-C (stock conc. 1.5 mM) was added to the Banker’s culture 
to avoid further growth of glial cells. Once every week, cells were fed by removal of 500 µl and 
addition of 1 ml equilibrated NBA-Media Mix no. 1. 
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 Mixed culture of glial cells and neurons  
Coverslips were prepared some weeks prior to cell preparation. Glass cover slips were baked for 
6 h at 200 °C, coated with poly-L-lysine solution for 3 days washed three times with sterile 
filtered MQ and placed in 12-well plates to dry. Afterwards they were stored in a dry and dark 
space until use. 
Immediately prior to the start of cell preparation, coverslips were incubated with 200 µl 
FCS/media mix applied as a droplet right into the middle of the cover slip, allowing only the 
cover slips’ surface to be incubated and not the plastic bottom of the well, and placed in the 
incubator at 37 °C, 5 % CO2, humidified atmosphere. Media was freshly prepared every week. 
Newborn pups were used between P 0 to P 1. Animals were sacrificed by cephalic-segregation, 
cortices and hippocampi were taken immediately and placed into ice cold HBSS -/-. HBSS -/- was 
discarded completely and tissue was mixed with PPD-mix (2 ml for two cortices and 1 ml for two 
hippocampi). Eppis with cells were placed in a water bath set at 37 °C. 10 min later, tissue was 
triturated using 1 ml-pipette tips ten times. This trituration step was repeated twice more. After 
the third trituration, cells were filtered through a 70 µm nylon cell strainer and the filter was 
washed once with 1 ml of NBA-Media Mix no. 2 or 3. Cell suspension was then centrifuged 5 min 
at 120 g. Supernatant was discarded and cell pellet triturated five times with 1 ml of NBA-Media 
Mix no. 2 or 3. This washing step was repeated twice. Following the last suction, 1 ml media for 
cortices and 150 µl for hippocampi was applied to the Eppis. Cells were counted with a 
Neubauer counting chamber as described above and diluted to a concentration of 200,000 
cells/100 µl media/cover slip with NBA-Media Mix no. 2 or 3. 
The media droplet, which had been applied previously to the cover slips before the start of cell 
preparation, was discarded and cells were also seeded in the middle of each cover slip, forming a 
droplet. These cells were incubated at 37 °C, 5 % CO2, humidified atmosphere, for 1 h. Following 
this 1 h pre-incubation step, all wells were finally filled carefully with 1 ml of NBA-Media Mix no. 
2 or 3. Cells were fed every 7 days by removal of 500 µl old media and application of 500 µl fresh 
equilibrated media. 
 
 Genotyping 
Tail cuts of 1 mm length were taken from the tip of the animals’ tails by the animal care 
attendance at the FPZ. 
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 ASM KO mouse strain 
To lyse tissue, each tail cut was mixed with 88 µl sterile MQ, 10 µl of 10x KAPA Express Extract 
Buffer, 2 µl of 1 U/µl KAPA Express Extract Enzyme. Samples were placed in a ThermoCycler and 
lysed for 15 min at 75 °C. Afterwards enzymes were inactivated at 95 °C for 5 min. For PCR 
reaction, 1 µl of DNA extract, 12.5 µl 2x KAPA2G FAST HotStart Genotyping Mix, 1 µl of 10 
pmol/µl Primer #ASM-PS, 0.5 µl of 10 pmol/µl Primer #ASM PA1, 0.5 µl of 10 pmol/µl Primer 
#ASM PA2 and 9.5 µl MQ were mixed. PCR was conducted in a ThermoCycler while settings 
were: 3 min at 95 °C, 35 cycles of 15 s at 95 °C / 15 s at 58 °C / 30 s at 72 °C, 3 min at 72 °C and a 
holding temperature of 15 °C. To analyse PCR products, a 1.5 % agarose gel was prepared 
containing ethidium bromide. Gel was loaded with samples and run at 120 V for 35 min. Staining 
was analysed using a GelDoc device with UV, where the upper band 523 bp corresponded to 
“KO”, the lower band 269 bp to “WT” and both bands 269 bp + 523 bp to a “heterozygous” 
genotype. 
 
       1        2       3        4         5        6       7        8         9 
Figure 6: Representative image of ASM KO genotyping 
Lane 1 = RNA ladder, lane 2, 3, 5, 8 = het, lane 4, 6 = KO, lane 7 = WT, lane 9 = water control 
 
Table 9: Primers for ASM KO genotyping 
Primer  
 
Company 
ASM-PA 1 3’ (SM31) Eurofins Scientific (Luxembourg, Luxembourg) 
CGAGACTGTTGCCAGACATC 
ASM-PA 2 3’ (SM32) Eurofins Scientific  
GGCTACCCGTGATATTGCTG 
ASM-PS 5’ (SM30) Eurofins Scientific  
AGCCGTGTCCTCTTCCTTAC 
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 ASM-transgenic mouse strain 
Tissue was lysed as described for the ASM KO mouse strain. Afterwards two PCR reactions were 
performed. For Run A, 1 µl of DNA extract, 2.5 µl of 5x Tifi Puffer, 0.25 µl of 10 mM dNTP, 0.325 
µl of 50 mM MgCl2, 0.25 µl of 10 pmol/µl Primer #ASMtg-A1, 0.25 µl of 10 pmol/µl Primer # 
ASMtg-A2, 0.25 µl of 5 U/µl Tifi Taq and 7.675 µl MQ were mixed. For Run B, Primer #ASMtg-B1 
and Primer #ASMtg-B2 were used. PCR was conducted in a ThermoCycler while settings were: 2 
min at 94 °C, 35 cycles of 30 s at 94 °C / 30 s at 65 °C / 60 s at 68 °C, 7 min at 68 °C and a holding 
temperature of 15 °C. A 1.5 % agarose gel was prepared containing ethidium bromide to analyse 
PCR products. Samples were loaded in the gel and run at 120 V for 35 min. Staining was analysed 
using a GelDoc device with UV. Run A gave a band at 345 bp and Run B at 360 bp, where band 
345 bp corresponded to “female or male, WT”, band 360 bp to “female, tg” and both bands 345 
bp + 360 bp to “male, heterozygous for tg”. 
 
           1        2       3       4       5      6      7       8       9     10 
Figure 7: Representative image of ASM tg genotyping 
Lane 1 = RNA ladder, lane 2, 4, 8, 9 = tg (female), lane 3, 6 = WT (female or male), lane 5, 7 = tg/wt (male), 
lane 10 = water control 
 
 
 
 
 Materials and methods 
91 
Table 10: Primers for ASM tg genotyping 
Primer  
 
Company 
ASMtg-A1 5’ (SM26) Eurofins Scientific  
TGTCCTTAGAAAACACATATCCAGGGTTTAGG 
ASMtg-A2 3’ (SM27) Eurofins Scientific  
CTGGCTTAAAGACAACATCTGGGAGAAAAA 
ASMtg-B1 5’ (SM24) Eurofins Scientific  
TGAGGCAGGAGAATCGCTTGAACC 
ASMtg-B2 3’ (SM25) Eurofins Scientific  
GCCTCCCAGATGCTAATAGGTTGTGG 
 
 BCA assay 
A BCA assay is widely used to determine the unknown protein concentration of a sample using a 
standard curve. Tissue and cells were pretreated and lysed according to respective experimental 
protocol. For the establishment of the standard curve, a blank as well as seven standard 
solutions with specific concentrations (50 µg/ml, 100 µg/ml, 200 µg/ml, 400 µg/ml, 600 µg/ml, 
800 µg/ml, 1,000 µg/ml) were prepared (using a BSA standard 2mg/ml). A buffer for blank and 
standard solutions was chosen according to the respective lysis buffer of individual experiments.  
12 µl of blank, standard concentrations and lysates were filled in a 96 well plate. A mixture of 
bicinchoninic acid and coper (II) sulfate was made (1:50), and 100 µl of this solution was added 
to each well and incubated at 37 °C for 30 min. During this incubation time, Cu2+ was reduced to 
Cu+ mostly by cysteine, tryptophan, tyrosine, and the peptide bond. Bicinchoninic acid formed 
purple chelate complexes with Cu+, where the amount of resulting Cu+ was proportional to the 
protein concentration (Smith et al. 1985; Wiechelman, Braun, and Fitzpatrick 1988). Afterwards, 
absorption was analysed at 550 nm and unknown protein concentration was determined with 
ClarioStar software according to a standard curve. 
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 ASM activity: sample preparation and 
biochemical enzyme assay 
Cells were grown in 6-well plates, with a density of 1,000,000 cells/well for PC12, 500,000 
cells/well for rat neurons and 500,000 cells/well for rat glia. PC12 cells were treated with 
fluoxetine 10 µM, sertraline 10 µM, nortriptyline 10 µM, venlafaxine 10 µM or MQ for 1 h, or 
they were treated with ARC39 10 µM or MQ for 48 h. For another experiment, PC12 cells were 
treated with hyperforin 0.3 µM for 24 h. Rat neurons were either treated with fluoxetine 1 µM 
for 24 h or with 10 µM, or MQ for 0.5 h, 1 h or 24 h. Some other rat neurons were treated with 
hyperforin 0.3 µM, 0.5 µM or 1 µM for 24 h. Rat glia was treated with fluoxetine 10 µM or MQ 
for 0.5 h, 1 h or 24 h. After treatment, cells were washed twice with cold PBS 1x and lysed in 
RIPA buffer. Protein concentration was determined with a BCA assay. 0.5 µg of protein lysate 
was applied to a 96-well plate with a round bottom together with 50 µl of ASM reaction buffer 
and incubated at 37 °C for 1 h (Mühle and Kornhuber 2017). This buffer contained 0.58 µM 
BODIPY FL C12, a derivate of sphingomyelin C12 attached to a fluorescence molecule at the 
ceramide moiety. As soon as the ASM of the sample catalyzed breakdown of BODIPY FL C12 into 
phosphorylcholine and ceramide, the fluorescence molecule remained still attached to 
ceramide, which enabled detection of substrate and product. Following incubation, 3 µl of 
solution were spotted onto a silica gel plate, the plate was placed in a chromatographical 
chamber with mobile phase and the sample was allowed to separate for 30 s. Afterwards, the 
plate was left under the hood to dry for 10 min and finally scanned with typhoon after laser 
excitation at 488 nm. Sphingomyelin and ceramide were detected at retention factor 0.0 and 0.5 
respectively and spot intensities were analysed using Quantity One software. 
 
    S1         S2        ctl 
Figure 8: Representative visualisation of BODIPY-fluorescence on a thin layer chromatography 
plate 
S1: cell lysate 1; S2: cell lysate 2; ctl: buffer control. Lower staining indicates sphingomyelin, 
bound to BODIPY (retention factor 0.0), upper staining represents the degradation product 
ceramide, bound to BODIPY (retention factor 0.5). 
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 LDH cell viability assay 
The lactate dehydrogenase (LDH) cell viability assay is a colorimetric assay to assess LDH activity 
in the supernatant of cells, which is usually high in dying cultures as LDH leaks from damaged 
cells. LDH reduces NADH to NAD+ concomitantly with the conversion of pyruvate to lactate. In 
turn, NAD+ interaction with a specific dye enables a quantitative analysis of the reaction due to 
absorbance at 490 nm. 
Rat neurons were plated in a 6-well plate with a density of 500,000 cells/well. Immediately prior 
to the start of incubation, a sample of supernatant was taken (LDH0) and cells were treated with 
fluoxetine 10 µM or MQ for 24 h. After incubation a second sample of supernatant was taken 
(LDH24). Furthermore, a control sample was produced to check for maximum LDH release after 
cell damage. To do this, 45 min prior to the end of incubation time 10 µl CytoTox lysis buffer 
(10x) was applied to a control well that had only been treated with vehicle control. CytoTox 
substrate mix was reconstituted in CytoTox assay buffer to form CytoTox Reagent. 50 µl of each 
sample were added to a 96-well plate, mixed with CytoTox Reagent and incubated for 30 min at 
37 °C. 50 µl of CytoTox stop solution were added. Afterwards the plate was colourimetrically 
analysed with a plate reader recording absorbance at 490 nm. Values at LDH0 were subtracted 
from respective values at LDH24 to check for changes in LDH production during incubation time 
(= ∆LDH). Finally, ∆LDH values of MQ and fluoxetine were normalized to maximum LDH release 
and displayed as % cytotoxicity. 
 
 Ca2+-Imaging 
The media was removed and cells were washed twice with HBSS+/+ and stained with 1 µM 
Fura2-AM in HBSS+/+ at 37 °C for 30 min. Afterwards cells were washed again twice with 
HBSS+/+ and left for another 30 min at RT in HBSS+/+, allowing the dye to de-esterase to Fura2 
and building up a diffusion balance. Cover slips were placed into an imaging chamber made of 
plexi glass, covered with 500 µl of HBSS+/+, and fixed to a platform adjusted at the Olympus 
BX51W1 immersion microscope (light source: Tilluxe PX45 Xenon-light). Application of 10 µM 
hyperforin induced TRPC6-mediated Ca2+-influx, which was the subject of analyses. To this end, 
500 µl of a 20 µM Na-hyperforin solution in HBSS+/+ was prepared, resulting in a desired 10 µM 
concentration as soon as it was mixed with 500 µl HBSS+/+ already covering the cover slip. Ca2+-
influx was immediately visualized in TillVision Live Acquisition and Offline Analysis software as a 
ratio of 340/380nm at 40 x. This ratio was calculated by analyses of emission which was 
detected at 510 nm after excitation at 340 nm and 380 nm, with Ca2+-bound Fura2 being 
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excitable at 340 nm and the unbound state of Fura2 being excitable at 380 nm. The amplitude 
between baseline and highest peak (PC12) or first plateau (neurons, ca. after 40 s past 
hyperforin application) was calculated and interpreted as maximum Ca2+-influx inducible with 
hyperforin 10 µM. 
 
 PC12 cells 
To analyse TRPC6-mediated Ca2+-influx in a neuronal cell model with manipulation in ASM 
activity, PC12 cells were plated on LaCon cover slips with a density of 500,000 cells. 24 h later, 
cells were treated for 1 h with fluoxetine 1 µM or 10 µM, venlafaxine 1 µM or 10 µM or were left 
untreated. 
 
 Rat neurons 
To investigate hyperforin-induced Ca2+-influx in primary cells, which were manipulated 
pharmacologically in ASM activity, rat neurons were plated as previously described in section 
3.2.2, and treated either 1 h or 24 h with MQ, venlafaxine 10 µM, fluoxetine 10 µM or ARC39 10 
µM. 
 
 Mouse neurons and glial cells 
To analyse TRPC6-mediated Ca2+-influx in ASM-deficient mouse neurons, cells were plated as 
previously described in section 3.2.3.3.  
For a rescue experiment, mouse neurons were plated as previously described in section 3.2.3.2, 
with ASM KO neurons growing next to ASM WT glial cells.  
 
 Immuno-cytochemistry 
Cells on cover slips were fixed with 4 % PFA for 3 min and afterwards blocked with a blocking 
solution for 45 min. In the meantime, primary antibody solution was prepared: primary antibody 
was applied to a staining solution and centrifuged for 10 min, 10,000 g at 4 °C to pellet antibody 
precipitates. Supernatant was used for staining. Parafilm was laid on a plane surface and 50 µl 
antibody solution was dropped carefully on to it. Cover slips were transferred upside down onto 
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the antibody drop with the cells facing the solution, and incubated over night at 4 °C. The next 
day cover slips were washed three times in PBS 1x for 10 min. A secondary antibody solution 
was prepared, and cells were incubated according to the primary antibody. The incubation time 
for the secondary antibody was 1 h at room temperature. Cells were washed as previously 
described. After the last washing step, cover slips were washed once more in MQ and finally 
mounted on glass slides with Fluoroshield (containing Dapi) or Mowiol. Cover slips were stored 
at 4 °C until imaging at a Nikon Eclipse Ti microscope. As a light source a LED Hub was used and 
pictures were taken as 16-bit images with an ANDOR camera at 20 x for pCREB analyses (except 
for rat pCREB analyses, which was 60 x) or 60 x resolution for synaptic analyses. Images were 
processed with Nis Elements or VisiView software and stored as TIF files. Before analysis was 
started, the mean background of respective experiments of individual channels was subtracted 
from all pictures in ImageJ. To do this, for each image an area without staining was randomly 
selected and measured, and an average background intensity was determined for each channel. 
 
 Immuno-cytochemistry: rat pCREB analysis 
Rat cell cover slips were used between DIV 20-23. 24 h prior to fixation, cells were treated either 
with MQ or ARC39 10 µM to block ASM activity. Additionally, DMSO or Hyp 1 µM was added 
directly to the media. After the declared incubation time, the ICC general protocol was applied. 
A circular region of interest was created in ImageJ, which fit nuclear size displayed as DAPI 
staining (diameter: 11µm). All nuclei of one region that collocated to neuronal MAP2 staining 
were taken into consideration and a mean value of average pixel intensity of pCREB staining was 
determined per region. Using a co-staining of GAD65, neurons could be separated into excitatory 
and inhibitory. 
 
 Immuno-cytochemistry: murine pCREB analysis 
Mouse cell cover slips were used between DIV 12-16. Depending on the individual experimental 
approach, cells were left either untreated or treated with DMSO or Hyp 1 M for 20 min, 1 h, 6 h 
or 24 h. Afterwards, the ICC general protocol was applied. Another circular region of interest was 
created in ImageJ for mouse neurons, which fit nuclear size displayed as DAPI staining (diameter 
for glia: 8.5 µm; diameter for neurons: 7.5 µm). Afterwards, pCREB staining was analysed as 
described for rat pCREB staining analyses. A co-staining of GAD65 served to separate neurons 
into excitatory and inhibitory. A staining of S100B was used to stain glial cells. 
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Figure 9: Representative neuronal ICC co-stainings for pCREB experiments 
Representative stainings of (A) an excitatory murine neuron and (B) an inhibitory murine 
neuron. A and B: MAP2 = red (neuronal microtubules), GAD65 = green (enzyme of inhibitory 
neurons), DAPI = blue (DNA). Scale bar indicates 5 µm. 
 
 
Figure 10: Representative glial ICC co-staining for pCREB experiments 
Representative staining of a glial cell surrounded by neuronal dendrites. Densely packed small 
blue regions on the right side represent DNA of dead cells. MAP2 = red (neuronal microtubules), 
S100B = green (astrocyte marker), DAPI = blue (DNA). Scale bar indicates 5 µm. 
 
 Immuno-cytochemistry: murine synapse density 
Mouse cell cover slips were plated in a Banker’s culture with WT mouse glia and used between 
DIV 10-12. An ICC general protocol was applied. Regions of proximal dendrites were cropped to 
90x50 pixels (16.9 µm x 9.4 µm) in ImageJ software and forwarded for further analyses to 
OpenView software. To analyse synapse number, only signals where staining for presynapses 
(synapsin1/2) collocated to postsynaptic staining (SHANK2) were considered. 
 
 Immuno-cytochemistry: synaptotagmin-1-antibody uptake assay 
Protocol was established in AG Fejtová’s lab, Molecular Psychiatry, Leibnitz Institute, Magdeburg 
(Lazarevic et al. 2011). Cells were treated with hyperforin 0.3 µM or DMSO for 24 h. To analyse 
spontaneous synaptic activity, Synaptotagmin-1 antibody coupled to Oyster550 was diluted 
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1:250 in Tyrodes Buffer with a physiological KCl content of 5 mM. Cells were incubated in 
prepared antibody dilution for 20 min at 37 °C in the dark.  
To investigate synaptic activity under evoked conditions, the Synaptotagmin-1 antibody coupled 
to Oyster 550 was mixed with Tyrodes Buffer 1:250 containing 52.5 mM KCl. Cover slips were 
incubated with the prepared antibody solution for 4 min at RT. 
Afterwards an ICC general protocol was conducted. 7 to 10 individual images (= regions) were 
taken per cover slip. Areas of proximal dendrites were cropped with ImageJ to 90x50 pixels (16.9 
µm x 9.4 µm) and cropped images were processed to OpenView software. By colocalisation of 
synaptotagmin-1 staining to synapsin1/2 and vGlut1, only active and excitatory synapses were 
considered. The mean pixel intensity of synaptotagmin-1, synapsin1/2 and vGlut1 were analysed. 
 
 Wessel-Flügge protein precipitation 
1 ml of sample was mixed with 4 ml MeOH 100 % in a glass tube. 3 ml chloroform was applied 
and the solution was vortexed. 4 ml MQ was added, vortexed and the mixture was centrifuged 
for 20 min at 9,000 rpm in a Sorvall centrifuge with rotor SS-34. The upper aqueous phase was 
discarded while taking care not to suck the proteins at the interphase. 3 ml MeOH 100 % was 
added, mixture was vortexed and centrifuged for 30 min at 9,000 rpm. Supernatant was 
removed and pellet was air dried for 5 min (Wessel and Flügge 1984). Finally, proteins were 
resuspended in Lipid Raft Buffer.  
 
 Western Blot 
Protein concentration was determined with a BCA assay. Samples were mixed with 4x PAP and 
diluted with the relevant sample buffer to yield the desired concentration. Mixtures were 
denaturated at 95 °C for 10 min and filled in a 10 % polyacrylamide TGX stain free (= TCE 
containing) Bio-Rad gel. Gel was run at 260 V, 120 A, 25 min in Laemmli Buffer. 
Immobilon-FL PVDF membranes or Bio-Rad PVDF membranes were activated with MeOH 100 % 
for 30 s or 5 min and incubated in a transfer buffer for at least 5 min. A semi-dry transfer was 
conducted by a TurboTransfer protocol of Bio-Rad: 7 min, 2.5 A, 25V in Bio-Rad transfer buffer. 
Membranes were blocked with 5 % BSA/TBST for 3 h and the primary antibody was 
subsequently incubated over night at 4 °C. The next day, membranes were washed three times 
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with TBST 1x for 10 min and the secondary antibody was applied for 1 h at RT. Membranes were 
washed again three times with TBST 1x for 10 min and finally staining was analysed via 
fluorescence or chemiluminescence. 
 
 Biotinylation assay of PC12 cells 
For each respective condition, four T 75 of PC12 cells with a confluence of 95 % were required. 
Cells were treated with fluoxetine 10 µM, venlafaxine 10 µM or MQ for 1 h, media was 
discarded, and cells washed twice with cold PBS 1x. PBS 1 x was discarded, and 10 ml of Biotin 
Solution was applied and incubated at 4 °C for 30 min using a rocking platform. During this step 
the biotin derivative of the biotin solution crosslinked to all amino acids like lysin, which were 
represented at the surface. Afterwards 500 µl of Quencing Solution was added and cells were 
scraped into solution. Volumes of the same treatments were pooled together in one 50 ml 
falcon and centrifuged for 3 min at 500 g. Supernatant was removed and cells were resuspended 
in cold TBS 1x, and centrifuged again for 3 min at 500 g. Supernatant was discarded and pellet 
was resuspended in 500 µl of Lysis Buffer 2.0 and transferred to a 1.5 ml Eppi. To disrupt cells, 
five one-second bursts of sonication were used alternating with vortexing of the sample every 5 
min for 30 min. Lysate was centrifuged for 2 min at 4 °C at 10,000 g. Supernatant was used for 
further preparation and the pellet was trashed. A column was inserted into a collection tube and 
filled with 500 µl of NeutrAvidin Agarose suspension. NeutrAvidin formed a stable interaction to 
biotin and was required to separate biotinylated and non-biotinylated fraction. This column and 
tube were centrifuged for 1 min at 1.000 g and flow-through was discarded. Gel in column was 
washed three times using 500 µl of Wash Buffer 1.0 and centrifuged for 1 min at 1.000 g. A 
bottom cap was fixed to avoid leaking and clarified cell lysate was filled in the column, a top cap 
was attached. Column and sample were incubated at RT for 60 min exposed to end-over-end 
mixing using a rotator. Caps were removed and column was put into the collection tube and 
centrifuged for 1 min at 1,000 g. Flow-through was collected and determined as non-
biotinylated fraction. Gel was washed three times with Wash Buffer 2.0 and centrifuged for 1 
min at 1,000 g. Biotinylated fraction remained in the gel due to the interaction of NeutrAvidin 
and biotin. To also collect biotinylated fraction, disulfide bonds of the Sulfo-NHS-SS-Biotin-
moiety were broken by the application of 400 µl Sample Buffer and subsequent reduction of 
sulfur. The column was capped and incubated at RT for 60 min during end-over-end mixing. The 
column was de-capped and placed in a collection tube. Flow-through was collected by 
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centrifugation for 2 min at 1,000 g. Eluate was determined as a biotinylated fraction. Both 
fractions were analysed for TRPC6 levels in Western Blots. 
 
Since normalization to GAPDH was not possible for this biotinylated fraction, normalization to 
UV-activated TCE staining was used for these PC12 biotinylation experiments (TCE staining 
described in section 3.2.12). At the time of experimental performance, no immobilon-FL PVDF 
membrane was available, so proteins were transferred to Bio-Rad PVDF membranes and an 
image of TCE staining in gels (taken in a GelDoc device) was used for calculation of lane 
normalization factors. 
Antibody staining was analysed by chemiluminescence as described above. A TRPC6 rb antibody 
(Alomone) was used as primary antibody. Images were taken with an Amersham Imager. 
 
 TRPC6 expression analyses of rat primary culture 
Rat neurons were grown in 6-well plates with a density of 500,000 cells/well and treated with 
hyperforin 1 µM, DMSO, fluoxetine 10 µM, venlafaxine 10 µM or MQ for 24 h. Cells were 
washed twice with cold PBS 1x and lysed with RIPA buffer. 20 µg of protein was used for 
Western Blot analyses. 
 
For rat experiments, proteins were transferred to a Bio-Rad PVDF membrane.  
After the last washing step, chemiluminescence analyses were performed. To do this, 
membranes were exposed to ECL Western Blotting Reagent for 5 min and images were 
immediately taken with an Amersham Imager.  
As primary antibodies were used: TRPC6 rb (Alomone), GAPDH ms (Millipore). TRPC6 staining 
was normalized to housekeeping protein GAPDH. 
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 Lipid raft isolation of PC12 cells and sample 
preparation for Western Blot 
PC12 cells were plated with a density of 10,000,000 cells/T 75 flask. Cells were treated for 48 h 
with ARC39 10 µM or MQ. Cells were washed twice with cold PBS 1x and next cooled HB (1 VE) 
with cold 1.85x TNE (1.2 VE) was applied. PC12 were immediately removed from the flask 
surface using plastic scrapers and collected. Cells were exposed to a regime of vortex and ultra-
sonication in an ice bath every 15 min for 1 h. Subsequently, samples were centrifuged at 
100,000 g for 20 h at 4 °C with an ultracentrifuge. The next day, supernatant (= TS) was 
collected, and the pellet (= TP) was resuspended in Lipid Raft Buffer. For TS, the Wessel-Flügge 
protein precipitation method was used to increase the concentration of the protein amount in 
Lipid Raft Buffer (= TSP). As there were usually few residual non-soluble precipitates, TP and TSP 
were centrifuged at 13,000 g for 10 min, supernatant was collected and finally used for 
experiments. 5 - 10 µg of protein were used for Western Blot analyses. 
For PC12 lipid raft isolation experiments, gel was placed after the run to a Gel Doc device to 
activate trichloroethanol (TCE) by UV light. This method led to a cross-linking of TCE to aromatic 
resides of amino acids, like tryptophan, and therefore enlargement of π-electron system and 
visualization of the entire protein amount. This was needed for protein load control, calculation 
of lane normalization factor and finally normalization of antibody staining to the amount of 
loaded protein. Afterwards cross-linked proteins were transferred to an immobilon-FL PVDF 
membrane and an image of membranes was taken at UV light for later analyses in ImageJ.  
An additional blocking step was introduced. Membranes were incubated 30 s to MeOH 100 % 
and afterwards air-dried. Then the general protocol was followed as described above, and 
membranes were blocked with 5 % BSA/TBST. 
The very last washing step was supplemented by an additional washing step with TBS 1x, as the 
resulting lack of tween was thought to improve fluorescent staining. 
Staining was imaged with a LI-COR Odyssey infrared scanner for 680 nm and 800 nm and 
quantitatively analysed in Image Studio. 
As primary antibodies were used: TRPC6 rb (CST), GAPDH ms (Millipore), flotillin-1 rb (CST). 
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 RNA analyses, cDNA synthesis and quantitative 
PCR 
Mice were bred as described above. Between the age of 12 to 17 weeks, animals were killed 
with CO2, brains were taken, and regions of frontal cortex and hippocampus were dissected. 
Tissue was placed in a 1.5 ml Eppi, equipped with a metal bead and 1 ml trizole, and finally 
homogenized for 90 s at 50 Hz in a TissueLyzer. After 10 min of incubation at RT, 200 ml 
chloroform was applied, Eppis were vortexed for 15 s and incubated again at RT for 5 min. The 
subsequent centrifugation step separated phases at 13,000 g for 15 min at 4 °C. 350 µl of upper 
aqueous phase was mixed with 350 µl EtOH 70 %. Lower phase was discarded. The sample was 
transferred to a spin cartridge with a collection tube and centrifuged at 12,000 g for 15 s at RT. 
Flow-through was discarded. 10 µl of DNase stock solution was mixed with 70 µl of RDD buffer 
and the mixture was added to the spin cartridge. Furthermore 500 µl of wash buffer II with EtOH 
was applied. The sample was centrifuged at 12,000 g for 15 s at 4 °C, flow-through was trashed. 
This washing step was repeated once. To dry the membrane, the tube was centrifuged at 12,000 
g for 1 min. Afterwards the collection tube was discarded, and the spin cartridge was equipped 
with a recovery tube. 30 µl of RNase-free water was added to the spin cartridge and incubated 
for 1 min at RT. Finally, the spin cartridge was centrifuged together with the recovery tube at 
12,000 g for 2 min at RT and RNA was collected. Sample concentrations were determined using a 
NanoDrop. 
For preparation of cDNA, 2 µl of 5x Reaction Mix were added to 0.5 µl qScript RT, mixed with 500 
ng RNA in MQ and placed in a PCR machine, while settings were: 5 min at 22 °C, 30 min at 42 °C, 
5 min at 85 °C, holding temperature 4 °C. 
The gene expression was analysed by quantitative PCR and TaqMan technology in a LightCycler 
System. 2.5 µl of cDNA (diluted 1:10 with MQ) were mixed with 5 µl of iTAQ probes Bio-Rad, 2 µl 
MQ, 0.5 µl TaqMan TRPC6-FAM (20x) and 0.5 µl TaqMan GAPDH-VIC (20x), aliquoted in a 96-well 
plate and placed in the LightCycler System with following settings: 30 s at 95 °C, 45 cycles of 15 s 
at 95 °C / 30 s at 60 °C, and finally 30 s 40 °C. GAPDH served as a reference gene. Using Abs 
Quant/2nd Derivative Max software, normalized expression was calculated. 
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 Lipidomics 
PC12 cells were treated either for 1 h with fluoxetine 10 µM, venlafaxine 10 µM, MQ or for 48 h 
with ARC39 10 µM, MQ, and two different kind of samples were prepared - whole cells and a P2 
fraction. Analyses of sphingolipid changes in whole cells provided an insight into general changes 
due to ASM inhibition, analyses of P2 fraction should provide better knowledge about specific 
alterations of plasma membrane composition and enable speculation about rearrangement of 
microdomains. 
For whole cell samples, PC12 cells were grown in 6-well plates with a density of 1,000,000 
cells/well and treated as described above. Following the incubation time, cells were washed 
twice with cold PBS 1x and ice-cold MeOH 100 % was applied. Cells were scraped into the 
suspension, collected in 0.5 ml Eppis and immediately stored at -80 °C. 
For preparation of a P2 fraction, PC12 cells were grown in T 25 with a density of 3,000,000 
cells/flask and treated as described above. After incubation time, cells were washed twice with 
precooled PBS 1x and finally ice-cold HB was applied. Cells were scraped into solution and stored 
on ice. Samples were exposed to a regime of vortexing and ultra-sonication in an ice-bath for 10 
s, every 15 min for 30 min. Afterwards they were centrifuged for 10 min at 1,000 g to remove 
nuclei. Supernatant was collected and centrifuged once more for 20 min at 13,000 g to separate 
cytoplasmic fraction from membrane fraction P2. The supernatant was discarded and the P2 
pellet was resuspended in MeOH 100 % and immediately stored at -80 °C. 
All samples were sent for lipidomical analyses via mass spectronomy to Dr. Schumacher, Prof. 
Kleuser’s lab, Institute of Nutritional Science, University of Potsdam, Germany. Samples were 
processed as described in ZEITLER ET AL. 2019 (Zeitler et al. 2019). Results were given as pmol of 
sphingolipid species/sample, for graphical representation a ratio of ceramide 
species/sphingomyelin species was calculated and displayed. 
 
 Animal welfare declaration 
All experiments were performed according to the European Committees Council Directive 
2010/63/EU, German law for animal care “TierSchG” 18.05.2006 (BGBl. I S. 1206, 1313), last 
updated 17.12.2018 (BGBl. I S. 2586) and the German regulation for protection of animals used 
for scientific purposes “TierSchVersV” 01.08.2013 (BGBl. I S. 3125, 3126), last updated 
31.08.2015 (BGBl. I S. 1474). 
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 Statistical analyses 
All data sets were analysed statistically in GraphPad Prism 7. Data is shown as mean ± standard 
error of the means (SEM). Data distribution was checked with D’Agostino Pearson omnibus 
normality test. If experiments consisted of two data sets, analyses were performed either with 
the unpaired student’s t-test or the Mann-Whitney test. More than two data sets were analysed 
with one-way ANOVA ad hoc Dunnett’s or Tukey’s multiple comparison test. When two different 
parameters needed to be considered, two-way ANOVA was used ad hoc Sidak’s multiple 
comparison test. Appropriate tests were used wherever statistically necessary. p ≤ 0.05 was 
considered as statistically significant: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, 
indicated in respective results section. 
 
 Research facilities 
Molecular biological and pharmaceutical lab work was conducted in Prof. Friedland’s lab for 
Molecular and Clinical Pharmacy (Department of Chemistry and Pharmacy, Schuhstraße 19, 
Erlangen, FAU Erlangen), and in Prof. Kornhuber’s lab for Molecular Neurobiology (Psychiatric 
and Psychotherapeutic Clinic of the University Hospital, Schwabachanlage 6, Erlangen, FAU 
Erlangen). 
Ultracentrifugation was performed in Prof. Winner’s lab for Stem Cell Biology (Nikolaus-Fiebiger 
Center, Glücksstraße 6, Erlangen, FAU Erlangen). 
Lipidomical analyses were performed at Prof. Kleuser’s lab for Toxicology, together with Dr. 
Schumacher (Institute of Food Science, Arthur-Scheunert-Allee 114-116, Nuthetal, University of 
Potsdam). 
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4 Results 
4.1 Several Antidepressants inhibit ASM activity in 
neuronal cells 
 FIASMA antidepressants inhibit ASM activity in 
PC12 cells 
In earlier studies, the inhibition of ASM activity induced by FIASMA antidepressants was 
investigated mainly in human brain neuroglioma H4 cells (Kornhuber et al. 2008). FIASMAs 
introduced significant enzyme inhibition at concentrations of 10 µM to 30 µM when applied for 
30 min. For this study, it was necessary to test whether FIASMAs exert ASM inhibitory effects 
also in the neuron-like PC12 cell line. PC12 cells were either treated with FIASMA 
antidepressants fluoxetine, sertraline or nortriptyline, or with non-FIASMA antidepressant 
venlafaxine or MQ control for 1 h with concentrations of 1 µM or 10 µM. FIASMAs at 10 µM 
concentration showed a significant inhibitory effect in our PC12 cell model [ctl: 1 ± 0; fluox: 
0.4497 ± 11.8, p = 0.0102 (-55 %); sert: 0.295 ± 0.053, p = 0.0083 (-71 %); nor: 0.435 ± 0.102, p = 
0.0011 (-57 %)]. The FIASMA concentrations of 1 µM did not show any significant inhibitory 
effect. Also, venlafaxine did not exert an inhibitory effect, independent of its concentration (fig. 
11 A) (Zeitler et al. 2019). 
To pinpoint ASM as the meditating target, the specific ASM inhibitor ARC39 (described as 
compound 7c in ROTH ET AL. 2009 (Roth et al. 2009)) was used. To confirm reported enzyme 
inhibition effects (IC50 0.02 mM (Roth et al. 2009)) in our PC12 cell model, three concentrations 
were tested (1 µM, 3 µM, 10 µM) for 48 h. ARC39 strongly inhibited ASM activity in a 
concentration dependent manner [ctl: 1 ± 0.037; 1 µM: 0.5054 ± 0.043 p < 0.0001 (-49 %); 3 
µM:0.3109 ± 0.0080, p < 0.0001 (-69 %); 10 µM: 0.2409 ± 0.0089, p < 0.0001 (-76 %)] (fig. 11 B) 
(Zeitler et al. 2019). 
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Figure 11: FIASMA antidepressants and ARC39 inhibit ASM activity in PC12 cells concentration-
dependently 
A: FIASMA antidepressants fluoxetine 10 µM (fluox; p = 0.0102), sertraline 10 µM (sert; p = 0.0083) and 
nortriptyline 10 µM (nor; p = 0.0011) inhibited ASM activity in PC12 cells, while non-FIASMA 
antidepressant venlafaxine 10 µM (venla; p = 0.9997) showed no effect. Incubations with 1 µM drug 
concentration exhibited no inhibitory effect (pfluox = 0.4891; psert = 0.8763; pnor = 0.8903; pvenla = 0.9994). 
One-way ANOVA ad hoc Dunnett’s test, compared with ctl (MQ). ±SEM, N = 3 (N = number of cell 
batches), performed as a biological single. B: Specific ASM inhibitor ARC39 exerted its inhibitory effect 
concentration dependently (1 µM: p < 0.0001; 3 µM: p < 0.0001; 10 µM: p < 0.0001). One-way ANOVA ad 
hoc Dunnett’s test, compared with ctl (= MQ). ±SEM, N = 1 (N = number of cell batches), performed as a 
biological triplicate. 
 
 Fluoxetine impacts ASM activity in neuronal and 
glial primary cells differentially 
In a next step, it was determined whether FIASMA properties were also evident in primary cells. 
Fluoxetine 10 µM was applied to rat cortical neurons for30 min, 1 h and 24 h. Cells were also 
treated with fluoxetine concentration of 1 µM for 24 h. Short incubation times of 30 min or 1 h 
with 10 µM, as well as the fluoxetine concentration 1 µM for 24 h, resulted in no inhibitory 
effects, whereas treatment with fluoxetine 10 µM for 24 h clearly resulted in an ASM activity 
inhibition [ctl: 1.063 ± 0.165; fluox 10 µM, 24 h: 0.3007 ± 0.099, pctl against fluox = 0.0145 (-72 %)] 
(fig. 12 A). 
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Additionally, I wanted to check if observed enzyme inhibition in neurons was due to ASM activity 
inhibition itself or to impaired cell viability. For this purpose, rat cortical neurons were treated 
with fluoxetine 10 µM or solvent control H2O. 24 h later, LDH release in the supernatant was 
analysed. Fluoxetine and H2O treatment did not differ regarding cell viability [ctl: 100 ± 5.214; 
H2O: 10.18 ± 3.8 % of ctl (max. LDH release), p < 0.0001 (-90 %); fluox: 12.17 ± 3.2 % of ctl (max. 
LDH release), p < 0.0001 (-88 %)] (fig. 12 B). 
*
2
 
Figure 12: Fluoxetine inhibits ASM in rat cortical neurons concentration- and time-dependently 
A: Fluoxetine exerted an inhibitory effect concentration- and time-dependently (10 µM, 30 min: p = 
0.9872; 10 µM, 1 h: p = 0.6530; 1 µM, 24 h: p = 0.8811; 10 µM, 24 h: p = 0.0145) in rat cortical neurons. 
One-way ANOVA ad hoc Tukey’s test, compared with individual ctl of time points, ctl = MQ. ±SEM, N = 3 (N 
= number of cell batches), performed as a biological single or duplicate. B: Treatment with fluoxetine 10 
µM or solvent control H2O exerted a similar effect for cell viability in rat cortical neurons (H2O: p <0.0001; 
fluox: p < 0.0001; pH2O against fluox = 0.9398). Ctl = max. LDH release. One-way ANOVA ad hoc Tukey’s test. 
±SEM, N = 3 (N = number of cell batches), performed as a biological duplicate. 
 
To get a deeper understanding of effects of FIASMAs on different cell types, ASM inhibition by 
fluoxetine in primary rat glial cells was investigated. Cultures of rat glial cells were treated with 
fluoxetine 10 µM for different time spans (30 min, 1 h, 24 h). Fluoxetine exhibited a strong ASM 
inhibitory effect for all time periods of the treatment [ctl30 min: 1 ± 0; fluox30 min: 0.2059 ± 0.076, p 
< 0.0001 (-79 %); ctl1 h: 0.9744 ± 0.0291; fluox1 h: 0.1398 ± 0.0349, p < 0.0001 (-86 %); ctl24 h: 
1:003 ± 0:0753; fluox24 h: 0.0868 ± 0.045, p < 0.0001 (-91 %)] (fig. 13). 
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Figure 13: Fluoxetine inhibits ASM activity in rat glial cells time-dependently 
Fluoxetine 10 µM inhibits ASM activity (30 min: p < 0.0001; 1 h: p < 0.0001; 24 h: p < 0.0001) in rat glial 
cells. ANOVA ad hoc Tukey’s test, compared with individual ctl of time points, ctl = MQ. ±SEM, N = 3 (N = 
number of cell batches), performed as a biological single. 
 
 Hyperforin does not affect ASM activity 
The antidepressant hyperforin is known as activator of TRPC6. In terms of its physiochemical 
properties, hyperforin cannot be characterized as a cationic amphiphilic drug and was 
hypothesized not to exert any ASM activity inhibition. Hyperforin was applied to rat cortical 
neurons for 24 h in concentrations commonly used for long-term experiments (0.3 µM, 0.5 µM, 
1.0 µM). None of these concentrations impacted ASM activity (fig. 14). 
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Figure 14: Antidepressant hyperforin has no impact on ASM activity in rat cortical neurons 
Hyperforin exerts no inhibitory effect on ASM activity (0.3 µM: p = 0.8593; 0.5 µM: p = 0.9933; 1.0 µM: p = 
0.8998) in rat cortical neurons. One-way ANOVA ad hoc Dunnett’s test, compared with DMSO. ±SEM, N = 
5 (N = number of cell batches), performed as a biological single or duplicate. 
 
4.2 ASM activity influences TRPC6 biology 
 TRPC6 RNA expression is regulated by ASM 
activity 
To elucidate if the modulation of ASM activity impacted TRPC6 biology, hippocampal and cortical 
tissue of female and male ASM KO and ASM tg mice were taken and TRPC6 RNA expression 
analysed. In hippocampus, these experiments revealed a significant decrease in TRPC6 RNA 
expression of ASM KO male compared with ASM KO female mice [ASM KO female: 0.004892 ± 
0.0004; ASM KO male: 0.003652 ± 0.00011, pASM KO female against ASM KO male = 0.0352 (-25 %)], while 
clearly indicating a sex-genotype interaction in two-way ANOVA [interaction: F(1.16) = 5.026, p = 
0.0395]. In cortex, no such interaction was detectable neither between sex nor genotype (fig. 
15). 
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Figure 15: ASM deficiency regulates TRPC6 RNA expression region- and sex-specifically 
A: TRPC6 RNA expression in hippocampal tissue is regulated sex-specifically in ASM-deficient mice. Two-
way ANOVA revealed an effect for interaction: F(1.16) = 5.026, p = 0.0395; but no effect for gender or 
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genotype [gender: F(1.16) = 2.234, p = 0.1545; genotype: F(1.16) = 0.2749, p = 0.6073]. Sidak’s test 
exhibited specific differences for ASM KO male and females in the context of TRPC6 RNA levels (pASM KO 
female against ASM KO male = 0.0352). B: In cortical tissue no significant interaction was detectable. Two-way 
ANOVA revealed further no effect for gender or genotype [interaction: F(1.16) = 0.7122, p = 0.4111; 
gender: F(1.16) = 0.261, p = 0.6164; genotype: F(1.16) = 0.2472, p = 0.6258]. A and B: ±SEM, N = 5 (N = 
number of tissue batches), performed as a biological single.  
 
Further, an ASM-transgenic mouse model crossed with an EMX1/CRE mouse line was used, that 
had a constituently overexpression of ASM in excitatory neurons and glia of the forebrain. Tissue 
of hippocampus and cortex was taken. No alterations in TRPC6 RNA levels of hippocampal and 
cortical tissue were found (fig. 16). 
 
Figure 16: ASM overexpression does not impact TRPC6 RNA levels 
A: Two-way ANOVA revealed no effect for interaction, gender or genotype in ASM tg (tg/wt) hippocampus 
[interaction: F(1.10) = 0.03335, p = 0.8587; gender: F(1.10) = 0.1921, p = 0.6705; genotype: F(1.10) = 
0.2106, p = 0.6561]. B: Two-way ANOVA test revealed no effect for interaction, gender or genotype in 
ASM tg (tg/wt) cortex [interaction: F(1.10) = 0.3254, p = 0.5810; gender: F(1.10) = 0.005847, p = 0.9406; 
genotype: F(1.10) = 0.1205, p = 0.7356]. A and B: ±SEM, N = 5 (N = number of tissue batches), performed 
as a biological single.  
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 Antidepressive treatment increases TRPC6 
protein expression 
In animal experiments hyperforin treatment has been shown to induce TRPC6 expression in 
cortical tissue of brain samples (Gibon et al. 2013). The question raised how antidepressant 
treatment and also inhibition of ASM activity might influence TRPC6 protein expression in 
cortical neurons. Cortical rat neurons were treated for 24 h with fluoxetine 10 µM, venlafaxine 
10 µM, ARC39 10 µM, and hyperforin 0.3 µM. As a solvent control for the antidepressants and 
ARC39, Millipore water (H2O) was used. As a control for hyperforin, DMSO was applied. 
Treatment with hyperforin increased TRPC6 expression compared with solvent control H2O [H2O: 
1 ± 0; hyp: 1.245 ± 0.067, phyp 0.3 µM compared with H2O = 0.0154 (+25 %)] and induced a trend compared 
with DMSO control (phyp 0.3 µM compared with DMSO = 0.0958). Treatments with antidepressants 
fluoxetine [fluox: 1.208 ± 0.0552, pfluox 10 µM compared with H2O = 0.0477 (+21 %)] or venlafaxine [venla: 
1.214 ± 0.0621, pvenla 10 µM compared with H2O = 0.0398 (+21 %)] led both to an increase in TRPC6 
expression, independent on their FIASMA properties. Also, direct ASM activity inhibition with 
ARC39 10 µM increased TRPC6 protein expression significantly [ARC39: 1.206 ± 0.0655, pARC39 10 
µM compared with H2O = 0.0494 (+21 %)] (fig. 17).  
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Figure 17: Antidepressants induce TRPC6 protein expression in rat cortical neurons 
A: Cortical rat cultures were treated with controls (H2O, DMSO), antidepressants (hyp 0.3 µM, fluox 10 
µM, venla 10 µM) and ASM inhibitor ARC39 10 µM for 24 h. All antidepressant treatments and ASM 
activity inhibition led to an increase in TRPC6 protein expression (phyp 0.3 µM = 0.0154; pfluox 10 µM = 0.0477; 
pvenla 10 µM = 0.0398; pARC39 10 µM = 0.0494; one-way ANOVA ad hoc Dunnett’s test compared with H2O). 
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Treatment with hyp 0.3 µM showed a positive trend compared with DMSO (phyp 0.3 µM = 0.0958; student’s t-
test). ±SEM, N = 5-6 (N = number of cell batches), performed as a biological single. B: Representative 
image of Western Blot after indicated treatments, TRPC6 was detected at 110 kDa, GAPDH was detected 
at 37 kDa. 
 
 Fluoxetine treatment increases TRPC6 surface 
expression 
In a next step, I wanted to elucidate how antidepressant treatment affected TRPC6 surface 
levels. For this approach, all proteins at the surface were labelled with a biotin construct, 
allowing me to separate a surface (biotinylated) and internal (non-biotinylated) protein fraction. 
The analyses of fractions by Western Blotting revealed an increase in TRPC6 internal fraction 
after the 1 h treatment with venlafaxine 10 µM or fluoxetine 10 µM [ctl: 1 ± 0; venla: 1.34 ± 
0.0273, pA: venla 10 µM against ctl = 0.0109 (+34 %); fluox: 1.539 ± 0.1201, pA: fluox 10 µM against ctl = 0.0002 
(+54 %)] (fig. 18 A). Analysis of the surface fraction exhibited a rise in TRPC6 protein levels after 
fluoxetine treatment, while incubation with venlafaxine did not impact TRPC6 surface protein 
levels [ctl: 1 ± 0; fluox: 1.235 ± 0.0795, pC: fluox 10 µM against ctl = 0.0282 (+24 %)] (fig. 18 C) (Zeitler et 
al. 2019). 
ctl
ve
nla
 10
 µM
flu
ox
 10
 µM
0.0
0.5
1.0
1.5
2.0
2.5
TR
PC
6 
sig
na
l [
no
rm
. t
o 
ct
l] ***
*
A
TRPC6
(110 kDa)
fluox 10 µMvenla 10 µMctl
B
 
 Results 
112 
ctl
ve
nla
 10
 µM
flu
ox
 10
 µM
0.0
0.5
1.0
1.5
2.0
2.5
TR
PC
6 
si
gn
al
 [n
or
m
. t
o 
ct
l]
*
C
TRPC6
(110 kDa)
fluox 10 µMvenla 10 µMctl
D
 
Figure 18: Fluoxetine increases TRPC6 protein expression in internal and surface fractions of PC12 
cells 
A: The non-biotinylated (internal) fraction exhibited an increase in TRPC6 levels (pvenla 10 µM against ctl = 
0.0109; pfluox 10 µM against ctl = 0.0002). One-way ANOVA ad hoc Tukey’s test, ±SEM, N = 3 (N = number of cell 
batches), measured as duplicates. B: Representative Western Blot image of internal fraction after 
indicated treatments, stained for TRPC6 at 110 kDa. C: The biotinylated (surface) fraction showed an 
increase in TRPC6 levels solely after treatment with fluoxetine (pvenla10 µM against ctl = 0.7715; pfluox 10 µM against ctl 
= 0.0282). One-way ANOVA ad hoc Tukey’s test, ±SEM, N = 3 (N = number of cell batches), measured as 
duplicates. D: Representative Western Blot images of surface fraction after indicated treatments, stained 
for TRPC6 at 110 kDa. 
 
4.3 ASM activity regulates TRPC6 Ca2+ influx 
 FIASMA antidepressant fluoxetine reduces the 
TRPC6-mediated Ca2+ influx in PC12 cells 
One of the main functions of TRPC6 activation by hyperforin is an increase in Ca2+ influx into the 
cell. In this experiment, I wanted to assess the role of ASM activity in TRPC6 Ca2+ influx using 
Fura-2 imaging. PC12 cells were incubated for 1 h with fluoxetine 1 µM or 10 µM, or with 
venlafaxine 1 µM or 10 µM. Subsequently, hyperforin 10 µM was applied to cells and immediate 
Ca2+ influx was recorded. Fluoxetine 10 µM preincubation inhibited TRPC6-mediated Ca2+ influx 
compared with untreated control [untreated (ut): 1 ± 0.0063; venla 10 µM: 0.8257 ± 0.0423; 
fluox 1 µM: 0.8129 ± 0.0432; fluox 10 µM: 0.3875 ± 0.0549, put compared with fluox 10 µM < 0.0001 (-61 
%), pvenla 10 µM compared with fluox 10 µM = 0.0005 (-44 %), pfluox 1 µM compared with fluox 10 µM = 0.0007 (-43 %)], 
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while fluoxetine 1 µM had no impact. Venlafaxine did not influence analysed Ca2+ currents (fig. 
19). 
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Figure 19: Fluoxetine inhibits TRPC6-mediated Ca2+ influx in PC12 cells 
A: Fluoxetine inhibits hyperforin-induced Ca2+ influx in PC12 cells concentration-dependently compared 
with untreated control (pfluox 1 µM = 0.1895; pfluox 10 µM < 0.0001). Venlafaxine had no impact on Ca2+ influx 
(pvenla 1 µM = 0.5175; pvenla 10 µM = 0.2432) compared with untreated control. Treatment with fluoxetine 10 
µM induced lower Ca2+ influx directly compared with venlafaxine 10 µM (p = 0.0005) or fluoxetine 1 µM (p 
= 0.0007). One-way ANOVA ad hoc Tukey’s test, ±SEM, N = 3 (N = number of cell batches), performed as a 
biological single or duplicate. B: Representative Ca2+ currents after indicated treatments; arrow indicates 
application of hyperforin 10 µM. 
 
 Pharmacological ASM activity inhibition does 
not impact TRPC6-mediated Ca2+ influx in rat cortical 
neurons 
To assess Ca2+ imaging in primary cells, rat cortical neurons were used for pharmacological ASM 
activity inhibition. Cells were treated for 1 h or 24 h with FIASMA antidepressant fluoxetine 10 
µM or specific ASM inhibitor ARC39 10 µM, with non-FIASMA antidepressant venlafaxine 10 µM 
or solvent control MQ. Application of hyperforin 10 µM induced immediate TRPC6-mediated 
Ca2+ influx. Neither after 1 h of preincubation (fig. 20 A) nor after 24 h (fig. 20 C) any significant 
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modification of calcium flow was measurable, except for a small trend showing a reduction in 
Ca2+ influx after 24 h treatment with fluoxetine and ARC39 (fig. 20 C). 
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Figure 20: Pharmacological ASM activity inhibition does not exert any effect for TRPC6-mediated 
Ca2+ influx in rat cortical neurons 
A: Venlafaxine 10 µM, fluoxetine 10 µM or ARC39 10 µM were incubated for 1 h to rat cortical neurons. 
TRPC6-mediated Ca2+ influx was activated by hyperforin 10 µM. No treatment showed any significant 
impact on Ca2+ influx (pvenla 10 µM = 0.9999; pfluox 10 µM = 0.9792; pARC39 10 µM = 0.1817). One-way ANOVA ad 
hoc Dunnett’s test, compared with ctl (MQ). ±SEM, N = 3 (N = number of cell batches), performed as a 
biological single, duplicate or triplicate. B: Representative Ca2+ currents after indicated treatments for 1 h; 
arrow indicates application of hyperforin 10 µM. C: Venlafaxine 10 µM, fluoxetine 10 µM or ARC39 10 µM 
were incubated for 24 h to rat cortical neurons. TRPC6-mediated Ca2+ influx was activated by hyperforin 
10 µM. No treatment showed any significant impact on Ca2+ influx (pvenla 10 µM = 0.9911; pfluox 10 µM = 0.8528; 
pARC39 10 µM = 0.7088). One-way ANOVA ad hoc Dunnett’s test, compared with ctl (MQ). ±SEM, N = 3 (N = 
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number of cell batches), performed as a biological single, duplicate or triplicate. D: Representative Ca2+ 
currents after indicated treatments for 24 h; arrow indicates application of hyperforin 10 µM. 
 
 Genetic ASM deficiency decreases TRPC6-
mediated Ca2+ influx in mouse cortical neurons 
In a next step, TRPC6-mediated Ca2+ influx in genetically ASM-deficient mouse cortical neurons 
compared with ASM WT neurons was analysed. Basal Ca2+ levels were not changed (fig. 21 A). 
However, Ca2+ flow, which was induced by hyperforin 10 µM, was decreased significantly in 
ASM-deficient mouse cortical neurons compared with ASM WT neurons [ASM WT: 1 ± 0.082; 
ASM KO: 0.7235 ± 0.0442, p = 0.0081 (-28 %)] (fig. 21 B). 
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Figure 21: Reduced TRPC6-mediated Ca2+ influx in ASM-deficient mouse cortical neurons 
A. No changes in basal Ca2+ levels (p = 0.1683). B: Ca2+ influx is significantly reduced in ASM-deficient 
cortical mouse neurons (p = 0.0081). (A) Mann-Whitney test and (B) Student’s t-test, compared with ASM 
WT cortical neurons. ±SEM, N = 4 (N = number of cell batches), performed as a biological single, duplicate, 
triplicate or quadruplicate. C: Representative time-curve of TRPC6-mediated Ca2+ influx in cortical mouse 
neurons. Arrow indicates application of hyperforin 10 µM. 
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 Concomitant culturing of ASM WT glia with 
ASM KO neurons does not rescue impaired Ca2+ influx 
in ASM KO neurons 
To investigate if the diminished Ca2+ influx in ASM KO neurons could be rescued by the 
concomitant culturing of ASM KO neurons on ASM WT glia cells, both cell types were plated in a 
Banker’s culture. TRPC6-mediated Ca2+ influx in ASM KO neurons, which was induced by 
hyperforin 10 µM, was reduced compared with ASM WT neurons [ASM WT: 1 ± 0; ASM KO: 
0.6393 ± 0.095, p = 0.0234 (-36 %)] (fig. 22). 
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Figure 22: Concomitant culturing of ASM WT glia with ASM KO neurons does not rescue impaired 
TRPC6-mediated Ca2+ influx in ASM KO neurons 
A: Ca2+ influx is reduced in ASM-deficient cortical mouse neurons (p = 0.0234) which were grown together 
with ASM WT glial cells. Student’s t-test, compared with ASM WT cortical neurons grown on ASM WT glial 
cells. ±SEM, N = 3 (N = number of cell batches), performed as a biological single or duplicate. B: 
Representative time-curve of TRPC6-mediated Ca2+ influx in cortical mouse neurons. Arrow indicates 
application of hyperforin 10 µM. 
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4.4 ASM activity impacts the phosphorylation status of 
CREB  
 Physiological differences in CREB 
phosphorylation in primary mouse neurons 
Earlier studies showed that TRPC6-mediated Ca2+ currents result in the phosphorylation of 
transcriptional factor CREB, which induces gene transcription of several important genes related 
to neuronal functioning (Gibon et al. 2013; Heiser et al. 2013). Immuno-cytochemistry was 
applied to investigate differences in CREB phosphorylation between ASM genotypes and cell 
types. 
The question raised if there were differences in CREB phosphorylation at Ser133 under 
unstimulated basal conditions. To address this question, unstimulated ASM-deficient cortical 
and hippocampal cultures were compared with ASM WT. First, apparent differences were 
revealed concerning ASM WT and ASM KO. ASM-deficient neurons showed an excessive CREB 
phosphorylation in cortical [ASM WT: 1 ± 0.096; ASM KO: 1.792 ± 0.165, p = 0.0006 (+79 %)] as 
well as hippocampal [ASM WT: 0.6736 ± 0.0267; ASM KO: 1.265 ± 0.0774, p < 0.0001 (+88 %)] 
neurons compared with ASM WT cells. Basal CREB phosphorylation was more pronounced in 
ASM WT cortex compared with ASM WT hippocampus (hippocampus: -33 %). Second, neither 
differences in pCREB staining in ASM WT glia or ASM KO glia, nor between cortex glia and 
hippocampus glia were detectable (fig. 23). 
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Figure 23: Excessive CREB phosphorylation under basal conditions in ASM-deficient mouse culture 
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A: ASM deficiency in cortical mouse neurons induced CREB phosphorylation (p = 0.0006). Student’s t-test, 
compared with ASM WT. B: Representative images of pCREB staining in single nuclei of murine cortical 
neurons. Scale bar indicates 5 µm. C: ASM deficiency in hippocampal mouse neurons induces CREB 
phosphorylation (p < 0.0001). Student’s t-test, compared with ASM WT. D: Representative images of 
pCREB staining in single nuclei of murine hippocampal neurons. Scale bar indicates 5 µm. E: No changes in 
pCREB in ASM-deficient glial cells isolated from cortex (p = 0.0861). Mann-Whitney t-test, compared with 
ASM WT. F: No changes in pCREB in ASM-deficient glial cells isolated from hippocampus (p = 0.8064). 
Mann-Whitney t-test, compared with ASM WT. A, C, E, F: ±SEM, N = 2-3 (N = number of single mice), 4-5 
regions per cover slip, performed as a biological single or duplicate. 
 
Next, CREB phosphorylation under basal conditions in ASM-transgenic cultures was analysed. In 
ASM tg (tg/wt) cortical neurons, the staining for pCREB was strongly reduced compared with 
ASM WT neurons [ASM WT: 1 ± 0.0301; ASM tg (tg/wt) 0.6907 ± 0.0232, p < 0.0001 (-31%)]. 
Interestingly, also pCREB staining was decreased in ASM tg (tg/wt) hippocampal neurons [ASM 
WT: 0.5422 ± 0.021; ASM tg (tg/wt): 0.4715 ± 0.024, p = 0.0310 (-13 %)] compared with ASM WT 
hippocampal neurons. In general, CREB phosphorylation in ASM WT hippocampal neurons was 
decreased compared with ASM WT cortical neurons (-46 %). Also the pCREB staining of ASM tg 
(tg/wt) cortical glia cells was decreased compared with ASM WT glial cells [ASM WT: 0.04232 ± 
0.003; ASM tg (tg/wt): 0.03087 ± 0.002, p = 0.0045 (-27 %)], while CREB phosphorylation in ASM 
tg (tg/wt) glial cells isolated from hippocampus remained unaffected compared with ASM WT 
glial cells (fig. 24). 
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Figure 24: Reduced CREB phosphorylation under basal conditions in ASM-overexpressing mouse 
culture 
ASM-transgenic mice were crossed with an EMX1/Cre mouse to selectively overexpress ASM in excitatory 
forebrain neurons and glial cells. A: ASM overexpression in cortical mouse neurons decreased CREB 
phosphorylation (p < 0.0001). B: Representative images of pCREB staining in single nuclei of murine 
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cortical neurons. Scale bar indicates 5 µm. C: ASM overexpression in hippocampal mouse neurons 
decreased CREB phosphorylation (p = 0.0310). D: Representative images of pCREB staining in single nuclei 
of murine hippocampal neurons. Scale bar indicates 5 µm. E: ASM overexpression decreased CREB 
phosphorylation in cortical glial cells (p = 0.0045). F: No changes in pCREB in ASM-transgenic glial cells 
isolated from hippocampus (p = 0. 4671). Student’s t-test (A, E) or Mann-Whitney test (C, F). All compared 
with ASM WT. ±SEM, N = 3 (N = number of single mice), 5 regions per cover slip, performed as a biological 
duplicate.  
 
 ASM activity inhibition impacts TRPC6-mediated 
CREB phosphorylation in primary rat neurons 
Observed differences in CREB phosphorylation under basal conditions led to the question how 
pCREB might be regulated under TRPC6 activation. In a piloting experiment, it was investigated if 
pharmacological ASM activity inhibition could interfere with TRPC6 induced changes in CREB 
phosphorylation. Only pCREB staining of neurons were taken into account which were negative 
for GAD65 to selectively analyse excitatory cortical neurons, since TRPC6 was postulated to be 
mainly expressed at excitatory synapses (Zhou et al. 2008). 
Cortical rat neurons were treated for 24 h with ARC39 10 µM or solvent control water (H2O) 
concomitantly with TRPC6 activator hyperforin 1 µM or respective solvent control DMSO. In cells 
treated with water, hyperforin induced an increase in CREB phosphorylation [H2ODMSO: 1 ± 0.097; 
H2Ohyp: 1.316 ± 0.0793, pH20: DMSO against hyp = 0.0294 (32 %)]. In cells where ASM activity was 
inhibited with ARC39, this effect could not be detected. However, two-way ANOVA revealed an 
effect of treatment [F(1.57) = 6.27, p = 0.0152]. Interestingly, a small trend was visible that 
pharmacological ASM activity inhibition could lead to an increase in CREB phosphorylation even 
without TRPC6 activation, similar to findings in ASM KO neurons under basal conditions (see 
section 4.4.1, fig. 23) (fig. 25). 
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Figure 25: ASM activity inhibition counteracted TRPC6-induced CREB phosphorylation in 
excitatory rat cortical neurons 
A: Hyperforin 1 µM induced CREB phosphorylation in rat excitatory cortical neurons (pH20: DMSO against hyp = 
0.0294, Sidak’s test), this effect was partly abolished when ASM activity was inhibited with ARC39 10 µM 
(pARC39: DMSO against hyp = 0.5137, Sidak’s test). Two-way ANOVA revealed an effect for hyperforin treatment, 
and no effect for interaction or ASM inhibition [interaction: F(1.57) = 1.043, p = 0.3114; ASM inhibition: 
F(1.57) = 0.1383, p = 0.7114; treatment: F(1.57) = 6.27, p = 0.0152]. ±SEM, N = 1 (N = number of cell 
batches), 5 regions per cover slip, performed as a biological triplicate. B: Representative images of pCREB 
staining in single nuclei of excitatory murine neurons after indicated treatments. Scale bar indicates 5 µm. 
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 Genetic ASM deficiency impacts TRPC6-
mediated CREB phosphorylation in primary mouse 
neurons 
Next, I aimed at analysing hyperforin-induced CREB phosphorylation under full ASM deficiency in 
ASM KO cortical neurons. To broaden the insight in pCREB regulation, for all following mouse 
neuronal experiments, both, excitatory and inhibitory neurons were analysed. To reveal also 
dynamic aspects of CREB phosphorylation, a time course was conducted. 
Excitatory neurons: CREB phosphorylation was analysed after treatment with hyperforin 1 µM at 
four specific time points (20 min, 1 h, 6 h, 24 h). This experiment showed distinctive hyperforin 
induced changes after 20 min treatment for ASM WT and ASM KO cells [ASM WTDMSO: 1 ± 0.080; 
ASM KODMSO: 2.336 ± 0.4856, pDMSO: ASM WT against ASM KO = 0.0032 (+134 %); ASM KOhyp 1.204 ± 0.283, 
pASM KO: DMSO against hyp = 0.0175 (-49 %)]. Two-way ANOVA revealed an effect for genotype-
treatment interaction and genotype alone [interaction: F(1.36) = 6.143, p = 0.0180; genotype: 
F(1.36) = 4.414, p = 0.0427]. This difference disappeared gradually over time. Two-way ANOVA 
revealed an effect for treatment at the 6 h time point [F(1.35) = 4.688, p = 0.0373]. After 24 h, 
effects were almost of the same extent for both ASM mouse genotypes [ASM WTDMSO: 0.9163 ± 
0.166; ASM WThyp: 3.366 ± 0.704, pASM WT: DMSO against hyp = 0.0118 (+267 %); ASM KODMSO: 1.497 ± 
0.176; ASM KOhyp: 4.382 ± 0.921, pASM KO: DMSO against hyp = 0.0029 (193 %)]. Two-way ANOVA 
revealed and effect for treatment at the 24 h time point [F(1.36) = 20.31, p < 0.0001] (fig. 26). 
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Figure 26: ASM deficiency impacts pCREB time-dependently in excitatory cortical mouse neurons 
A: After 20 min treatment, pCREB was induced in ASM KO cortical neurons compared with ASM WT 
neurons (pDMSO: ASM WT against ASM KO = 0.0032, Sidak’s test) and hyperforin 1 µM decreased CREB 
phosphorylation in ASM-deficient cells compared with ASM WT cells (pASM KO: DMSO against hyp = 0.0175, Sidak’s 
test). Two-way ANOVA revealed an effect for genotype-treatment interaction and genotype, and no effect 
for treatment [interaction: F(1.36) = 6.143, p = 0.0180; genotype: F(1.36) = 4.414, p = 0.0427; treatment: 
F(1.36) = 1.961, p = 0.1700]. B and C: After 1 h and 6 h treatment, the effects described for 20 min time 
point were abolished. (B) Two-way ANOVA revealed no effect for interaction, genotype or treatment 
[interaction: F(1.35) = 0.2107, p = 0.6490; genotype: F(1.35) = 1.073, p = 0.3074; treatment: F(1.35) = 
2.616, p = 0.1148] and (C) Two-way ANOVA revealed an effect for treatment, but no effect for interaction 
or genotype [interaction: F(1.35) = 0.2636, p = 0.6109; genotype: F(1.35) = 0.3976, p = 0.5324; treatment: 
F(1.35) = 4.688, p = 0.0373]. D: After 24 h, no differences between ASM WT and ASM KO cells were 
obvious, while both strains reacted with pCREB level increase after long-term hyperforin application (pASM 
WT; DMSO against hyp = 0.0118; pASM KO; DMSO against hyp = 0.0029, Sidak’s test). Two-way ANOVA revealed and effect 
for treatment, but no effect for interaction or genotype [interaction: F(1.36) = 0.135, p = 0.7154; 
genotype: F(1.36) = 1.82, p = 0.1857; treatment: F(1.36) = 20.31, p < 0.0001]. A-D: ±SEM, N = 2 (N = 
number of single mice), 3-7 regions per cover slip, performed as a biological single. E: Representative 
images of pCREB staining in single nuclei of excitatory murine neurons after indicated treatments and time 
points. Scale bar indicates 5 µm. 
 
Inhibitory neurons: Results found in excitatory cortical mouse neurons diverged from results 
found in inhibitory neurons. While hyperforin 1 µM did not induce any CREB phosphorylation in 
inhibitory ASM WT neurons at the 20 min time point, pCREB staining in inhibitory ASM KO 
neurons was significantly decreased after 20 min hyperforin treatment compared with ASM WT 
neurons. Furthermore, ASM deficiency induced an increase in pCREB levels under DMSO 
treatment in inhibitory neurons compared with ASM WT neurons [ASM WTDMSO: 1 ± 0.102; ASM 
KODMSO: 2.666 ± 0.448, pDMSO: ASM WT against ASM KO = 0.0032 (+167 %); ASM KOhyp: 1.404 ± 0.356, pASM 
KO: DMSO against hyp = 0.0175 (-47 %)]. Two-way ANOVA revealed an effect for genotype-treatment 
interaction and genotype at the 20 min time point [interaction: F(1.34) = 5.32, p = 0.0273; 
genotype: F(1.34) = 11.31, p = 0.0019]. This difference vanished with time. After 24 h, pCREB 
levels showed a small positive trend in ASM WT and were significantly induced in ASM KO when 
incubated with hyperforin [ASM KODMSO: 1.477 ± 0.200; ASM KOhyp: 2.971 ± 0.608, pASM KO: DMSO 
against hyp = 0.0191 (+101 %)]. Two-way ANOVA revealed an effect for genotype and treatment at 
the 24 h time point [genotype: F(1.36) = 4.753, p = 0.0359; treatment: F(1.36) = 9.211, p = 
0.0045] (fig. 27). 
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Figure 27: ASM deficiency impacts pCREB time-dependently in inhibitory cortical mouse neurons 
A: After 20 min treatment, pCREB levels were induced in ASM KO cortical neurons (pDMSO: ASM WT against ASM KO 
= 0.0003, Sidak’s test) and hyperforin 1 µM decreased CREB phosphorylation in ASM-deficient cells 
compared with DMSO treatment (pASM KO: DMSO against hyp = 0.0103, Sidak’s test). Two-way ANOVA revealed an 
effect for interaction and genotype, and no effect for treatment [interaction: F(1.34) = 5.32, p = 0.0273; 
genotype: F(1.34) = 11.31, p = 0.0019; treatment: F(1.34) = 3.949, p = 0.0550].B: After 1 h treatment, no 
significant differences were observed. Two-way ANOVA revealed no effect for interaction, genotype or 
treatment [interaction: F(1.34) = 0.2579, p = 0.6149; genotype: F(1.34) = 0.0834, p = 0.7745; treatment: 
F(1.34) = 2217, p = 0.6408]. C: After 6 h treatment, no significant differences were observed. Two-way 
ANOVA revealed no effect for interaction, genotype or treatment [interaction: F(1.33) = 0.00005, p = 
0.9943; genotype: F(1.33) = 1.577, p = 0.2180; treatment: F(1.33) = 0.6351, p = 0.4312]. D: After 24 h 
treatment, in ASM WT neurons hyperforin exhibited only a non-significant trend, while in ASM KO cells, 
there was a rise in pCREB levels due to 24 h long-term hyperforin incubation (pASM WT: DMSO against hyp = 
0.2405; pASM KO: DMSO against hyp = 0.0191, Sidak’s test). Two-way ANOVA revealed an effect for genotype and 
treatment, but no effect for interaction [interaction: F(1.36) = 0.6968, p = 0.4094; genotype: F(1.36) = 
4.753, p = 0.0359; treatment: F(1.36) = 9.211, p = 0.0045]. A-D: ±SEM, N = 2 (N = number of single mice), 
3-7 regions per cover slip, performed as a biological single. E: Representative images of pCREB staining in 
single nuclei of inhibitory murine neurons after indicated treatments and time points. Scale bar indicates 5 
µm. 
 
Next, I investigated the impact of a depolarized neuronal network on CREB phosphorylation 
(Kornhauser et al. 2002), so the neurons were grown in a cell media with high KCl and MgCl2 
concentrations (NBA mouse media mix no.3). Hyperforin 1 µM or solvent control DMSO were 
applied to cells for 24 h. 
In excitatory neurons of ASM WT, hyperforin induced CREB phosphorylation [ASM WTDMSO: 1 ± 
0.029; ASM WThyp: 1.145 ± 0.030, pASM WT: DMSO against hyp = 0.0071 (+15 %)]. This effect was 
completely abolished and inversed in ASM-deficient neurons [ASM KODMSO: 1.19 ± 0.0366; ASM 
KOhyp: 0.9913 ± 0.046, pASM KO: DMSO against hyp = 0.0003 (-17 %); phyp: ASM WT against ASM KO = 0.0056 (-13 
%)]. Analogous with fig. 23, ASM deficiency itself induced pCREB when treated with solvent 
control DMSO compared with ASM WTDMSO [pDMSO: ASM WT against ASM KO = 0.0004 (+19 %)]. Two-way 
ANOVA revealed an effect for genotype-treatment interaction [F(1.155) = 23.37, p < 0.0001] (fig. 
28 A). 
In inhibitory neurons, TRPC6 activation displayed a complete diverging picture. Hyperforin 1 µM 
did not induce any CREB phosphorylation in ASM WT neurons but even showed the trend to a 
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decrease in pCREB. ASM deficiency even stressed this effect and decreased pCREB staining 
significantly after hyperforin treatment compared with ASM WT neurons [ASM KODMSO: 1.129 ± 
0.108; ASM KOhyp: 0.7777 ± 0.057, pASM KO: DMSO against hyp = 0.0005 (-31 %)]. Two-way ANOVA 
revealed an effect for treatment [F(1.132) = 13.51, p = 0.0003] (fig. 28 C). 
 
**
***
**
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Figure 28: ASM deficiency inversed TRPC6-induced CREB phosphorylation in excitatory neurons 
and amplified effect in inhibitory mouse neurons which were grown in cell media enriched in KCl 
and MgCl2 
A: Hyperforin 1 µM induced pCREB levels in rat excitatory neurons (pASM WT: DMSO against hyp = 0.0071, Sidak’s 
test), this effect was inversed in ASM-deficient neurons (pASM KO: DMSO against hyp = 0.0003; phyp: ASM WT against ASM 
KO = 0.0056, Sidak’s test). Enzyme deletion induced CREB phosphorylation already under treatment with 
solvent control DMSO (pDMSO: ASM WT against ASM KO = 0.0004, Sidak’s test). Two-way ANOVA revealed an effect 
for genotype-treatment interaction, and no effect for genotype or treatment [interaction: F(1.155) = 
23.37, p < 0.0001; genotype: F(1.155) = 0.2722, p = 0.6026; treatment: F(1.155) = 0.5864, p = 0.4450]. B: 
Representative images of pCREB staining in single nuclei of excitatory murine neurons after indicated 
treatments. Scale bar indicates 5 µm. C: Hyperforin 1 µM induced a small trend but did not affect pCREB in 
rat inhibitory neurons significantly (pASM WT: DMSO against hyp = 0.3048), however this trend became significant 
in ASM-deficient neurons (pASM KO: DMSO against hyp = 0.0005). Two-way ANOVA revealed an effect for 
treatment, and no effect for interaction or genotype [interaction: F(1.132) = 3.02, p = 0.0846; genotype: 
F(1.132) = 0.06242, p = 0.8031; treatment: F(1.132) = 13.51, p = 0.0003]. D: Representative images of 
pCREB staining in single nuclei of inhibitory murine neurons after indicated treatments. Scale bar indicates 
5 µm. A and C: ±SEM, N = 4 (N = number of single mice), 5-10 regions per cover slip, performed as a 
biological single or duplicate. NBA mouse media mix no.3 was used. 
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4.5 ASM activity impacts TRPC6 localisation in the plasma 
membrane  
 Lipidomic analyses reveals changes in lipid 
composition after ASM activity inhibition 
ASM activity impacts the plasma membrane composition and signalling of molecules located at 
the plasma membrane by modulating the ratio between sphingomyelin and ceramide (Zhang et 
al. 2009; Grassmè, Riethmüller, and Gulbins 2007; Stancevic and Kolesnick 2010). Therefore, I 
aimed at investigating if changes in membrane composition could lead to misbalances of TRPC6 
distribution within the plasma membrane and microdomains. For this purpose, it was analysed if 
ASM activity inhibition induced changes to membrane sphingolipids. PC12 cells were treated 
with ASM inhibitor ARC39 10 µM for 48 h and two different kinds of fractions were generated – 
a whole cell fraction and a membrane-enriched fraction (P2). Samples were sent for mass-
spectrometric analyses to Prof. Kleuser’s lab and Dr. Schumacher at University of Potsdam, 
Germany. Analyses of whole cell fractions indicated a strong modulation of ARC39-mediated 
ASM activity inhibition on sphingolipid compositions. Cer/SM molar ratios of Cer/SM 20:0 [H2O: 
0.1135 ± 0.004; ARC39: 0.0951 ± 0.005, pA: Cer/SM 20:0 ctl compared with Cer/SM 20:0 ARC39 = 0.0133 (-16 %)] 
and Cer/SM 24:0 [H2O: 0.2491 ± 0.004; ARC39: 0.1911 ± 0.006, pA: Cer/SM 24:0 ctl compared with Cer/SM 24:0 
ARC39 < 0.0001 (-23 %)] displayed a decrease, while the analyses of Cer/SM molar ratios of Cer/SM 
18:0 and Cer/SM 24:1 revealed a small negative trend. For Cer/SM 16:0 no changes were 
detected. In membrane enriched (P2) samples the Cer/SM 24:1 molar ratio of very-long chain 
sphingolipid species 24:1 presented a negative trend. All other Cer/SM did not display any 
regulations in the P2-fraction (fig. 29) (Zeitler et al. 2019). 
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Figure 29: ASM activity inhibition impacts ceramide/sphingomyelin molar ratio in PC12 
preparations 
A: 48 h ASM activity inhibition with ARC39 10 µM affected levels of sphingolipid species in whole cell 
samples. Cer/SM molar ratio was decreased for Cer/SM 20:0 and Cer/SM 24:0 (pCer/SM 20:0 ctl compared with Cer/SM 
20:0 ARC39 = 0.0133; pCer/SM 24:0 ctl compared with Cer/SM 24:0 ARC39 < 0.0001). Furthermore, the analyses of Cer/SM 
molar ratio of Cer/SM 18:0 and Cer/SM 24:1 revealed negative trends for these species (pCer/SM 18:0 ctl 
compared with Cer/SM 18:0 ARC39 = 0.0641; pCer/SM 24:1 ctl compared with Cer/SM 24:1 ARC39 = 0.0799), Cer/SM 16:0 was not 
affected. Student’s t-test was used for all statistical analyses. ±SEM, N = 3 (N = number of cell batches), 
measured as duplicates. B: 48 h ASM activity inhibition with ARC39 10 µM did not significantly affected 
levels of sphingolipid species in P2 fraction samples. However, the analyses of Cer/SM 24:1 revealed a 
negative trend for this species (pCer/SM 24:1 ctl compared with Cer/SM 24:1 ARC39 = 0.0634). Student’s t-test was used for 
statistical analysis. ±SEM, N = 3 (N = number of cell batches), measured as duplicates. A and B: p values 
which were ≥ 0.1 are not displayed for this experiment. 
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 Lipid Raft isolation elucidates TRPC6 distribution 
at the plasma membrane 
Since TRPC6 ion channels are plasma membrane located proteins and their function was 
compromised by ASM activity inhibition or ASM-deficiency, I asked if observed modulation in 
sphingolipidome might affect TRPC6 localisation within subcompartments at the plasma 
membrane. To shed light on the mechanism behind ASM-mediated disturbed TRPC6 signalling, 
the TRPC6 distribution at the plasma membrane in lipid raft microdomains and non-raft domains 
was analysed. For this, PC12 cells were treated with ASM inhibitor ARC39 10 µM for 48 h or 
solvent control MQ (ctl) and incubated with hyperforin 10 µM for 1 min. Afterwards, lipid raft 
fraction (flotillin-1 positive, as suggested by earlier studies (Pérez-Cañamás et al. 2017)) and non-
raft fraction (flotillin-1 negative) were isolated. TRPC6 could be found in both fractions, in the 
lipid raft and non-raft fraction. After ARC39 application, the lipid raft fraction displayed a 
significant reduction in TRPC6 levels compared with solvent control treatment [ctl: 1 ± 0; ARC39: 
0.8069 ± 0.079, pA: ARC39 compared with ctl = 0.0019 (-19 %)]. In contrast, the non-lipid raft fraction 
showed no significant changes in TRPC6 levels, however, gave a hint to a small positive trend. 
Therefore, the ARC39-mediated ASM activity inhibition prevented the clustering of TRPC6 in lipid 
rafts. The partial exclusion of TRPC6 from lipid rafts could explain the modulation of TRPC6 
function by ASM activity (fig. 30) (Zeitler et al. 2019). 
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Figure 30: Inhibition of ASM activity disturbs TRPC6 distribution at the plasma membrane of PC12 
cells 
A: ASM activity inhibition partially prevented TRPC6 localisation in lipid raft microdomains (pA: ASM39 compared 
with ctl = 0.0019). B: Representative Western Blot image of lipid raft fraction after indicated treatments, 
stained for TRPC6 at 110 kDa and flotillin-1 at 48 kDa. C: Furthermore, the TRPC6 levels in non-raft 
fractions were not significantly changed, but displayed a positive trend compared with solvent control MQ 
(ctl) (pC: ASM39 compared with ctl = 0.0545). D: Representative Western Blot image of non-raft fraction after 
indicated treatments, stained for TRPC6 at 110 kDa and flotillin-1 at 48 kDa. Mann-Whitney test (A) and 
Student’s t-test (C) was used for statistical analyses. A and C: ±SEM, N = 3 (N = number of cell batches), 
measured as duplicate or triplicate. 
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4.6 Both ASM and TRPC6 systems influence synapse 
physiology  
 ASM deficiency affects synapse number 
Modulations in TRPC6 Ca2+ signalling and downstream transcriptional factor activation can 
induce changes in synaptic plasticity (see section 2.3.2) and ASM-deficient mice have presented 
a strong synaptic phenotype in previous studies (see section 2.2.2.2). Therefore, I asked if ASM 
or TRPC6 could induce changes in synapse physiology. Piloting experiments were conducted. 
 
In a first piloting experiment, the synapse number of proximal dendrites of murine cortical 
cultures was determined. For this, ASM KO and ASM WT neurons were stained for SHANK2 and 
synapsin1/2 and colocalising regions were considered as functioning synapses. Numbers of 
synapses were counted. ASM KO neurons exhibited a reduced number of synapses compared 
with neurons from wildtype controls [ASM WT: 31.03 ± 1.03; ASM KO: 27.07 ± 1.365, pA: ASM KO 
compared with ASM WT = 0.0239 (-13 %)] (fig. 31). 
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Figure 31: ASM deficiency leads to a reduced number of synapses of murine cortical neurons 
A: ASM KO cortical neurons showed a smaller number of synapses at proximal dendrites compared with 
ASM WT (pASM WT compared with ASM KO = 0.0239). Student’s t-test was used for statistical analyses. ±SEM, N = 3 
(N = number of mice), each experiment considered 10 proximal dendrites (ca. 17 µm distance to soma). B: 
Representative image of SHANK2 (green) and synpasin1/2 (magenta) immuno-staining of a proximal 
dendrite in murine cortical culture. Scale bar indicates 5 µm. 
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 TRPC6 induces synapse activity 
In a second piloting experiment, I aimed at investigating how TRPC6 impacted on synaptic vesicle 
recycling. For this, rat cortical neurons were treated with hyperforin 0.3 µM or solvent control 
DMSO (ctl) for 24 h. Afterwards cultures were exposed to a fluorescence-tagged antibody 
directed against an epitope at synaptotagmin-1’s luminal domain. Experiments were performed 
under physiologic KCl (spontaneous activity, 20 min at 37 °C) or increased KCl conditions 
(depolarized/evoked activity, 4 min at RT). This procedure enabled a live immuno-staining of 
synaptic activity. Afterwards cells were fixed and immuno-stained for vGlut1 (fig. 30 A), 
synapsin1/2 (fig. 30 B). Stainings were analysed and all puncta were counted (fig. 30 C). Activation 
of TRPC6 channels with hyperforin 0.3 µM increased the staining of vGlut1 [ctl: 1 ± 0.048; hyp: 
1.328 ± 0.064, pA: hyp 0.3 µM compared with ctl <0.0001 (+33 %)], while synapsin1/2 staining remained 
unaffected. Furthermore, the number of analysed puncta also remained unchanged by 
hyperforin treatment. Under both, spontaneous [ctl: 1 ± 0.056; hyp: 1.312 ± 0.077, pD: hyp 0.3 µM 
compared with ctl = 0.0055 (+31 %)] and evoked/depolarized [ctl: 1 ± 0.057; hyp: 1.31 ± 0.068, pF: hyp 0.3 
µM compared with ctl = 0.0012 (+31 %)] activity, hyperforin induced a strong increase in the synaptic 
vesicle recycling (fig. 32 D, F). 
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Figure 32: TRPC6 activation induces synaptic vesicle recycling in rat cortical excitatory synapses 
A: Hyperforin induced vGlut1 staining (pA: hyp 0.3 µM compared with ctl <0.0001). B, C: synapsin1/2 or number of 
puncta were not affected (pB: hyp 0.3 µM compared with ctl = 0.9644; pC: hyp 0.3 µM compared with ctl = 0.1342). D, F: 
Synaptotagmin-1 antibody uptake was increased under both, spontaneous and depolarized activity (pD: hyp 
0.3 µM compared with ctl = 0.0055, pF: hyp 0.3 µM compared with ctl = 0.0012). Student’s t-test (A, C, F) or Mann-Whitney 
test (B, D) was used for statistical analyses. ±SEM, N = 2 (N = number of cell batches), D, F measured as 
duplicate or triplicate, and A, B, C measured as quadruplicate or quintuplicate. Each experiment 
considered 10 proximal dendrites (ca. 17 µm distance to soma). E, G: Representative images of stainings at 
low KCl/spontaneous activity (E) or high KCl/depolarized activity (G) conditions. Composite image: 
synapsin1/2 (magenta), vGlut1 (green), synaptotagmin-1 (white). Scale bar indicates 5 µm.  
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5 Discussion 
The present data show the interaction of ASM with TRPC6 channels in a neuronal context. Both, 
ASM and TRPC6, are crucial proteins for the maintenance of brain physiology and in depression 
disorder. 
I have exhibited FIASMA antidepressants and the direct ASM inhibitor ARC39 to inhibit ASM 
activity in several different cell types. The genetic and pharmacological manipulation of ASM 
activity introduced a dysregulation in TRPC6 RNA levels and promoted TRPC6 protein expression, 
respectively. TRPC6-mediated Ca2+ influx was impaired after pharmacological ASM inhibition in 
PC12 cells and in ASM-deficient cortical mouse neurons. Moreover, after hyperforin application, 
levels of TRPC6 downstream effector, phospho-CREB, were reduced in ASM-deficient and ASM-
inhibited neurons. Lipidomics of PC12 cells, conducted after ASM inhibition, revealed a shift in 
ceramide/sphingomyelin molar ratio in particular for very-long chain sphingolipid species. This 
led to a dysregulation of TRPC6 localisation to lipid rafts at the plasma membrane. Taken 
together, disturbed subcompartmental localisation of TRPC6 due to ASM inhibition could serve 
as a mechanistical explanation for observed impaired TRPC6-mediated Ca2+ influx and 
downstream signalling. 
In summary, the revealed interaction of ASM and TRPC6 could be involved in the pathology of 
MD and help to understand this devastating disease. 
 
5.1 ASM inhibition is mediated by FIASMA 
antidepressants 
Several findings indicate a role of ASM in MD. Depressed patients present an elevated ASM 
activity in blood samples, which can be reversed by antidepressive treatment (Kornhuber et al. 
2005). Moreover, animal experiments have shown that ASM overexpression leads to a 
depression-like phenotype, which can be reversed by FIASMA antidepressant (Gulbins et al. 
2013). Interestingly, many antidepressants have shown to inhibit ASM activity via electrostatic 
detachment of ASM from the inner lysosomal membrane which leads to enzyme degradation, 
and are therefore called FIASMAs (Kornhuber et al. 2011). This finding might serve as a link 
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between the uncovering of antidepressant action and a new approach to the pathogenesis of 
MD. 
The antidepressants fluoxetine, sertraline, nortriptyline and venlafaxine were tested for their 
FIASMA properties in our PC12 cell line. PC12 were suitable as neuronal model for this study, 
since these cells have neuronal properties and express TRPC channels endogenously. In line with 
described findings for H4 and PC12 cells (Kornhuber et al. 2008), fluoxetine, sertraline and 
nortriptyline dose-dependently inhibited ASM after 1 h of incubation, while venlafaxine did not 
show such effect. This finding was therefore interesting, since venlafaxine was further used as 
control for antidepressants with no FIASMA characteristics. Also, the specific ASM inhibitor 
ARC39 inhibited ASM activity in a dose-dependent manner in PC12 cells. Divergent from 
FIASMAs, ARC39 inhibits the ASM in a direct way by interfering with the catalytic center of this 
enzyme (Roth et al. 2009). 
 
Cell lines as H4 or PC12 are immortalized and are often derived from cancer tissue. They are 
used to approach a question, while for further detailed analyses primary cells are frequently 
employed. To investigate how primary neurons interfered with FIASMAs, I analysed how FIASMA 
antidepressant fluoxetine impacted ASM activity in cortical rat neurons. I observed that 
fluoxetine inhibited ASM in a concentration- and time-dependent manner. Hyperforin was also 
applied to cells, and showed, as anticipated, no FIASMA properties. While in FIASMA-treated 
PC12 cells enzyme inhibition was evident after 1 h, surprisingly, for cortical rat neurons similar 
effects were pronounced not before 24 h of incubation time. A cell viability assay confirmed that 
loss in enzyme activity related to ASM inhibition and not cell death. Contrary to findings in rat 
neurons, when I applied fluoxetine to rat cells, ASM was also time-dependently inhibited, 
however completely different from neurons. In glial cells, first strong effects were already 
significant after 30 min of treatment. These experiments showed that FIASMAs impacted ASM 
activity in a cell-specific manner. I assumed, the reason for that could be ascribed to divergent 
diffusion constants of fluoxetine across the respective cell membrane of PC12, neurons or glial 
cells, or the capability of the cell to induce efflux of antidepressants. Furthermore, it could also 
be possible that neurons rapidly react to the loss of ASM and promote enhanced protein 
translation or decreased endogenous degradation. These effects could protect ASM enzyme 
levels in neurons compared to glial cells or PC12.  
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Recent studies, investigating brain cell composition, suggested a glia:neuron ratio of 1:1 
(reviewed in VON BARTHELD ET AL. 2016 (von Bartheld, Bahney, and Herculano-Houzel 2016)). This 
emphasizes the marked impact of glial cells on brain function, raising the question of how 
antidepressant treatment and especially FIASMA antidepressants affect different brain cell 
types. To date, little is known about fluoxetine’s effects on glial cells. Though fluoxetine is 
characterized as SSRI and FIASMA, some researchers have claimed that fluoxetine mediates its 
antidepressant effect via ATP gliotransmission of astrocytes in addition to inhibition of serotonin 
reuptake at the neuronal synapse (Kinoshita et al. 2018). Moreover, it has been shown in 
different studies that glial cells and in particular glia cell line-derived neurotrophic factor (GDNF) 
play a role in mood disorders and antidepressant action (Tsybko, Ilchibaeva, and Popova 2017), 
whereby GDNF production can be induced by sphingolipids as S1P (Yamagata et al. 2003). 
Further research needs to be done to elucidate if ASM inhibition in glial cells could also 
contribute the antidepressive effects of FIASMAs in MD.  
 
5.2 ASM and TRPC6 interact in a neuronal context 
ASM is an enzyme of the sphingolipid metabolism and degrades sphingomyelin to generate 
phosphorylcholine and ceramide in lysosomes and at small acidified domains at the outer leaflet 
of the plasma membrane. Therefore, changes in ASM activity are postulated to introduce 
alterations to the sphingolipidome and consequently impact the properties and formation of 
plasma membrane located microdomains and rafts. This in turn, might influence the localisation 
and signalling of receptors and ion channels, like TRPC6, at the plasma membrane. Dependence 
of TRPC6 activity towards its localisation in microdomains was observed in non-neuronal tissue 
as lung endothelial cells, fibroblasts, T-cells, podocytes and glomerular mesangial cells (Carrillo 
et al. 2012; Zhang and Ji 2013; Kim et al. 2013; Tabeling et al. 2015; Lei et al. 2014). A direct 
interaction of ASM and TRPC6 was described in smooth artery muscle cells in the context of 
inflammation (Samapati et al. 2012). 
TRPC6 is a crucial mediator in BDNF signalling and for synaptic plasticity, consequently the 
question raised if ASM and TRPC6 also interact in a neuronal context. 
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 ASM modulates TRPC6 RNA and protein levels 
Chronic unpredictable stress applied to rodents can be used as a model for MD. Under this 
condition researchers found a decline in dendritic length of neurons, dendritic spine density and 
the number of excitatory synapses, which all were accompanied with a reduced expression of 
TRPC6 (Liu et al. 2015). Therefore, I asked if a misbalance of ASM, as present in MD, could 
impact TRPC6 in terms of RNA and protein levels. 
First, I aimed at analysing TRPC6 RNA levels in cortical and hippocampal brain tissue of ASM-
deficient and ASM-overexpressing mice. It was revealed that TRPC6 levels in ASM KO 
hippocampus exhibited a genotype-sex specific interaction compared with ASM WT tissue. A 
significant increase in RNA TRPC6 levels in hippocampus of ASM KO females compared to a 
decrease in ASM KO males was evident. Neither in ASM KO or ASM tg cortex, nor in ASM tg 
hippocampus any further significant effects were manifested. The transcription of the TRPC6 
gene can be controlled by pCREB, which is a downstream effector of BDNF receptor activation. 
Other researchers have shown that pCREB and BDNF are differentially regulated in stress-
induced depressive behaviour dependent on the sex of animal (Lin et al. 2009) and in general 
CREB phosphorylation and BDNF expression seem to depend on estrogen levels (Rubinow and 
Schmidt 2019). Phospho-CREB was found to be oppositely regulated in ASM-deficient and ASM-
overexpressing neurons, in both the cortex and the hippocampus (see section 5.2.3). In contrast 
to an increase in ASM KO cells, pCREB levels were decreased in ASM tg. Therefore, TRPC6 RNA 
expression might be critically regulated under ASM disbalance. Why this regulation solely affects 
ASM KO hippocampus and no other tissues needs to be further elucidated. In MD, prefrontal 
cortex, limbic cortex, anterior cingulate cortex, amygdala, and hippocampus have shown to play 
a major role in pathology (Kalia 2005). Cortex and hippocampus are both important for emotion 
regulation (Rive et al. 2013). Defects in memory were linked specifically to the dentate gyrus in 
the hippocampus (Travis et al. 2015), while both hippocampus and cortex, are related to deficits 
in cognitive functions (Trivedi and Greer 2014). For further experiments, cortical neurons were 
more interesting compared to neurons derived from other brain regions, since modulatory 
effects of hyperforin, as CREB phosphorylation, were mostly described in cortical tissue (Gibon 
et al. 2013). 
Second, I investigated TRPC6 expression after antidepressant treatment and also after ARC39-
mediated ASM inhibition in whole rat cortical neuronal lysates. Western blotting of TRPC6 
displayed that all antidepressant treatments, independent of their FIASMA properties, elevated 
TRPC6 levels. Interestingly, also ASM inhibitor ARC39 induced TRPC6 expression. Since 
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antidepressants have shown to increase pCREB levels (Nibuya, Nestler, and Duman 1996; Thome 
et al. 2000; Tiraboschi et al. 2004), I speculated that antidepressant treatment might introduce 
neuronal plasticity changes which could therefore lead via CREB phosphorylation to an increase 
in TRPC6 protein expression. It would be possible that FIASMA- and ARC39-mediated ASM 
inhibition also induced pCREB levels, as seen in ASM KO cells and described above and in section 
5.2.3. Furthermore, the proteolytic enzyme calpain is involved in the degradation of TRPC6 and 
has been described to be regulated by small ceramide species as Cer2 and Cer6 (Xie and Johnson 
1997). Thus, ASM inhibition might implement changes in TRPC6 degradation and therefore the 
TRPC6 turn-over could be decreased, which might also lead to an increase in TRPC6 levels.  
The fine-tuning of ceramide concentrations in the cell has shown to play a role for surface 
representation of membrane molecules as the nicotinic acetylcholine receptor (Gallegos, 
Pediconi, and Barrantes 2008). Subsequently, I aimed to exert a more detailed insight into how 
increased TRPC6 protein levels might distribute across the cell compartments. PC12 cell were 
incubated with FIASMA antidepressant fluoxetine and non-FIASMA antidepressant venlafaxine. 
In the internal fraction of PC12 cells TRPC6 levels were increased for both antidepressants, 
whereby a rise in TRPC6 in the surface fraction was solely significantly induced by fluoxetine. 
Although both antidepressants promote higher TRPC6 levels in the cell, the ASM-inhibitory 
characteristic of fluoxetine could be responsible for changes in TRPC6 subcellular localisation. 
FIASMA antidepressant fluoxetine has already shown to interfere with ion channel trafficking in 
another study (Rajamani et al. 2006). Therefore, ASM inhibition might modify TRPC6 trafficking. 
 
 ASM inhibition impacts TRPC6 channel activity 
TRPC6 channels can be activated by endogenous diacylglycerol or exogenous hyperforin. Elicited 
non-selective cation currents can consist of Na+ and Ca2+ ions (Hofmann et al. 1999; Leuner et al. 
2007). Both ions relate to the antidepressive action of hyperforin. TRPC6-mediated Na+ influx 
has shown to inhibit monoamine reuptake out of the synaptic cleft (Chatterjee et al. 1998), 
while Ca2+ influx leads downstream to transcription activation which promotes neuronal 
plasticity (Heiser et al. 2013). 
To examine the interaction of ASM and TRPC6, it was therefore crucial to analyse TRPC6-
mediated Ca2+ currents in a next step. For this end, FIASMA-antidepressant fluoxetine and non-
FIASMA antidepressant venlafaxine were applied to PC12 cells for 1 h and afterwards hyperforin-
induced Ca2+ influx into the cell soma was recorded. In line with previous findings (Zeitler et al. 
 Discussion 
142 
2019; Samapati et al. 2012), ASM inhibition confirmed to inhibit the cation current dose-
dependently, while venlafaxine had no impact. Therefore it was reasoned that fluoxetine-
mediated ASM inhibition might be the regulatory factor for this effect. 
Consequently, I wanted to test this hypothesis in a primary system, in rat cortical neurons. 
Therefore, rat cortical neurons were incubated with venlafaxine, fluoxetine and ARC39, and Ca2+ 
influx was measured. Against expectations, all treatments failed to show any effect neither after 
1 h of incubation nor after 24 h. After 24 h of treatment, only a small non-significant trend 
towards decreased influx after ASM inhibition was visible. Low residual ASM activity of 5 % has 
shown to be capable to fully protect NPD B patients from neurological symptoms (Graber, 
Salvayre, and Levade 1994; Jones et al. 2008), I therefore reasoned that either ASM inhibition 
was not strong enough to impact on TRPC6 activity after 24 h in neurons, or effects were too 
small of being resolved in this assay.  
Thus, I shifted towards the examination of mouse cortical neurons which were fully deficient in 
ASM and exhibited therefore no residual ASM activity. In this setting hyperforin-induced Ca2+ 
influx was significantly reduced compared to observed influx in ASM WT cortical neurons. 
Conclusively, I was able to describe for the first time that ASM dysregulation impacts TRPC6 
function in neurons.  
In our study, conducted on PC12 cells, we were able to rescue FIASMA-mediated impaired 
TRPC6 function, by the addition of bacterial sphingomyelinase (Zeitler et al. 2019). Therefore I 
asked, if the concomitant culturing of ASM KO neurons with ASM WT glial cells would be able to 
rescue this phenotype, due to excreted S-ASM of glial cells. However, Ca2+ flux was not changed 
by this procedure. This could mean that ASM secretion of glial cells was not high enough to have 
any impact on the neuronal cell surface or cytosolic lipidome, or genetic dysregulation in ASM 
KO neurons provided a too strong phenotype to be rescued in this assay. 
 
 ASM inhibition interferes with TRPC6 
downstream signaling 
The TRPC6-mediated Ca2+ influx leads to the activation of different kinase pathways which 
converge in the phosphorylation and activation of the transcriptional factor CREB (Heiser et al. 
2013). This induces the transcription of genes which are involved in neuroplasticity as the BDNF 
signalling (Lonze and Ginty 2002). 
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To gain first insights into changes in neuronal plasticity under ASM dysregulated conditions, 
CREB phosphorylation was analysed in ASM KO and ASM tg neurons and glial cells isolated from 
cortex or hippocampus. The cells did not undergo any further stimulation and thus conditions 
are referred to as “basal”. Remarkably, ASM deficiency induced a strong increase in pCREB levels 
in cortical and hippocampal neurons already under these basal conditions, while ASM 
overexpression completely showed an inversed picture and led to a decrease in pCREB levels. 
The pCREB staining of glial cells was mostly unaffected, solely ASM tg glial cells, isolated from 
cortex, also displayed a reduce in pCREB. GULBINS ET AL. 2013 presented a study which fits to my 
finding (Gulbins et al. 2013). They analysed biochemical markers for neurogenesis and studied 
affective behavioural phenotypes of max. 12-week old ASM KO and ASM tg mice in comparison 
to ASM WT animals. Summing up, they found throughout unusual exaggerated neurogenesis or 
behavioural aspects in ASM KO mice, whereby in ASM tg mice neurogenesis was depressed and 
behavioural experiments exerted depression-like behavioural features (Gulbins et al. 2013). 
Certainly, long-term ASM deficiency in mice will lead to devastating neurodegenerating effects 
(Ledesma et al. 2011), however, young animals present a suitable model to analyse ASM 
inhibitory effects. The ASM-overexpressing mouse, however, presents a depression model 
induced by extraordinary high ASM activity in the brain. My findings indicate that depression 
(which relates to high ASM activity) could lead to a decrease in CREB phosphorylation and 
consequently to impaired neuronal plasticity, while ASM inhibition might induce CREB 
phosphorylation which could promote beneficious plasticity modulations. 
 
Since CREB phosphorylation is involved in hyperforin’s antidepressant action, I tested the 
interaction of ASM and TRPC6 in terms of CREB phosphorylation. In a piloting experiment, rat 
cortical neurons were used, treated with ASM inhibitor ARC39 or solvent and stimulated with 
hyperforin to evaluate combined effects on pCREB levels. In cells where ASM was not 
modulated, as anticipated, hyperforin facilitated CREB phosphorylation. In cells where ASM was 
inhibited by ARC39, hyperforin failed to induce a significant increase in pCREB levels. 
Interestingly, ARC39 treatment alone already exhibited a slight non-significant increase towards 
elevated CREB levels which is in line with findings in ASM KO cortical neurons. This experiment 
shows, even though Ca2+ imaging experiments in rat cortical neurons failed to display a 
significant effect of ASM inhibition on Ca2+ currents, TRPC6 function can be indeed modulated by 
pharmacological ASM manipulation. 
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To analyse this effect under full ASM-deficient conditions, ASM KO cortical mouse neurons were 
cultured, cells were stimulated with hyperforin and pCREB staining of excitatory and inhibitory 
neurons analysed. Furthermore, I wanted to elucidate how hyperforin-induced CREB 
phosphorylation was regulated in a time-depended manner to highlight dynamical changes. To 
this end, cortical ASM KO and ASM WT mouse neurons were incubated with hyperforin for 20 
min, 1 h, 6 h and 24 h. With this time schedule it was possible to monitor the regulation in 
immediate and long-term CREB phosphorylation. In excitatory ASM WT neurons, after a short 
incubation time of 20 min, hyperforin induced a positive trend towards CREB phosphorylation, 
which was not statistically significant. However, in excitatory ASM KO neurons, hyperforin 
induced a decrease in pCREB levels. This might be ascribed to saturated pCREB levels in ASM KO 
neurons while further stimulation with hyperforin induced a regulatory compensatory 
mechanism of CREB activation. Surprisingly, this genotype-specific difference between pCREB 
levels vanished over time and exhibited nearly the same extend after 24 h. Similar effects could 
be detected in inhibitory neurons. In inhibitory ASM WT neurons, hyperforin application showed 
no significant impact on CREB phosphorylation at any time point. However, in inhibitory ASM KO 
neurons, hyperforin induced an immediate decrease in pCREB levels, which disappeared with 
time and inversed, since stainings displayed even an enhanced CREB phosphorylation after 24 h 
of incubation. This remarkable finding emphasises the cell type-specific regulation of TRCP6 
downstream signalling by hyperforin in excitatory and inhibitory ASM WT cortical neurons, 
which most probably relates to the predominant expression of TRPC6 at excitatory synapses 
(Zhou et al. 2008). Intriguingly, this effect is completely missing in ASM KO neurons. I speculate 
that, as described for Ca2+ imaging experiments, TRPC6 activity is disturbed in ASM-deficient 
neurons, which leads to modulations in downstream signalling. Moreover, GALVAN ET AL. 2008 
showed that ASM deficiency in general impacts on protein distribution to dendrites and axons, 
and therefore in ASM KO neurons proteins were located at compartments where they usually do 
not appear under physiological conditions (Galvan et al. 2008). Thus, in ASM KO neurons, TRPC6 
expression and trafficking could be differentially regulated which might lead to observed effects 
in CREB phosphorylation. 
 
Several findings indicate that the phosphorylation pattern of CREB can be regulated by 
depolarization of neurons. Furthermore, according to dynamic changes over time, different 
phosphorylation sites could be used to activate this transcriptional factor (Kornhauser et al. 
2002). To analyse how this context impacted TRPC6-mediated CREB phosphorylation under 
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ASM-deficient conditions, ASM KO cortical mouse neurons were cultured in high electrolyte-
containing cell media (enriched in KCl and MgCl2), and cells were stimulated with hyperforin and 
pCREB staining of excitatory and inhibitory neurons was analysed. Neurons were incubated with 
hyperforin for 24 h to especially check for long-term effects on pCREB staining. In excitatory ASM 
WT neurons, hyperforin induced CREB phosphorylation, which was inversed in ASM KO neurons, 
where hyperforin even decreased pCREB levels. Interestingly, in inhibitory ASM WT neurons, 
hyperforin application induced a small non-significant trend towards a decrease in CREB 
phosphorylation, whereby in ASM KO neurons, this trend was amplified and CREB 
phosphorylation was decreased after hyperforin treatment. On the one side, these findings 
clearly indicate a cell-type specific reaction towards hyperforin treatment, which is in line with 
findings described above. On the other side, it was found that cell media composition influences 
TRPC6 downstream signalling. The same effects on CREB phosphorylation which were found 
after 24 h of hyperforin incubation in cells grown under high electrolyte conditions, were evident 
already after 20 min in cells grown under physiological electrolyte concentration (see above). 
CREB phosphorylation therefore seems to be regulated by the activity of the cells and their inter-
cell signalling. 
The CREB phosphorylation at Ser133 can be elicited by different stimuli, while the 
phosphorylation at position Ser142 or Ser143 depends on Ca2+ currents of L-VSCCs or NMDA 
receptors. Cell depolarization promotes Ser142 and Ser143 phosphorylation which further 
facilitates CREB activation. An immediate and short-term increase in Ser133 pCREB levels seems 
to be regulated by CaMK IV, while the RAS pathway induced a long-term action and also the 
CREB phosphorylations at Ser142 and Ser143 represent a prolonged reaction (Wu, Deisseroth, 
and Tsien 2001; Kornhauser et al. 2002). In my experiment, possibly the long-term exposure of 
neurons to high-electrolyte cell media, induced changes to voltage depended channels, silenced 
the cells and inter-cell communication. This may have led to the lack of Ser142 and Ser143 
phosphorylation after 24 h of hyperforin treatment. Therefore, in this context the induction of 
long-term CREB activation might have been missing, compared to neurons cultured in 
physiological cell media after 24 h of hyperforin stimulation. Under physiological conditions, 
CREB phosphorylation in ASM WT and ASM KO cells mainly diverges in the short-term effects 
and not in the long term CREB phosphorylation. Since short term CREB phosphorylation mostly 
relates to CaMK IV activation, this could be therefore the major effector responsible for pCREB 
level differences in ASM WT and ASM KO neurons. 
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 Importance of membrane lipid composition for 
microdomain organization 
Several analyses of the sphingolipidome in ASM KO mice have revealed that the SM content in 
brain and in non-lysosomal membranes was dramatically increased (Galvan et al. 2008), 
whereby the main constituent out of all SM species was SM18 (Buccinna et al. 2009). Also, the 
total gangliosides in brain lysates were elevated, whereby GM2 and GM3 levels were increased 
even 12 times (Ledesma et al. 2011; Scandroglio et al. 2008). It can be reasoned that this change 
in membrane composition could induce changes to membrane fluidity, and therefore under 
ASM-deficient conditions not only the defect in lysosomal catabolism, but also the ASM 
deficiency at the plasma membrane could alter plasma membrane composition and function of 
molecules. 
Proteins at the plasma membrane as ion channels can be located in small ceramide-enriched 
microdomains or rafts, which impact on the channel’s signalling. The composition of domains 
constituents seems to play a crucial role for subcompartmental localisation of proteins (Simons 
and Ikonen 1997; Stuermer 2011). How ASM influences this setting is only partially understood. 
Scientists claim that small membrane domains are modified by ceramide to confluent to larger 
domains. These large domains serve to cluster receptor molecules, whereby a high receptor 
density might be required for initiation of receptor-specific signalling (Gulbins and Grassmé 
2002). Therefore, I aimed at investigating sphingolipidome changes after pharmacological ASM 
inhibition. PC12 cells were incubated with ARC39 to inhibit ASM activity. Afterwards 
sphingolipidome in whole cell lysates and in a membrane enriched fraction (P2) were analysed. 
In whole cell lysates, ceramide/sphingomyelin molar ratio was decreased for Cer/SM 18 and 
Cer/SM 24 and showed negative trends for Cer/SM 20 and Cer/SM 24:1. In the P2 fraction, a 
negative trend was detectable for Cer/SM 24:1, however high standard deviations prevented 
any further statistically significant effect. Nevertheless and in summary, regulation of 
sphingolipids were visible after ASM inhibition. Differences in whole cell samples and P2 fraction 
could be caused by the lack of lysosomes in the P2 fraction. The change in microdomain 
composition on P2 might be too small compared to the entire plasma membrane and therefore 
it could be hard to detect these changes in P2. Furthermore, ASM is claimed to promote mainly 
the degradation to Cer 16 and Cer 24:1 (Taniguchi et al. 2015), however no alterations in Cer/SM 
16 molar ratio were detected. This emphasizes the understanding that the sphingolipidome 
regulation might be more complex as supposed and the modification of one enzyme has high 
impact on the whole sphingolipid system. Moreover, also in MD patients, a change in lipidomics 
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was found and presented elevated concentrations of long and very-long chain ceramide species 
in this context (Brunkhorst-Kanaan et al. 2019). This highlights that a dysregulation of ASM in 
MD does not impact only one sphingolipid species but the whole system. 
To figure out what these changes in sphingolipidome meant for TRPC6 distribution at the cell 
surface and more precisely the raft colocalisation, cells were treated with ARC39 to inhibit ASM 
activity and applied hyperforin to activate TRPC6 channels. A triton-resistant flotillin-1 enriched 
lipid raft fraction was isolated and compared to the residual triton-soluble membrane in terms 
of TRPC6 expression. This experiment revealed that modification in Cer/SM molar ratio, 
introduced a shift in subcellular localisation of TRPC6 at the plasma membrane. On the one side, 
the ASM inhibition induced a decrease in TRPC6 levels in the lipid raft fraction, which means that 
fewer TRPC6 proteins collocated to flotillin-1 enriched rafts. On the other side, a slight non-
significant positive trend was detectable for the non-raft fraction under ARC39 treatment. This 
means that TRPC6 proteins which were excluded from lipid rafts could be found in the non-raft 
fraction. This emphasizes the interference of ASM inhibition on dynamic TRPC6 localisation 
regulation. The changes in channel environment due to subcompartmental localisation might 
therefore impact TRPC6 function via a protein-lipid interaction, a disturbance in tetramerization 
or a conformational change, and serve as an explanation for observed impaired Ca2+ influx und 
CREB phosphorylation in response to hyperforin-induced TRPC6 activation.  
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Figure 33: Summary of findings: Interaction of the ASM/ceramide system and TRPC6 
A: Physiological condition. TRPC6 co-localises in the plasma membrane to lipid raft and non-raft regions. 
Here it is activated by hyperforin to induce Ca2+ influx. The increased internal Ca2+ concentration induces 
via calmodulin and several kinase pathways the phosphorylation of the transcriptional factor CREB 
(pCREB) (Heiser et al. 2013). This promotes the transcription of neurotrophic genes (Gibon et al. 2013). B: 
ASM activity inhibition or ASM deficiency. The treatment with FIASMA antidepressant fluoxetine or ARC39 
increases TRPC6 levels. This can be a result of induced protein expression or a decrease in TRPC6 
degradation. Nevertheless, the relocalisation of TRPC6 at the surface is altered. This change is displayed by 
a reduction in lipid raft TRPC6 levels which is due to a decrease in ceramide/sphingomyelin molar ratio of 
very-long chain sphingolipid species. The dysregulated TRPC6 surface localisation leads to a reduction in 
the TRPC6-mediated Ca2+ current. The reduced Ca2+ influx is downstream linked to a time-dependent 
reduction and cell type-specific modulation in CREB phosphorylation. Figure adapted and modified from 
ZEITLER ET AL. 2019 (Zeitler et al. 2019). 
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5.3 Future perspective of this study: impact of ASM and 
TRPC6 on synapse function 
MD pathology is tightly connected to changes in synaptic function (Duman and Aghajanian 2012; 
Duman et al. 2016), and ASM and TRPC6 are both proteins which have implications at nerve 
termini. While ASM is claimed to induce presynaptic activity by the generation of ceramide and 
the subsequent facilitation of sphingosine production (Verderio, Gabrielli, and Giussani 2018), 
TRPC6 has shown to be highly involved in spine formation and also enhances miniature synaptic 
transmission (Leuner et al. 2013). Thus, the interaction of ASM and TRPC6 especially in the 
context of synaptic function could deepen our understanding of pathologies in MD. 
Since the handling of this question exceeded the scope of the studies, some piloting experiments 
were conducted. 
First, other researchers claimed a strong degenerated spine phenotype connected to an 
impaired stability of cytoskeleton under ASM deficiency (Arroyo et al. 2014) or smaller size in 
synapses and reduced synaptic signalling (Camoletto et al. 2009) in ASM KO neurons. Therefore, 
I aimed at investigating synaptic density in ASM KO cortical neurons. For this end, cultures were 
stained for pre- and postsynaptic markers, and only when staining overlaid, it was considered as 
a “functioning” synapse. In accordance with previous findings, my results exhibited a decrease in 
synapse number. In a translational context and together with the findings of the other scientists, 
this could be in line with the mental retardation found in NPD A patients (Ledesma et al. 2011). 
Second, the FIASMA antidepressant fluoxetine has shown to beneficially modulate synaptic 
dynamics (Popova, Castrén, and Taira 2017). Therefore, I wanted to elucidate whether TRPC6 
activity could modulate synaptic vesicle recycling. Cortical rat neurons were stimulated with 
hyperforin for 24 h and synaptotagmin-1 antibody uptake in excitatory presynapses was 
analysed. Stainings revealed that under both, spontaneous and evoked network activity, 
antibody uptake was enhanced indicating an increase in vesicle recycling. Furthermore, staining 
for vGlut1 was amplified. This may relate to a rise in vesicle recruitment or vesicle size, or to an 
increase in vGlut1 protein density of single vesicles, which might be a regulatory effect to 
increased excitatory synaptic signalling. Vesicle pool size is tightly regulated by the 
phosphorylation pattern of synapsin1, which is in turn controlled by kinases that depend on 
internal Ca2+ concentrations (Cesca et al. 2010). Since TRPC6 regulates intracellular Ca2+ levels, its 
activation could modulate vesicle recycling. However, if this could serve as the principle how 
TRPC6 regulate described findings remains to be uncovered in the future. 
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As presented in the two preceding experiments, ASM and TRPC6 fulfil diverse important 
functions at the synapse. The potential interaction of ASM and TRPC6 in synaptic plasticity is still 
not investigated and might therefore serve as a promising research topic for the future in the 
understanding of MD pathology related to an ASM dysregulation.  
Moreover, it can be speculated that TRPC6 function depends on a sensitive ceramide balance. In 
a previous study it was found that ceramide applied to PC12 also inhibited TRPC6 activity (Ye 
2015). This means that both, ASM overexpression (as evident in MD patients) as well as ASM 
inhibition (as seen in ASM KO neurons as a model for pharmacological effects of FIASMA 
antidepressants), interfere with TRPC6 function. It is possible that in MD, high ceramide levels 
might negatively regulate TRPC6 function, which could be rescued by antidepressant-mediated 
ASM inhibition via restoration of the physiological sphingolipid balance. Further experiments 
using the ASM tg animal model are needed to confirm this hypothesis in the future. 
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